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Vitiligo is an autoimmune disease of the skin characterized by epidermal depigmentation 
that results from CD8+ T cell-mediated destruction of pigment producing melanocytes. Vitiligo 
affects up to 1% of the population and current treatments are moderately effective at facilitating 
repigmentation by suppressing cutaneous autoimmune inflammation to promote melanocyte 
regeneration. In order to cause disease, CD8+ T cells must overwhelm the mechanisms of 
peripheral tolerance in the skin and if we understand the suppressive mechanisms that are 
compromised during vitiligo, we can potentially use this information to improve existing 
treatments or engineer novel interventions.  Therefore, my goal is to characterize the regulatory 
factors in the skin that suppress depigmentation during vitiligo. Our lab has developed a mouse 
model of vitiligo that accurately reflects human disease and I used this model to demonstrate that 
regulatory T cells suppress CD8+ T cell-mediated depigmentation and interact with CD8+ T 
cells in the skin during vitiligo. In this model of disease, I investigated the molecules involved in 
regulatory T cell function and observed that the chemokine receptors CCR5 and CCR6 play 
different roles in regulatory T cell suppression. While CCR6 facilitates regulatory T cell 
migration to the skin, CCR5 is dispensable for migration but required for optimal regulatory T 
cell function. Additionally, I used our mouse model to demonstrate that Langerhans cells 
suppress the incidence of disease during vitiligo. Taken together the results from these studies 
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CHAPTER I: INTRODUCTION  
1.1 Vitiligo is an autoimmune disease characterized by epidermal depigmentation. 
Vitiligo is an autoimmune disease that affects up to 1% of the population and is 
characterized by patchy epidermal depigmentation resulting from the loss of pigment-producing 
melanocytes in the skin [1, 2]. Two forms of vitiligo exist with distinct clinical features: non-
segmental, or generalized, vitiligo and segmental vitiligo [1, 2]. Generalized vitiligo, 
characterized by widespread depigmentation, affects the majority of patients, while segmental 
vitiligo is less common (~5%) and occurs in a unilateral distribution that does not cross the 
midline [1-3]. Vitiligo equally affects men and women; 50% of patients exhibit depigmentation 
before the age of 20 and 80% before 30. Depigmentation can affect any part of the skin, but 
depigmentation most frequently presents on the face, hands, feet, and genitals [1, 2]. The risk for 
developing other autoimmune disease like thyroiditis, type 1 diabetes, pernicious anemia, 
Addison's disease, or alopecia areata is increased for vitiligo patients and their family members 
[1, 2]. Interestingly, while lesional skin lacks epidermal melanocytes, melanocytes in hair 
follicles located within depigmented skin are often spared [4]. This is likely a result of the 
immune privilege of the hair follicle [5] and successful treatments induce epidermal 
repigmentation that spreads from melanocyte stem cell reservoirs that persist protected from 
autoimmunity in hair follicles [4].  
 
1.2 Treatments for vitiligo are effective but can be improved 
No cure for vitiligo exists but there are a number of treatment options. Narrow band 
ultraviolet B (UVB) radiation is one of the preferred treatments for patients. Both adults and 
children with vitiligo positively respond to this treatment strategy and studies report that narrow 
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band UVB therapy resulted in more than 75% repigmentation in a majority of adults and children 
who received treatment [6, 7]. This treatment requires two treatments per week for at least 9 
months to achieve maximal repigmentation and this may present a challenge, even for patients 
who are fortunate enough to live near a treatment center [1]. Hair-bearing skin responds well to 
treatment while other locations do not, and relapse frequently occurs within a year of 
discontinuing treatment [8].  
 Topicals like corticosteroids and calcineurin inhibitors can also be used to treat 
depigmentation. A majority of patients treated with potent corticosteroids exhibited more than 
75% repigmentation in the treated areas, and these drugs are most useful for treating small, 
localized areas of depigmentaion [9]. This treatment does have adverse side effects, including 
epidermal atrophy, steroid-induced acne, and rosacea, so prolonged use should be avoided [10]. 
Calcineurin inhibitors can be used for sensitive areas of skin like the face, and have been shown 
to be effective in multiple double blind trials [11-14] but may need to be combined with UVB 
therapy to be most effective [15].  
Vitiligo patients can also pursue surgical options if other treatment methods fail. 
Minigrafting [16], which encompasses transplantation of autologous epidermal cell suspensions 
[17], or application of ultrathin epidermal grafts [18] can be used therapeutically and, in one 
study, patients with stable generalized vitiligo exhibited extensive repigmentation of an area 
treated with a transplanted epidermal cell suspensions as well as UVB light [19]. Surgery is 
expensive, invasive, and only effective in a small subset of patients with highly stable disease 
rendering this option unreasonable for many patients. While the treatments available for vitiligo 
patients can promote repigmentation, new durable treatments that are minimally invasive will 
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improve the quality of life of afflicted patients. In order to design novel interventions or improve 
existing ones, it is crucial to understand the factors driving pathogenesis.  
 
1.3: Evidence that genetics contribute to vitiligo pathogenesis 
The pathogenesis of vitiligo has been extensively studied and a growing body of evidence 
suggests that a myriad of factors synergize to initiate and maintain depigmentation. Vitiligo 
patients are likely genetically predisposed to disease. While the general population has a 1% 
chance of developing vitiligo, first degree relatives of vitiligo patients have a 6% chance of 
developing disease and identical twins have a 23% chance of developing disease [20]. This 
observation strongly supports a role for genetics in disease pathogenesis. Further supporting this, 
linkage and association studies of vitiligo and HLA suggest that the HLA region is involved in 
the genetic susceptibility to vitiligo [21] and Liu et al. conducted an analysis that uncovered a 
strong association of vitiligo with HLA-A2 [22]. These initial observations hinted that genetics 
contribute to disease and future genome wide association studies (GWAS) reaffirmed these 
findings. Jin et al. in particular performed GWASs of vitiligo and found up to 60 distinct genetic 
loci associated with disease, with many of these regions encoding factors involved in melanocyte 
function, immunoregulation, adaptive or innate immunity [23-26]. These results demonstrate that 
vitiligo patients may be genetically predisposed to disease and implicate pathways involved in 
pathogenesis. 
 
1.4: Evidence that intrinsic defects in melanocytes contribute to vitiligo pathogenesis 
Intrinsic defects in melanocytes may contribute to vitiligo pathogenesis. Separate studies 
comparing the ability of melanocytes from vitiligo patients or healthy patients to grow in in vitro 
4 
 
studies reported somewhat conflicting results. Puri et al. cultured melanocytes isolated from the 
skin of adult patients and healthy controls and while melanocytes from healthy patients readily 
grew in culture, melanocytes from non-lesional vitiligo skin did not begin to grow until 8 to 11 
days post culture [27]. After this initial lag, melanocytes from vitiligo and healthy skin grew at 
comparable rates but only melanocytes from healthy skin could be passaged multiple times [27]. 
These observations suggest that melanocytes in vitiligo skin, even those from uninvolved skin, 
may have some inherent growth defect. However, in contrast to these findings, Medrano and 
Nordlund et al. were able to establish long lasting cultures with melanocytes from vitiligo skin 
[28]. In this study melanocytes obtained from adult non-lesional vitiligo skin exhibited no lag 
before growth and were passaged multiple times suggesting melanocytes in vitiligo skin have no 
defects that inhibit their ability to grow in culture. 
Several studies note structural abnormalities in vitiliginous melanocytes compared to 
normal melanocytes. When Boissy et al. used electron microscopy to examine cultured 
melanocytes from non-lesional skin, they observed that the rough endoplasmic reticulum is 
morphologically different in melanocytes during vitiligo [29]. In light of these observations they 
suggested that melanocytes in normally pigmented skin have morphological aberrations that 
render them susceptible to disease [29].  Immunohistochemical analysis comparing healthy skin 
to vitiligo skin revealed that melanocytes express less c-kit in the skin during vitiligo [30]. Since 
c-kit signaling plays a key role in melanocyte proliferation, migration, and survival [31, 32], this 
apparent reduction in c-kit expression may result in reduced melanocyte longevity during 
disease.  
Melanocytes also exhibit functional defects during vitiligo and these may result from the 
structural defects that have been reported. Using electron microscopy, Tobin et al. observed 
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extracellular melanin granules in the interstitial spaces of non-lesional basal epidermis and 
concluded that melanocytes inefficiently transfer melanosomes in vitiligo skin [33]. Together 
these studies demonstrate that melanocytes in the skin during vitiligo exhibit various structural 
and functional defects that could lead to increased susceptibility to immune destruction. It is 
important to note that many of the previously detailed observations were made using more 
subjective techniques, like immunohistochemistry or electron microscopy, that are susceptible to 
sampling error and more work must be done to elucidate the full contribution of melanocyte 
defects to disease pathogenesis.  
 
1.5: Evidence that exposure to environmental factors contributes to disease pathogenesis 
Skin exposed to specific chemicals can exhibit depigmentation characteristic of vitiligo. 
The first example of this occurred when factory workers who wore gloves that contained 
monobenzyl ether of hydroquinone (MBEH) developed what was described as “occupational 
leukoderma” [34]. A significant proportion of workers developed patchy depigmentation on the 
skin that was exposed to the gloves and a number of them developed depigmented lesions on 
distal skin that did not contact gloves as well [34].  Oliver et al. performed patch tests on affected 
workers with ingredients used in the gloves and observed that patches containing MBEH 
ultimately induced depigmentation [34]. Later studies, thoroughly reviewed by Harris [35], 
confirmed that MBEH and other chemicals like 4-TBP and para-phenylenediamine (PPD) found 
in some commonly used products like hair dye, can indeed induce depigmentation [36, 37].  To 
explain how chemicals induce vitiligo a number of groups presented evidence linking increased 




1.6 Evidence that Cellular stress contributes to disease pathogenesis 
To maintain viability cells have to deal with a number of environmental or intracellular 
stressors that perturb homeostasis. These stressors can include DNA-damaging UV light, the 
accumulation of misfolded proteins during protein synthesis, heat shock, or chemical toxins that 
activate cellular sensors to initiate a cellular stress response [38].  During this response, multiple 
intracellular signaling pathways converge to ultimately manage stress and repair damage or 
mediate regulated cell death [38]. Epidermal melanocytes are particularly vulnerable to cellular 
stress due to their constant melanin production and exposure to UV light but a number of 
published studies demonstrated that melanocytes from vitiligo patients manage stress less 
efficiently than those from healthy controls. Maresca et al. observed that melanocytes cultured 
from non-lesional vitiligo skin were more susceptible to the toxic effects of an oxidizing agent 
than melanocytes from healthy donors [39] and another study similarly demonstrated that 
melanocytes from vitiligo patients exhibit increased susceptibility to UVB induced oxidative 
stress [40]. This increased susceptibility to stress could lead to melanocyte death and subsequent 
depigmentation when melanocytes undergo protein synthesis or encounter exogenous stressors 
like chemicals or UV light. In addition, a number of groups report high concentrations of H2O2 in 
the epidermis of vitiligo skin along with reduced levels of catalase an enzyme that protect cells 
from oxidative damage and both of these observations indicate increased cellular stress in the 
skin during vitiligo [41-46]. Taken together, these findings implicate a contribution of stress to 
disease pathogenesis.  
In some cases MBEH induced depigmentation at sites distant from that point of initial 
contact [34, 47, 48]. This suggests that exogenous stressors can instigate a whole body response 
against melanocytes to promote depigmentation and their toxicity is not limited to melanocytes 
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at the site of contact. To explain this phenomenon, Harris suggests that during vitiligo 
melanocytes that poorly manage stress respond to environmental factors by releasing self-
antigen. Antigen presenting cells (APCs) phagocytize melanocyte antigens while simultaneously 
receiving a danger signal that primes the APC to initiate an adaptive immune response against 
melanocytes [49]. Melanocytes cultured with chemicals previously shown to promote 
depigmentation, like 4tertiary butyl phenol (4-TBP) or MBEH, activated dendritic cells (DCs) to 
either kill melanocytes or induce cytotoxic melanocyte-targeting T cells [50, 51]. These 
observations support the hypothesis that environment factors can promote depigmentation by 
initiating an immune response against melanocytes. While intrinsic melanocyte defects and 
environmental factors likely contribute to the initiation of vitiligo, a growing body of evidence 
supports a clear role for autoimmunity in driving depigmentation during disease.  
 
1.7: Evidence that humoral immunity contributes to disease pathogenesis 
Early studies detected autoantibodies in the serum of vitiligo patients and these results 
were among the first to suggest a role for autoimmunity in disease pathogenesis. Harning et al. 
compared serum from patients with active vitiligo, inactive vitiligo, and no disease, and only 
observed antibodies to pigmented melanoma cells in the serum from patients with active disease 
[52]. Other studies reaffirmed this finding as they also identified melanocyte-specific 
autoantibodies using varying strategies [53, 54] but few of these studies identified antibodies 
targeted against surface expressed proteins [55, 56]. These findings suggest autoantibodies play a 
role in vitiligo pathogenesis but while CD4 and CD8 T cells infiltrate the skin during vitiligo, B 
cells are absent in lesional skin and thus it is possible other immune mechanisms contribute to 




1.8: Melanocyte specific CD8+ T cells mediate epidermal depigmentation 
Convincing evidence exists that CD8+ T cells drive depigmentation during vitiligo. 
CD8+ T cells are lymphocytes that express the CD8 co-receptor along with a TCR that 
recognizes pathogen peptides presented on MHC I molecules on infected cells or on cross-
presenting APCs. During a normal immune response, activated CD8+ T cells are dispatched to 
eliminate infected cells that display pathogenic antigens on surface expressed MHC I molecules 
[58]. Ogg et al. used HLA-A2 restricted tetramers to demonstrate that high frequencies of CD8 T 
cells in PBMCs from vitiligo patients exhibit specificity against MelanA peptides and express 
CLA, a receptor that facilitates skin homing [59]. Ogg et al. also observed that MelanA specific 
CD8+ T cells from vitiligo patient PBMCs were capable of lysing peptide-pulsed target cells and 
melanoma cells in vitro suggesting that the circulating T cells that exist in vitiligo patients are 
capable of destroying melanocytes [59].  Lang et al. used an ELISPOT assay to demonstrate that 
CD8+ T cells in the PBMCs of vitiligo patients recognize melanocyte antigens in actively 
progressing vitiligo [60]. PBMCs from patients reacted strongly against MelanA/MART1 
peptides as well as peptides derived from gp100 and tyrosinase proteins [60]. Additionally CD8+ 
T cells in PBMCs isolated from vitiligo patients produced IFNγ in response to stimulation with 
peptides from MelanA/MART1 and tyrosinase [60]. This data suggests that MelanA/MART1, 
gp100, and tyrosinase represent important antigenic targets for an autoimmune T cell response in 
vitiligo patients [60]. The studies performed by Ogg et al. and Lang et al. reported less 
melanocyte reactivity in PBMCs from controls without disease [59, 60]. In the few instances 
where control PBMCs exhibited reactivity against melanocyte antigens, T cells did not express 
the skin homing receptor CLA [59, 60].  
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The aforementioned studies established an increased presence of melanocyte specific 
CD8 T cells in the peripheral blood and subsequent studies discovered the presence of CD8+ T 
cells in lesional skin. Activated T cells were among the lymphocytes infiltrating perilesional skin 
when histology was performed on biopsies from vitiligo patients [61]. A later study reaffirmed 
that most of the skin-infiltrating lymphocytes during vitiligo are CD8+ T cells and these T cells 
were skin-homing, predominantly expressed the type 1 cytokines IFNγ and TNFα, and clustered 
near disappearing melanocytes [57, 62]. Van den Boorne et al. isolated T cells from perilesional 
skin or healthy controls and used HLA-A2 restricted tetramers to screen the ability of T cells to 
recognize peptides generated from melanocyte proteins like gp100, MART-1 and tyrosinase 
[63]. There were significantly increased levels of T cells recognizing melanocyte antigens in 
populations from perilesional skin compared to those from healthy skin and these melanocyte 
targeting T cells exhibited the capability to destroy melanocytes [63]. CD8+ T cells or CD8-
depleted lymphocytes isolated from perilesional skin were co-cultured with pigmented skin 
explants from non-lesional skin [63]. After analyzing skin explants with immunohistochemistry 
or immunofluorescence they observed that lymphocytes infiltrate the skin and localize near 
melanocytes in both experimental groups but only CD8+ T cells isolated from patient skin 
induced melanocyte apoptosis [63]. Taken together these data firmly establish that CD8+ T cells 
drive vitiligo pathogenesis by targeting and destroying melanocytes in lesional skin during 
disease.  
 
1.9: Mouse models developed to study Vitiligo 
To investigate the mechanisms of pathogenesis during vitiligo a number of mouse models 
have been developed and are extensively reviewed in Essien et al. [64]. While none of these 
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models perfectly encapsulate all the factors involved in pathogenesis, each can address specific 
components of disease if used appropriately. The mivit/mivit mouse spontaneously develops hair 
depigmentation without immune involvement due the loss of melanocyte function caused by a 
point mutation in the MITF gene [65, 66]. MITF regulates melanocyte development and genes 
important for melanin production like tyrosinase [67] but since the identical mutation results in 
partial albinism and deafness instead of vitiligo, this model does not appear to accurately mimic 
human vitiligo [68, 69]. Despite these differences this model could be useful for studying how 
melanocyte defects contribute to vitiligo.  
Zhu et al. developed a mouse model of vitiligo in which the application of MBEH to the 
abdomen of young mice resulted in local hair depigmentation that spread to distant sites. In Rag-
/- mice depigmentation is restricted to the site of local depigmentation suggesting that while 
direct toxicity of MBEH may be responsible for localized depigmentation at the site of 
application, an adaptive immune response is required for spread to other sites. CD8+ T cells 
infiltrate MBEH treated skin and this model may be useful for investigating how environmental 
factors and stress promote depigmentation [70]. 
Mice immunized with various vectors carrying human melanocyte antigens like TRP1 
[71]  and TRP2 [72, 73] exhibit hair depigmentation. In these models, melanocyte-specific 
autoantibodies are induced and either CD4+ T cells [71] or CD8+ T cells [72, 73] mediate 
depigmentation. TCR transgenic hosts bred to express human HLA-A2 and T cells with TCRs 
recognizing human melanocyte antigens develop depigmentation [74, 75]. In one of these models 
depigmentation is driven by CD8+ T cells and depended on IFNγ similar to human disease [74], 
but in the other model CD3+CD4-CD8- T cells drive depigmentation, a scenario very different 
11 
 
from human disease [75]. Nonetheless, these models are suitable for studying the role of T cell 
responses during vitiligo.   
In several inducible models of vitiligo, TCR transgenic T cells are adoptively transferred 
into hosts to induce depigmentation. In these models CD4+ T cells with TCRs recognizing 
human TRP1 [76] or CD8+ T cells with TCRs recognizing human gp100 [77-79] drive hair or 
epidermal depigmentation in host mice. The Harris mouse model of vitiligo is well-suited to 
study disease progression since this model develops prominent epidermal depigmentation while 
sparing the hair [79]. This scenario mimics the clinical presentation of human vitiligo, providing 
an opportunity to study mechanisms that direct T cell migration to the epidermis and topical 
agents that modify disease severity. Since this model also maintains immune privilege of the hair 
follicle [5], it allows the investigation of factors promoting epidermal repigmentation that has 
been shown to spread from melanocyte stem cell reservoirs that persist protected from 
autoimmunity in hair follicles [4]. The Harris model of vitiligo provides the opportunity to study 
vitiligo in context that closely matches human disease and I used this model to investigate the 
regulatory factors in the skin during vitiligo.  
 
1.10 A myriad of factors contribute to vitiligo pathogenesis 
The etiology of vitiligo is complex and a number of factors likely combine to cause skin 
depigmentation. Intrinsic melanocyte defects and exposure to environmental factors may initiate 
processes that activate CD8+ T cells to target melanocytes and drive disease. Since patients seek 
treatment for vitiligo once lesions have already appeared, focusing on the autoimmunity that 
drives depigmentation, as opposed to factors that initiate disease, will best serve patients looking 
for an effective treatment or cure. If we can learn how to dampen the CD8+ T cell response 
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against melanocytes in the skin we can halt melanocyte destruction and establish favorable 
conditions for repigmentation. To accomplish this one must appreciate that the skin hosts an 
extensive network of immune players that all interact to effectively protect the body from 
infections. Skin resident APCs, along with T cells, coordinate to initiate immune responses and 
in healthy people can also support peripheral tolerance to protect the skin from autoimmunity. 
Our group focuses on understanding the factors that drive CD8+ T cell-mediated autoimmunity 
and this work focuses on regulatory factors in the skin that suppress CD8+ T cell-mediated 
depigmentation during vitiligo. The following work will review the literature on factors that 
regulate effector T cell function during an autoimmune response in the skin. 
 
1.11: T cell development in the thymus deletes auto-reactive T cells 
Like all T cells, CD8+ T cells develop in the thymus. T cell progenitors that express 
neither CD4 nor CD8 leave the bone marrow and enter the thymus where they receive signals 
that initiate processes that lead to the expression of a functional surface pre T Cell Receptor or 
preTCR. The affinity of the preTCR for MHC-self-peptide complexes expressed in the thymus 
determines whether or not a cell survives positive and negative selection.  Cells bearing TCRs 
with low affinity for MHC-self-peptide complexes presented on thymic epithelium are positively 
selected and receive signals that lead to survival. Any positively selected cells expressing TCRs 
with strong affinity for MHC-self-peptide complexes presented on thymic APCs are negatively 
selected and receive signals that initiate apoptosis. Cells that survive positive and negative 
selection receive signals that induce the expression of a mature CD8 or CD4 TCR and egress 
from thymus to the circulation. This process of thymic selection serves as the first check to 
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protect the body from autoimmunity by preventing the escape of auto-reactive T cells to 
peripheral circulation.  
 
1.12: Naïve T cell activation and migration to skin 
A CD8+ T cell that leaves the thymus will circulate between the blood stream and 
secondary lymphoid organs (SLOs) until it encounters the antigen recognized by its TCR. In the 
SLO organs like lymph nodes (LNs), DCs that have migrated from the site of infection present 
MHCI-bound antigen to T cells while simultaneously providing co-stimulation and cytokine 
signals to activate naïve CD8+ T cells [80-83]. Activated naïve T cells differentiate into effector 
T cells (Teffs) and exponentially proliferate until the amount of antigen-specific Teffs reaches 
more than 10,000 fold their original number [84].  
During this clonal expansion Teffs migrate to sites of inflammation in peripheral tissues 
[85]. There they interact with pathogen-infected cells that express surface bound antigen-MHCI 
complexes and clear the infection by inducing apoptosis in infected cells with cytotoxic granules 
or by releasing inflammatory cytokines [86]. The lymphoid environment in which a T cell is 
activated has been shown to influence Teff migration after leaving SLOs. Naïve CD8+ T cells 
cultured with antigen-pulsed DCs isolated from skin draining lymph nodes (SDLNs) 
expressed higher levels of molecules required for skin entry and migration [87].  These T cells 
migrated efficiently to inflamed skin while T cells activated by DCs from gut-derived lymphoid 
tissues migrate to the gut [87]. Teffs licensed to migrate to the skin upregulate the adhesion 
molecule CLA. CLA binds E-selectin molecules that are constitutively expressed by the 
endothelial cells lining blood vessels in the skin and this interaction allows T cells to roll against 




1.13: Mechanisms that prevent Teff-mediated host tissue damage 
Immune-mediated tissue damage can result from an improperly regulated CD8+ Teff 
response. During hemophagocytic lymphohistiocytosis a failure to clear viral infections results in 
excessive CD8+ Teff activation that leads to the over expression of inflammatory cytokines and 
subsequent immune-mediated tissue damage [90]. Proinflammatory and anti-inflammatory 
signals must be balanced to ensure effective pathogen clearance with minimal host tissue damage 
and the immune system has evolved strategies to properly regulate Teff-mediated inflammation. 
TCR signaling, co-stimulation, and cytokine signals that Teffs receive during an infection induce 
the expression of anti-apoptotic BCL-2 molecules that promote Teff survival [91]. After Teffs 
clear an infection, the signals that drive Teff activation are gone and as a result Teffs stop 
expressing anti-apoptotic BCL-2 molecules and express pro-apoptotic molecules [92-94]. Thus 
the clearance of infection establishes conditions that lead to Teffs apoptosis to prevent potential 
Teff-mediated tissue damage. Activation-induced cell death (AICD) results from repeated TCR 
stimulation of previously activated Teffs and culminates in apoptosis mediated by FAS “death 
receptor” signaling to prevent excessive Teff responses [95, 96]. Teff responses during infection 
are regulated to prevent damage to host tissues and the immune system has also evolved 
mechanisms to suppress Teff-mediated autoimmunity. In some instances self-targeting T cell 
clones escape deletion in thymus and the mechanisms that suppress their autoimmune activity in 
peripheral tissue are collectively termed peripheral tolerance. During vitiligo these mechanisms 
must be overwhelmed to allow Teff activity to mediate depigmentation, and studying vitiligo 
provides a unique opportunity to understand how impaired peripheral tolerance contributes to 
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pathogenesis during vitiligo and other forms of autoimmunity. A number of immune cells can 
participate in the peripheral tolerance, and regulatory T cells (Tregs) play a crucial role.   
 
1.14: Discovery of Tregs 
Tregs are a subset of CD4+ T cells that potently suppress pathogenic immune responses 
mediated by autoreactive cells, and maintain tissue immune homeostasis. Researchers first 
discovered a thymus-derived population capable of suppressing autoimmunity in the late 60s. 
Experiments performed by Gershon and Kondo in 1970, revealed that thymus-derived 
lymphocytes prevent the inflammatory activity induced by bone marrow-derived cells transferred 
into recipient mice [97]. Nishizuka and Sakakura reported that removing the thymus of 2 to 4 
day old mice, led to autoimmune ovary damage,  inflammation in various tissues and the 
production of tissues specific autoantibodies [98]. In line with this discovery, another group 
found that removal of the thymus followed by sublethal irradiation in adult rats induces multiple 
forms of autoimmunity, including diabetes [99, 100]. Subsequent studies investigated the 
mechanism of the thymic-derived suppressor T cells. These efforts identified a network of 
soluble factors whose suppressive capabilities were attributed to a molecule termed I-J that 
mapped to the MHC locus [101]. Controversy concerning the existence of suppressor T cells 
arose after analysis of the MHC gene revealed that the region I-J mapped to could not encode an 
I-J polypeptide [102]. In addition to this finding, the inability to identify a reliable distinguishing 
marker for suppressor T cells combined with difficulty preparing antigen-specific suppressor 
clones, resulted in widespread skepticism regarding the existence of a suppressive T cell 




Work performed by Sakaguci et al. reaffirmed the suppressive capabilities of T cell 
populations. When Sakaguchi et al. removed the thymus from 2-4 day old mice to induce 
autoimmunity, they found that splenocytes from these mice could induce similar autoimmune 
inflammation when transferred to healthy T cell deficient neonatal mice [103]. Additionally, they 
found that  thymocytes from healthy adult mice injected 2 weeks after thymus removal could 
prevent autoimmunity that normally results from thymectomy [104]. The splenocytes that could 
adoptively transfer autoimmunity and the suppressive cells that could prevent it were both 
identified as CD4+ cells. This suggested that two populations of CD4s exist; one capable of 
effector function and another capable of suppressor function. Subsequent experiments identified 
that CD5highCD45RBlowCD4+ T cells possess suppressive capabilities as isolated CD5lowCD4+ T 
cells and CD45RBhighCD4+ T cells mediated multi-organ autoimmunity when transferred into T 
cell deficient mice [105, 106]. In both these cases co-transfer of whole CD4+ T cells prevented 
autoimmunity [105, 106]. Sakaguchi et al. later identified that CD25, the high affinity IL2 
receptor α-chain, is preferentially expressed on the CD5highCD45RBlow fraction of peripheral 
CD4+ T cells in naïve mice compared to peripheral CD8+ T cells and other CD4+ T cells [107]. 
CD25-CD4+ splenocytes induced autoimmunity when transferred into athymic mice and 
transferring CD25+CD4+ T cells inhibited autoimmunity confirming CD25 as a reliable marker 
for T cells with regulatory capabilities, Tregs [107].  
 
1.15 Foxp3 identifies Tregs and regulates Treg function. 
As argued by Schmidt et al., the discovery of CD25 as a reliable marker for Tregs opened 
the door for researchers to explore their presence and function [108]. Tregs identified by CD25 
can be found in peripheral tissues of normal mice 3 days after birth and make up 5-10% of CD4 
T cells in the periphery of adult naïve mice [109].  However, CD25 is not simply a marker for 
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Tregs, but the receptor is also crucial for Treg growth, survival and function. This is evidenced 
by the fact that IL-2 deficient mice have reduced numbers of Tregs, spontaneously develop 
autoimmunity, and disease in CD25-/- mice can be prevented by the adoptive transfer of Tregs 
[110, 111].  
CD25 identifies Tregs in humans as well, but while Tregs express very high levels of 
CD25, activated CD4+ T cells express CD25, albeit at lower levels [112]. Forkhead box P3 
(FoxP3), a transcription factor that regulates Treg identity and function, was later identified as a 
marker for Tregs in humans and in mice. Scurfy mice that have a mutation in the gene encoding 
FoxP3 have no Tregs and exhibit widespread autoimmunity [113] similar to autoimmunity in 
patients with Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome 
(IPEX), also caused by mutations in the FOXP3 gene [114].  Fontenot et al. observed that Tregs 
express Foxp3 and the Foxp3-/- mice that they generated had fewer CD4+CD25+ Tregs. They 
also developed a lymphoproliferative disorder that resolved when CD4+CD25+ Tregs were 
transferred [115]. Fontenot et al. used retrovirus to mediate the ectopic expression of Foxp3 in 
naïve CD4+CD25- T cells and found that these cells gained regulatory capabilities in vivo, 
suggesting Foxp3 is a crucial regulator of Treg function and is not only necessary but sufficient 
for this function [115]. Further supporting this claim, Hori et al. also reported retroviral 
transduction of Foxp3 is sufficient to give peripheral CD4+CD25- T cells suppressive 
capabilities and in humans ectopic overexpression Foxp3 allowed naïve T cells to mimic the 
suppressive function of Tregs in vitro [116, 117]. In mice Tregs express Foxp3 while resting or 
activated T cells do not express significant levels [115], but in humans Tregs express Foxp3 and 
activated T cells can transiently express the transcription factor [118].  
 
1.16: Natural Tregs develop in the thymus. 
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Two classes of Tregs have been identified based on their development, induced Tregs and 
natural Tregs. Induced Tregs develop in the periphery when naïve CD4+ T cells acquire 
suppressive capabilities after exposure to cytokines like TGF-β1 [119]. Natural Tregs develop in 
the thymus and the paucity of specific markers to differentiate between the two complicate 
attempts to study their differences. The following will focus on natural Treg development. In 
humans, Tregs develop in the thymus and can be found in the thymus at 12 to 13 gestational 
weeks. Fetal Tregs have the ability to suppress CD4+CD8- T cell proliferation in vitro and 
express canonical markers of Treg fate like CD25, FOXP3 and CTLA4 [120]. The mechanisms 
that commit progenitors to Treg fate in the thymus are still being studied. Observations that fetal 
thymic Tregs express markers associated with TCR stimulation like CD69 suggest positive 
selection based on affinity to MHC-self-peptide complexes contributes to Treg differentiation 
[120].  Caramalho et al. identified IL2 and IL15, ligands for CD25, as key cytokines involved in 
Treg development that preferentially promote Treg proliferation and survival in the thymus 
[121]. In addition to IL2 and IL15, various other signaling molecules contribute to Treg 
differentiation in thymic progenitors, suggesting that a combination of TCR stimulation and 
molecular signals likely control Treg development in the thymus [121-123]. 
In mice, induced and natural Tregs have been described and natural Tregs develop in the 
thymus. Similar to Treg development in humans, progenitor commitment to Treg differentiation 
in the thymus likely depends on a combination of different signals. In the thymus, Treg 
development depends on the expression of a TCR with strong affinity to MHC-self-peptide 
complexes, as Treg differentiation was enhanced in mice where superantigens that bind TCRs 
with high affinity were presented by MHC molecules on thymic epithelium [124]. Studies 
detailed that TCR-driven selection is accompanied by additional signaling from CD28, IL2/IL15 
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and TGFβ that drive Treg development in the thymus [125-127]. TCR affinity for MHC-self-
peptide complexes in combination with specific molecular signals drives Treg development in 
the thymus. 
 
1.17: Tregs can use a variety of mechanisms to mediate suppression. 
Autoreactive T cells can escape negative selection in the thymus and when this occurs 
Tregs play an important role in maintaining peripheral tolerance. Tregs can suppress naïve Teffs 
through a variety of mechanisms that ultimately prevent Teff activation and proliferation [128]. 
Tregs can also suppress activated T cells as Tregs inhibit the proliferative response of memory 
CD4+ Teffs to alloantigen [129] and Tregs suppress memory CD8+ T cell responses to HSV-1 
infection [130]. Tregs can suppress Teffs indirectly through mechanisms that reduce co-
stimulation signals antigen presenting cells provide to Teffs or directly through secreted anti-
inflammatory cytokines or cell contact-mediated mechanisms. I will briefly describe these 
mechanisms below. 
Suppression by modulation of APC co-stimulatory signals 
A DC can initiate immune responses by activating Teffs through multiple signals. First, 
DCs provide TCR signaling that initiates Teff activation when DCs present antigen on MHC 
molecules to Teff TCRs. DCs also provide CD28 co-stimulatory signaling that increases Teff 
survival and proliferation when CD80/CD86 expressed by DCs, ligates CD28 expressed by 
Teffs. When CD4+CD25+ T cells are co-cultured with bone marrow-derived DCs in the 
presence of anti-CD3 antibodies, Tregs reduced DC surface expression of CD80 and CD86 
[131]. Tregs are still able to reduce CD80 and CD86 when DCs are activated with anti-CD40 
antibodies and reduce mRNA levels of CD80 [131].  Another in vitro study echoed these results 
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but reported that this process requires CTLA4. They found that CTLA4-/- Tregs co-cultured with 
DCs could not reduce DC CD80 or CD86 expression [132]. DCs with reduced levels of co-
stimulatory molecules primed Teff responses less efficiently. Oderup et al. reported that DCs 
pre-cultured with Tregs exhibited reduced CD80 and CD86 expression and induced poor CD4+ 
T cell proliferation in secondary cultures [133]. In these cultures, the addition of anti-CD28 
antibodies rescued CD4+ T cell proliferation [133]. These observations suggest that Tregs can 
suppress Teffs indirectly by reducing the co-stimulatory signals that DCs provide.  
Suppression by anti-inflammatory cytokines 
IL-10. Tregs secrete cytokines that mediate Treg induced suppression. IL10 is an 
immunosuppressive cytokine that contributes to Treg suppression in several in vivo studies. 
Asseman et al. demonstrated that Tregs from IL10-/- mice fail to prevent disease in a mouse 
model of colitis while WT Tregs can abrogate inflammation [134]. Similarly, IL-10-/- Tregs fail 
to protect mice from inflammation in a mouse model of EAE while WT Tregs could suppress 
active disease [135]. These observations suggest IL-10 contributes to Treg suppression but the 
fact that IL-10-/- mice only exhibit colitis and not widespread autoimmunity, suggests Tregs may 
not always require IL-10 to suppress Teffs [136]. IL-10-mediated Treg suppression seems to 
depend on where Tregs encounter Teffs. IL-10-/- Tregs and WT Tregs can suppress CD4+ T Cell 
proliferation and IFN-γ production in the lymph node but IL-10-/- Tregs fail to control CD4+ T 
Cell IFNγ production in ear skin [137]. Tregs may not use IL-10 to suppress in peripheral tissue 
like skin and these findings highlight the importance of studying Treg mechanisms of 




IL-35. Collinson et al. identified IL-35 as a molecule capable of mediating Treg 
suppression. IL-35 is predominantly expressed by Tregs and IL35-/- Tregs are less suppressive in 
vitro and fail to control autoimmunity in an in vivo model of inflammatory bowel disease [138]. 
IL-35 suppresses T cell proliferation and T cells retrovirally transduced with vectors encoding 
IL-35, acquired regulatory capabilities [138].  
TGFβ. TGFβ is an immunomodulatory cytokine and a number of separate studies report 
contradicting evidence regarding the necessity of TGFβ for Treg suppression. In vitro assays 
performed by Piccirillo et al. demonstrated that suppressive Treg function does not require 
TGFβ, as Tregs were still able to suppress Teff proliferation in response to TCR stimulation in 
the presence of anti-TGF-β1 antibody [139]. Tregs also suppressed Teff proliferation in Teffs 
incapable of responding to TGFβ signaling and Tregs from TGFβ-/- mice suppressed Teffs in 
vitro, further demonstrating TGFβ is dispensable for Treg suppression [139]. In contrast to this, 
Levings et al. demonstrated that human Tregs require TGFβ for optimal suppression, as Tregs 
exhibited a reduced capacity to suppress TCR-mediated CD4+ T Cell proliferation in the 
presence of anti-TGF-β1 antibody [140]. Read et al. also reported that Treg suppression is 
mediated by TGFβ signaling in a mouse model of colitis as adoptively transferred Tregs lost the 
ability to prevent colitis when mice were treated with anti-TGFβ antibody [141].  
Contact-dependent Mechanisms of Treg suppression 
While direct suppression of Teffs by Tregs can be mediated by secretion of the 
immunomodulatory cytokines described above, mechanisms of suppression that require Tregs to 
directly contact Teffs have also been described. Cyclic adenosine monophosphate (cAMP) is a 
molecule that suppresses T cell growth, differentiation and proliferation [142]. Bopp et al. 
observed that Tregs express high levels of cAMP while CD4+ Teffs did not express appreciable 
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amounts [143]. CD4+ Teffs exhibited an increase in cAMP after they were co-cultured with 
Tregs, and Tregs suppressing CD4+ Teffs transfer cAMP to Teffs via gap junctions in co-
cultures [143].  This mechanism required contact, as separating Tregs from CD4+ T cells with a 
membrane abrogated Treg suppression [143].  
Several studies demonstrate that Tregs use surface bound TGF-β1 to suppress in a 
contact-dependent manner. Nakamura et al. reported that activated Tregs express surface bound 
TGF-β1 and antibodies that block TGF-β1 ablate the ability of Tregs to suppress CD4+CD25- T 
cell proliferation in vitro [144]. Andersson et al. also reported that in the presence of an antibody 
blocking surface bound TGF-β1, Tregs cannot suppress CD4+CD25- Teffs in in-vitro co-
cultures [145]. In these studies, Treg-mediated suppression required contact as Tregs could not 
suppress CD4+CD25- T cells when separated by a membrane [144, 145]. In a mouse model of 
diabetes, Green et al. reported that Tregs cannot control disease mediated by CD8+ T cells 
without TGFβ signaling and suggest that Treg suppression requires contact since disease is least 
severe in mice with Tregs expressing high levels of surface TGF-β1 [146]. 
Tregs can also directly kill Teffs through contact-dependent mechanisms that require 
granzyme. Grossman et al. observed that human Tregs isolated from peripheral blood 
upregulated granzyme A after activation with anti CD3/CD28 antibodies in the presence of IL2. 
These activated Tregs killed CD8+ and CD4+ target cells in vitro using perforin-dependent 
mechanisms [147]. Another study reported that Tregs may also use granzyme B for suppression 
as murine granzyme B deficient Tregs failed to efficiently suppress CD8+ T cells in co-cultures 
[148].  
While many mechanisms of Treg suppression have been described, questions remain 
about which mechanisms Tregs use in different contexts. As argued by Schmidt et al., Tregs may 
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not use only one distinct mechanism to suppress Teffs [108]. Tregs may have a variety of 
different options at their disposal and the mechanism that they use could depend on numerous 
factors like the activation status of the Teffs they encounter or the location where they encounter 
Teffs. Conflicting results where a specific molecule is crucial for suppressive function in one 
instance and dispensable for suppression in another suggest that Tregs can use redundant 
compensatory mechanisms to mediate suppression.  The context of Treg-Teff interactions could 
determine which mechanisms Tregs use and it is important to consider this when designing 
assays to test Treg function. For example, Tregs can suppress Teffs by decreasing the co-
stimulatory signals that APCs deliver. This strategy will successfully suppress the activation of 
naïve T cells in SLOs but will be ineffective when Tregs encounter already activated Teffs in 
peripheral tissue. A lot of work has been done to elucidate Treg function in vitro but these 
systems may not be able to fully appreciate the context of suppression and thus may not be able 
to inform how Tregs suppress in the periphery. In our model of vitiligo presents a model where 
Tregs suppress Teffs in the periphery and could help clarify how Tregs suppress Teffs in 
peripheral tissue. 
 
1.18: Tregs in the skin 
A growing body of evidence supports the fact that Tregs exist in peripheral tissue and 
Tregs have been reported in human and mouse skin. Using flow cytometry, Scharschmidt et al. 
found a wave of Tregs enter mouse skin as early as postnatal day 6 and Tregs account for 20-
60% of the CD4+ T cells in the skin of adult mice [149]. Tregs also exist in human skin as 
Sanchez Rodriguez et al. found that about 20% of CD4+ T cells in surgically obtained skin from 
healthy patients are Foxp3 expressing Tregs [150].  This group categorized the Tregs they found 
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in healthy skin as activated memory Tregs, since more than 90% of Tregs in healthy skin express 
markers characteristic of effector memory T cells like CD45RO and higher levels of activation 
markers like CTLA-4, CD25 and ICOS [150]. Rosenblum et al. used a mouse model to 
demonstrate that memory Tregs reside in mouse skin and provide expedited protection against 
skin inflammation [151]. In this model initial antigen expression activates and expands antigen-
specific Tregs in SDLNs that subsequently accumulate in the skin during antigen-induced 
disease [151]. After disease resolves, activated Tregs remain in skin even in the absence of 
antigen and facilitate a potentiated inflammatory response when antigen is re-expressed [151]. 
Immunofluorescence staining on healthy human skin revealed that Tregs reside in the 
dermis clustered near hair follicles [150]. Similar observations were made in mice, as 
immunohistochemical staining of 13 day-old mice revealed that Tregs primarily localized to hair 
follicles [152]. Hair follicle development plays a crucial role in the migration of Tregs to skin in 
developing mice and Scharschmidt et al. demonstrated this when they reported that the inducible 
ablation of murine hair follicle resulted in reduced Tregs accumulation in the skin of 13 day old 
mice [152]. Hair follicle-dependent Treg skin migration is augmented by commensal 
microorganisms and mediated by the chemokine CCL20 made by hair follicle epithelial cells 
[152]. Treg homeostasis in the skin most likely remains tied to hair follicle biology as murine 
Tregs are more abundant and activated in telogenic than anagenic skin [153] and areas of human 
skin with more hair follicles (face and scalp) have more Tregs than areas with low hair follicle 
density (trunk and upper proximal extremities) [150].  
Tregs circulating in mice and humans can traffic to the skin and the signals that Tregs can 
use to enter the skin have been studied. Murine Tregs require CCR6 to follow hair follicle-
derived CCL20 to migrate to the skin during neonatal development [152]. CCR4 may also 
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facilitate Treg migration to the skin. Murine Tregs, activated by antigen in lymph nodes, express 
CCR4 and CD103 and CCR4-/- Tregs exhibit a reduced ability to accumulate in the skin and 
control cutaneous inflammation [154]. Eby et al. demonstrated that the over expression of the 
CCR4 ligand CCL22 in murine skin, drove increased cutaneous Treg accumulation in mice 
further supporting a role for CCR4 in skin migration [155]. The enzyme α-1,3-fucosyltransferase 
VII (FucT7) was also demonstrated to be important for Treg skin migration as FuvT7-/- Tregs 
transferred into scurfy mice could migrate well to most tissues except the skin [156]. 
 
1.19: Tregs in autoimmune skin diseases. 
Autoimmune diseases affecting the skin are mediated by various forms of cutaneous 
auto-inflammatory activity. In a number of these diseases, many have implicated decreased Treg 
number in the skin or impaired Treg function as a causative factor for the break in tolerance that 
allows autoimmunity to proceed.  
In alopecia areata (AA) CD8+ T cells mediate hair loss by attacking the bulb of the hair 
follicle [157].  Han et al. observed that there are fewer Tregs in the scalp lesions of AA patients 
[158] and increasing Treg number in lesions may resolve AA. Castela et al. subcutaneously 
injected the lesional scalp of patients with low dose recombinant IL2 and saw partial hair 
regrowth in injected lesions and increased Treg number when comparing biopsies obtained 
before treatment and at the end of the study [159].   
The role of Tregs in systemic lupus erythematosus (SLE) remains unclear and conflicting 
reports on the numbers and function of Tregs in SLE have been published. Using flow 
cytometry, Bonelli et al. observed fewer Tregs in the peripheral blood of patients with active and 
inactive SLE compared to healthy controls [160] and Valencia et al. reported that Tregs isolated 
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from patients with active SLE failed to suppress the proliferation and cytokine production of 
CD4+ T cells [161]. These results suggest that reduced Treg number and impaired Treg function 
could contribute to SLE pathogenesis but a few studies contradict this hypothesis. Studies done 
by Alvarado-Sanchez et al. report no difference in Treg number in the PBMCs of SLE patients 
[162] and studies done by Vargas-Rojas et al. found that Tregs from SLE patient exhibit normal 
suppressive ability but CD4+ Teffs from SLE patients are resistant to Treg suppression [163]. 
Psoriasis patients suffer from widespread, scaly plaques that persist for weeks to months. 
Immunohistochemical analysis of punch biopsies from the lesional skin of psoriasis patients 
revealed lower Treg/CD4 ratios in perilesional skin compared to distal non-lesional skin and skin 
from healthy patients, suggesting decreased Treg number in the skin may contribute to 
pathogenesis [164]. Increased numbers of CD4+ T cells likely also contribute to disease but a 
favorable ratio of Tregs to Teffs is probably necessary to control inflammation. Tregs in PBMCs 
from psoriasis patients exhibit a reduced ability to inhibit Teffs in vitro suggesting impaired 
Tregs function may contribute to disease as well [165]. In an imiquimod induced mouse model 
of psoriasis, Tregs accumulate in lesional skin and Treg depletion results in increased CD8 Teff 
accumulation in the skin and exacerbated disease [166]. These observations suggest that the 
number of Tregs in the skin affects psoriasis pathogenesis. 
In the diseases previously detailed, the ability of effectors to mediate inflammation 
during skin autoimmunity may result from impaired Treg number or ability to suppress 
inflammation. If Teffs are mounting a massive immune response against skin tissue, the number 
of Tregs must be important to ensure effective concentrations of anti-inflammatory cytokines or 
enough opportunity for contact-dependent mechanisms of suppression to work. Too few Tregs or 
reduced Treg function could conceivably perpetuate a cycle where Teffs proceed unchecked. 
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Defects in Treg function or decreased Treg number may contribute to the reduced peripheral 
tolerance that allows disease pathogenesis during vitiligo and in this work I will investigate the 
contributions of Tregs to vitiligo. DCs are another cutaneous immune population that participate 
in peripheral tolerance. 
 
1.20: DCs are APCs capable of initiating innate and adaptive immune responses. 
When an infection occurs in peripheral tissue innate immune cells are quickly activated 
to non-specifically address infection but adaptive immune cells, like CD8+ and CD4+ T cells, 
are often required to ensure a sterilizing immune response. Antigen presenting cells (APCs) are 
unique in their ability to encounter pathogens and initiate both innate and adaptive responses.  
Dendritic cells (DCs) are APCs that express both classes of human leukocyte antigen (HLA) 
molecules, allowing them to present antigen to CD8+ and CD4+ T cells and subsequently 
activate the T cells to mediate adaptive responses. In mice DCs express MHC I and MHC II and 
can activate murine CD8+ T cells and CD4+ T cells. DCs frequently phagocytize both self and 
foreign proteins in the skin and rely on molecular sensors called Toll-like receptors (TLRs) or 
NOD-like receptors (NLRs) to signal whether DCs require to initiate an immune response. 
Surface bound or internal TLRs and NLRs recognize pathogen products and activate DCs. Upon 
activation DCs produce inflammatory cytokines that initiate innate immunity, process and 
present pathogenic antigen and migrate to lymph nodes where they present antigen to and 
activate CD4+ and CD8+ T cells bearing TCRs with affinity to the pathogenic antigen [167-
169]. 
 
1.21: Dendritic cells exist in skin and some can initiate T cell activation. 
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In 1868, Paul Langerhans used gold chloride and a light microscope to discovered non-
pigmented cells in human skin and while he initially thought they were nerve cells, they were 
later identified as skin resident DCs [170, 171]. Today we know that a few populations of DCs 
populate the skin and they can be distinguished based on the surface expression of specific 
proteins. Henri et al. used flow cytometry to look at MHCIIhigh DC populations in murine 
epidermis and dermis and found epidermal Langerhans cells (LHCs) that are CD207+CD103- 
and dermal dendritic cells (dDCs) that are CD207+CD103+ or CD207-CD103- [172, 173]. Skin 
dendritic cells can activate T cells to initiate adaptive immunity, as Henri et al. demonstrated that 
CD207+CD103+ dDCs isolated from the skin of transgenic mice with epidermal keratinocytes 
overexpressing ovalbumin (OVA) induced the proliferation of OT-1 CD8 T cells in in-vitro co-
cultures [172]. In these assays, only CD207+CD103+ dDCs were able to induce T cell 
proliferation, suggesting that not all skin DCs can activate T cells to initiate adaptive responses 
[172].  In fact a number of published studies established that DCs can suppress inflammatory 
immune responses and these DCs have been called tolerogenic DC. 
 
1.22: Tolerogenic dendritic cells can suppress inflammation. 
Some of the first evidence that demonstrated DCs can inhibit inflammation was presented 
by Jonuleit et al. They generated immature DCs and mature DCs from human PBMCs and 
observed that while mature DCs could induce the proliferation of naïve CD4+ T cells in in-vitro 
co-cultures, immature DCs induced irreversible impaired proliferation in naïve CD4+ T cells 
[174]. T cells co-cultured with immature DCs upregulated CTLA4 (which is also constitutively 
expressed by Tregs), produced anti-inflammatory IL10, and acquired the ability to suppress the 
antigen driven proliferation of Th1 T cells [174]. This data suggest DCs are able to induce a 
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regulatory-like state in naïve T cells promoting immunosuppression instead of inflammation.  
One in vivo study demonstrated that DCs internalize and present OVA antigens on MHC I and 
remain immature when mice are subcutaneously injected with OVA chemically linked to an 
antibody against CD205 (αDEC-205:OVA) [175]. After 12-14 days OT-1 cells injected into 
these mice are absent from LNs, spleen and blood and in a separate experiment, mice injected 
with αDEC-205:OVA mount no immune response after being re-challenged with OVA [175]. 
This data suggests that antigen presentation by immature DCs can induce peripheral tolerance 
and additional evidence reports that the maturation status of a DC when it presents antigen 
determines whether a DC promotes inflammation or tolerance.  
DCs exposed to TNF-α adopt a semi-mature phenotype and upregulate maturation 
markers like CD80, CD86, and CD40 but express reduced levels of IL-1β and IL-6 compared to 
DCs matured with LPS and anti-CD40 antibody [176]. TNFα-exposed semi-mature DCs 
protected mice from disease in a mouse model of EAE, but DCs matured with LPS plus anti-
CD40 could not [176]. Semi-mature DCs were also able to induce IL-10 producing Tregs and 
together these observations suggest specific cytokine signals induce tolerogenic function in DCs 
[176].  
Mature DCs may also promote tolerance in the right conditions by inducing Tregs. 
Varhasselt et al. reported that DCs generated from human PBMCs and matured with LPS 
induced the proliferation of CD4+ T cells better than immature DCs, when CD4+ T cells were 
cultured with either immature or mature DCs for 6 days [177]. CD4+CD25- T cells cultured with 
mature DCs acquired FoxP3 mRNA expression and were able to suppress the proliferation and 
cytokine production of allogeneic T lymphocytes activated by DCs in secondary cultures [177]. 
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DCs express the appropriate molecules to interact with both CD8+ and CD4+ T cells and 
tolerogenic DCs may induce Tregs to establish an anti-inflammatory environment.  
CD4+Foxp3+ inducible Tregs that develop from CD4+Foxp3- progenitors in peripheral 
lymphoid tissue instead of the thymus have been described by a number of groups. Yamagiwa et 
al. isolate naïve human CD4+ T cells that were CD45RA+ RO−. These CD4 cells incubated with 
TGF-β1 for 5 days acquired the ability to suppress T cells in secondary in vitro cultures [119].  
Similarly, murine CD4+CD25- cells incubated with anti-CD3 antibody, anti-CD28 antibody and 
TGF-β1 for 5 days in vitro, acquired Foxp3 expression [178]. These cells were able to suppress 
the proliferation of CD4+ T cells in response to anti-CD3 and CD28 antibodies in secondary in 
vitro cultures [178]. Together these data show that TGFβ can drive the induction of Tregs from 
CD4+Foxp3- progenitors and others have reported that the context of antigen presentation can 
induce Tregs as well. Kretschmer et al. transferred CD4+25- T cells into a Rag-/- mouse and then 
intraperitoneally injected mice with influenza antigen coupled to anti-DEC-205 antibody (αDEC-
HA) to target antigen to DCs without inducing DC maturation [179]. Adoptively transferred 
CD4+ cells proliferated, acquired CD25 and Foxp3 expression and also acquired suppressive 
capabilities in vivo and in vitro [179]. Kretschmer et al. examined optimal conditions for Treg 
induction and observed that low doses of αDEC-HA most efficiently induced Tregs [179]. 
Additionally, injecting anti-CD40 with αDEC-HA increased DC activation and reduced Treg 
induction [179]. Kretschmer’s observations suggest that low amounts of antigen presented by 
unactivated DCs can induce Tregs from naïve CD4 progenitors. Naïve CD4 cells can acquire 
regulatory function and tolerogenic DCs may coordinate with Tregs to maintain peripheral 




1.23: Langerhans cells are dendritic cells that reside in the epidermis and express specific 
markers. 
LHCs are the primary DC in the epidermis. Murine LHCs express MHCII and human 
LHCs express HLA-DR and whether or not LHCs prime adaptive responses or act as tolerogenic 
DCs is still debated. LHCs reside in the suprabasal layer of the epidermis in close proximity to 
melanocytes and attached to keratinocytes [180] and since they are the main APC in the outer 
most layer of skin, LHCs are potentially the immune system’s first point of contact with 
pathogens infecting the skin. In vitiligo melanocytes are targeted by the immune system and 
since LHCs are present in the skin adjacent to melanocytes, they may play some role in the 
immune processes mediating pathogenesis during disease.  
LHCs are distributed throughout the epidermis and in humans LHCs represent 
approximately 2% of all cells in the epidermis [181]. The density of LHCs in the skin varies as 
the palms and soles have the fewest LHCs, 200 per mm2, and the face and neck have the most 
LHCs, 970 per mm2 [182]. In epidermal sheets from adult mice, there are approximately 1000 
LHCs per mm2 [183, 184]. LHCs can be identified by the expression of a few particular 
markers. Birbeck granules are organelles found exclusively in LHCs and served as early markers 
to identify them [185] until intracellular and extracellular CD207 or Langerin, a type II Ca2+-
dependent lectin displaying mannose-binding specificity, was discovered as an LHC identifier 
[186, 187]. Other DCs in the dermis express Langerin as well but these DCs can be differentiated 
from LHCs based on the expression of CD103, EpCAM and CD8; with LHCs defined as 
CD207+CD103-EpCAM+CD8- [172, 173]. 
 
1.24: Langerhans cell development. 
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The ontogeny of LHCs has been well-studied in mice. LHC precursors seed the epidermis 
early in development and undergo a proliferative burst before LHC density in the skin settles to 
what we see in adult animals. Chorro et al. used flow cytometry to find LHC precursors in the 
epidermis of fetal mice at embryonic day 18. They found the number of epidermal precursors in 
the epidermis jumps from 50-100 cells/mm2 at embryonic day 18 to 1,000 cells/mm2 at 
postnatal day 2 [188].  This increased precursor number resulted from a proliferative burst in the 
first week of life as they reported 60-70% of precursors in the skin expressed the nuclear 
proliferation factor Ki67 at postnatal day 2 [188]. Tripp et al. prepared epidermal suspensions 
from epidermal sheets of mice and used flow cytometry to quantify MHCII and CD207 
expression. At postnatal day 3, MHCII+CD207dim populations could be identified and after 3 
weeks, MHCII+ LHCs in the epidermis expressed levels of CD207 comparable to adults [184].  
Once epidermal LHC numbers stabilize, they are extremely resilient. LHCs are 
radioresistant and progenitors can divide in the skin to replace LHCs that migrate to peripheral 
lymphoid tissue during the steady state or infection. Krueger et al. grafted human skin onto 
immunocompromised mice and found that human LHCs survived in the skin for up to 9 weeks, 
demonstrating that LHCs maintain their numbers for long periods of time without recruiting new 
bone marrow-derived progenitors [189].  Merad et al. lethally irradiated mice to generate bone 
marrow chimeras and found that while more than 90% of DCs, peritoneal macrophages, and 
blood monocytes came from donor bone marrow, 97% of LHCs in the skin were of host origin 
up to 18 months after transplantation [190]. These results imply that LHCs are resistant to lethal 
irradiation and further support the idea that LHCs can maintain epidermal numbers without 
recruiting cells from the bone marrow. In order to maintain epidermal numbers, LHCs precursors 
that reside in the skin undergo homeostatic proliferation. Merad et al. dosed their chimeras with 
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BrdU and found that after 30 days approximately 30% of the host-derived LHCs proliferated 
[190]. Kamath et al. also dosed mice with BrdU and found that 27% of LHCs in ear skin 
incorporated BrdU in a span of 14 days [191]. Together these results show that during adult life a 
significant portion of LHCs proliferate or proliferating precursors present in the skin give rise to 
new LHCs. LHCs also leave the skin during acute inflammation and under these extreme 
circumstances blood-derived LHCs precursors enter the skin and permanently replace LHCs 
[190, 192].  
 
1.25: Langerhans cells can migrate from the epidermis and enter skin draining lymph nodes. 
LHCs migrate from the epidermis to skin draining lymph nodes during the steady state 
and require CCR7 to do so [193]. LHCs also migrate to skin draining lymph nodes after 
exposure to inflammatory stimuli like UV light, tape stripping or contact sensitizers [190, 192, 
194]. One group further demonstrated this when they saw more LHCs migrating to skin draining 
lymph nodes in mice intradermally injected with West Nile virus or Semliki Forest virus than in 
mice dosed with vehicle [195]. Whether LHCs present antigen in an immunogenic or tolerogenic 
manner once they get to skin draining lymph nodes, is still not completely understood and a 
number of groups have presented conflicting evidence when attempting to answer that question.  
A number of studies used contact hypersensitivity (CHS) assays in mice to answer 
whether LHCs can prime T cell responses. To initiate a CHS response mice are first exposed to 
an antigen that is usually applied to shaved abdominal skin. This initial antigen exposure or 
sensitization stage will activate skin DCs that subsequently migrate to SDLNs and present the 
applied antigen to T cells with antigen-specific TCRs in an MHC-dependent manner. Antigen 
presentation primes the T cells and secondary exposure of murine skin to the same antigen some 
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days later, the elicitation stage, will provoke an immune response as skin DCs present the 
antigen to SDLN T cells and recruit them to antigen exposed skin [196, 197]. CHS experiments 
and other assays performed in the absence of LHCs in some instances revealed that LHCs prime 
T cell responses and sometimes suggested LHCs were dispensable for T cell priming and even 
suppressed priming.  
 
1.26: Evidence suggesting Langerhans cells prime T cell-mediated adaptive responses.  
To see what role LHCs play in initiating adaptive responses Bennett et al. used the 
Langerin-DTR mouse. Dosing this mouse with diphtheria toxin will deplete LHCs after 24 hours 
for 4 weeks allowing Bennett et al. to conditionally deplete LHC during CHS to test the 
requirement for LHC in priming T cell responses [198]. Bennett et al. induced a CHS response in 
LHC-depleted mice 3 days after i.p. injection of diphtheria toxin (DTX), and observed a reduced 
allergic response in mice without LHCs compared to controls with LHCs [198]. This result 
suggests that LHCs contribute to T cell priming, but this study was performed before Langerin+ 
dDCs were discovered and thus fails to consider that the reduced inflammation could result from 
reduced Langerin+ dDC numbers. Sullivan et al. used FACS sorting to isolate LCs from 
epidermal cell suspensions based on MHC II expression, cultured them with antigen in vitro and 
adoptively transferred these cells into naïve mice. These haptenized LCs were able to mediate 
CHS in naive animals suggesting LHCs can prime T cells [199].   
Data obtained in models aside from CHS also support an immunogenic role for LHCs. 
IL-1β injected intradermally into mouse ears upregulated MHC II expression on LHCs and when 
these LHCs were isolated from epidermal ear suspensions, they potently induced T cell 
proliferation when they were cultured with T cells in the presence of antiCD3 mAb [200]. 
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Human LHCs isolated from epidermal sheets have also been shown to stimulate allogeneic T 
cells in vitro, and in another study LHCs isolated from the epidermis induce the proliferation of  
naïve CD4+ T cells dDCs in vitro [201, 202].  Flacher et al. reported that mouse LHCs could 
prime antigen specific T cells. They targeted OVA antigen to LHCs by intradermally injecting 
mice with OVA coupled to an anti-DEC-205 antibody. They obtained epidermal sheets and 
culture sheets in vitro to isolate migratory LHCs and then cultured LHCs with CFSE labeled 
OVA specific OT-I CD8+ T cells or OT-II CD4+ T cells. LHCs were able to prime both OT-I 
and OT-II proliferation further supporting an immunogenic role for LHCs [203].  Mayerova et al. 
generated bone marrow chimeras using K14-OVAp mice, with keratinocytes that express OVA, 
as hosts. They lethally irradiated hosts and reconstituted mice with bone marrow from WT mice 
or bm8 mice that have a mutation in MHCI and can’t present OVA [204]. They found that OT-1 
cells could still proliferate in chimeras where only LHCs can present antigen suggesting LHCs 
can prime T cell responses [204]. Together this data suggests LHCs can prime T cell responses 
but a growing amount of evidence suggests LHCs play a tolerogenic role. 
 
1.27: Evidence suggesting Langerhans cells are dispensable for T cell priming or mediate 
tolerance. 
Some CHS studies have also demonstrated that LHCs are dispensable for T cell priming. 
Kissenpfennig et al. generated Langerin-DTR-EGFP mice with LHCs that express GFP and the 
DTR receptor [205]. Dosing mice with DTX effectively depleted LHCs and immune responses 
are comparable after CHS is induced in the absence or presence of LHCs [205]. This evidence 
suggests that LHCs do not contribute to T cell priming and Kaplan et al. made similar 
observations in mice that constitutively lacked LHCs. Unlike previous DTR models, in the 
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huLang-DTA mouse expression the active subunit of DTX is driven by the human Langerin 
promoter [206]. As a result, LHCs are constitutively depleted and Langerin+ dDC are unaffected 
[206]. Kaplan et al. induced CHS in these mice and observed that immune responses are 
increased by 2-fold in the absence of LHCs suggesting that LHCs are not only dispensable for 
priming immune responses, they may suppress immune responses as well [206]. Igyarto et al. 
also report exaggerated CHS responses in huLang-DTA mice and they saw increased numbers of 
antigen specific T cells in the skin and SDLNs LHC deficient mice [207]. Tregs were unaffected 
by the absence of LHCs as Igyarto et al. saw no difference in Treg number between WT and 
huLang-DTA mice and Tregs in SDLNs expressed similar levels of the skin homing receptor 
CCR4 in WT and LHC deficient mice [207]. LHC-derived IL-10 suppresses T cell priming 
during CHS as Langerin-Cre × IL-10fl/fl mice exhibited increased CHS responses compared to 
littermate controls [207].   
Shibaki et al. developed K14-mOVA mice that express membrane-bound OVA, under 
the control of a keratin 14 (K14) promoter to model self-antigen presentation and argue LHCs 
mediate peripheral tolerance [208]. They immunized K14-mOVA mice and littermate control 
mice with OVA and while control exhibited significant footpad swelling, K14-mOVA mice 
developed no significant immune reaction suggesting that transgenic mice are tolerant to OVA 
[208]. LCs from K14-mOVA mice but not WT mice could activate OT-I cells in in vitro co-
cultures suggesting that LHCs may mediate peripheral tolerance by presenting antigen to T cells 
in SDLNs [208]. Together these observations show that LHCs don’t participate in T cell priming 
during adaptive response and can in some cases induce tolerance.  
Since LHCs express both HLA molecules in humans and MHC molecules in mice they 
can present antigen to CD8+ T cells and CD4+ T cells. Skin resident memory Tregs that are 
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capable of attenuating immune responses upon activation have been described [151] and LHCs 
could conceivably mediate peripheral tolerance in the skin by activating these Treg populations. 
In support of this hypothesis, Seneschal et al. found that human LHCs can induce the 
proliferation of skin resident memory Tregs. LHCs or dDCs isolated from the skin of multiple 
individual donors were cultured with skin resident memory T cells in vitro. After 6 days LHCs, 
but not dDCs, induced T cell proliferation and the proliferating T cells in this culture were 
CD4+CD25+FoxP3+ skin resident memory Tregs [209]. Tregs obtained from this culture were 
able to suppress the proliferation of skin resident T effector memory (Tem) cells in secondary 
co-cultures and since LHC-mediated Treg proliferation is significantly reduced in the presence of 
HLA-DR and HLA-DP blocking antibodies, the proliferation of skin resident memory Tregs is 
antigen-dependent [209].   
Using immunoflorescent microscopy Seneschal found Tregs contacting LHCs in freshly 
obtained human skin and after performing Ki67 staining, found Tregs proliferate in the epidermis 
[209].  These in vivo observations were consistent with their findings that LHCs can induce skin 
resident Treg proliferation. LHCs cultured with CFSE labeled skin resident T cells in the 
presence of low doses of heat-inactivated C. albicans induces increased proliferation of Tregs 
[209]. Interestingly, high doses of C. albicans induced Tem proliferation and these studies 
suggest LHCs can be immunogenic or tolerogenic depending on the context of antigen 
presentation [209].  This result seems to reflect the conflicting findings of those studying the 
contributions of LHCs to immunity. In the data previously reviewed, LHCs can prime immunity 
in some cases but under the right circumstances LHCs can induce tolerance.  Additional studies 
performed in in vivo models of inflammation may contribute valuable information to this 
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discussion and our model of vitiligo presents a valuable opportunity to study how LHCs behave 
in a model of autoimmunity.  
While some cells reside in tissue like LHCs, others must be recruited to the periphery to 
participate in inflammation or peripheral tolerance. To get to peripheral tissues, cells like Teffs 
or Tregs that are activated and expanded in the SLO organs follow chemokines that provide 
migratory signals. Chemokines and their receptors coordinate a balanced immune response by 
carefully orchestrating the recruitment of inflammatory and tolerogenic mediators. If we 
understand the anti-inflammatory chemokine signals that facilitate tolerance and the pro-
inflammatory signals that facilitate Teff migration during vitiligo, we can design interventions 
that target the appropriate pathways to curtail cutaneous inflammation and promote 
repigmentation. As a part of this study I investigated the chemokine signals that promote Treg 
migration during vitiligo and the following reviews the role of chemokine in immunity.  
 
1.28: Chemokines and their receptors direct cell migration. 
Chemokines are small positively charged cytokines that can direct the migration of cells 
expressing the appropriate receptors. The immune system protects the entire body, and to 
respond to inflammation at any particular locale immune cells rely on the expression of 
chemokines to traffic to the appropriate places. Chemokines can be segregated into categories 
based on their structure. The two major groups are “CXC chemokines” that have two cysteine 
residues near the N-terminus that are separated by another amino acid, and “CC chemokines”, 
with two adjacent cysteine residues near the N-terminus [210].  “C chemokines” with one 
cysteine residue and “CX3C chemokines” with two cysteine residues separated by 3 amino acids 
exist as well, but few chemokines with these structural arrangements exist [210]. Cells can 
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secrete chemokines to direct cell migration or tether chemokines on their surface via interactions 
with molecules known as glycosaminoglycans (GAGs). Surface chemokine immobilization 
mediated by GAGs was demonstrated in vivo [211] and Proudfoot et al. used chemokines with 
reduced ability to oligomerize and bind GAGs to demonstrate that GAG-binding and chemokine 
oligomerization are essential for the ability of chemokines to promote trafficking [212]. 
Chemokine tethering ensures the stable expression of chemokine at the local production site to 
mediate the directed migration along an immobilized gradient for cells with the appropriate 
receptor [212, 213]. Chemokine receptors are differentially expressed on the surface of all 
leukocytes and cells that express the cognate receptor for a specific chemokine can migrate in 
response to chemokine gradients. Structurally, chemokine receptors have seven transmembrane 
domains that mediate signaling via G proteins after binding chemokine [214].  An effective 
immune response depends on the proper localization of immune cells and chemokines, and their 
receptors position immune cells during inflammation. 
 
1.29: Chemokine signaling facilitates T cell priming in secondary lymphoid organs. 
The repertoire of chemokine receptors that T cells express changes when T cells are 
primed in the SLOs. Ferguson et al. labeled OT-1 cells with CFSE, adoptively transferred them 
into mice with OVA-pulsed BMDCs, and used flow cytometry to reveal that the receptors CCR5 
and CXCR3 are upregulated on activated OT-1s [215]. CCR5 is the receptor for CCL3, CCL4 
and CCL5 and CXCR3 is the receptor for CXCL9, CXCL10 and CXCL11 [216]. Both of the 
receptors can be expressed by various immune cells, including CD8+ T cells, Th1 CD4+ T cells, 
and Tregs [216]. Ferguson’s observations demonstrated that initial priming events induce the 
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expression of CCR5 and CXCR3 on activated CD8+ T cells and CCR5 expression by CD8 T 
cells can facilitate CD8+ T cells interactions with antigen presenting DCs in lymphoid tissue.  
Castellino et al. used two-photon microscopy to image interactions between OT-II 
CD4+ T cells, OT-I CD8+ T cells, and DCs in the LNs of live mice after OVA immunization 
and they observed that interactions between T cells and DCs were facilitated by DC- and 
CD4+ T cell-expressed CCL3 and CCL4 [217]. Blocking antibodies against CCL3 or CCL4 
consistently reduced these interactions and CCR5-/- CD8 T cells contacted DCs with less 
frequency than WT CD8s, supporting the importance of CCR5 in mediating contact between 
CD8+ T cells and DCs during priming [217]. Furthermore, treating mice with CCL3 and 
CCL4 blocking antibodies interferes with the ability of mice to form a functional memory 
CD8+ T cell population in response to immunization with OVA, suggesting that CCR5 plays 
a crucial role in the initiation of immune responses [217]. Hughes et al. also used imaging to 
demonstrate that CCR5 mediates contact between DCs and CD8+ T cells in lymphoid tissue 
[218].  
Other chemokines may direct T cells to antigen presenting DCs during priming. DCs 
express CCL17 to attract CCR4-expressing CD8+ T cells and DC-derived CCL17 increased 
contact time between DCs and CD8+ T cells [219]. Furthermore, DCs in the lymph node tether 
T cells with CXCL10 [220], and in vitro studies demonstrated that the chemokines CCL19, 
CCL21, CXCL10, and CCL5 were bound to the surface of LN-derived DCs and tethered T 
cells in an antigen-independent manner [221]. These observations demonstrate that DCs can 
make chemokines to attract and tether T cells in lymphoid tissue and increase the efficiency of T 
cell priming in the initial phases of an immune response.  
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In peripheral tissue DCs have also been shown to use chemokines to facilitate 
interactions with disease-causing effectors. Immunofluorescence staining on psoriatic skin 
lesions revealed that CCL20 and CCR6 were highly expressed among dermal clusters between 
HLA-DR+ DCs and skin-infiltrating CD3+ T cells that routinely form in lesional skin [222]. 
DCs and T cells analyzed by flow cytometry both expressed CCR6 in psoriatic skin a 
CCL20/CCR6 signaling likely mediates the interactions observed between the two cells in 
lesional skin [222]. 
 
1.30: Chemokine signaling drives activated T cell migration to sites of peripheral 
inflammation. 
The chemokine signals that facilitate the migration of activated T cells out of the 
lymphoid organs have been extensively studied. After activation, effector T cells downregulate 
receptors like CCR7 that facilitate entry into the LN and after multiple divisions, activated T 
cells upregulate the S1P1 receptor that mediates LN exit [223]. After LN exit, T cells follow 
chemokine gradients that guide them to sites of inflammation and the chemokine receptors that 
an T cell expresses upon activation depends on the lymphoid environment that the cell is 
primed in. T cells activated by DCs from SDLNs expressed skin homing receptors like CCR4 
and CLA and migrated more efficiently to inflamed skin than those activated by DCs from gut-
derived lymphoid tissues [87]. DCs from gut-associated lymphoid tissue induce the expression of 
the chemokine receptor CCR9 and the integrin α4β7, both crucial for gut specific homing, on 
activated CD8+ T cells [224, 225]. Activated CD4+ T cells can differentiate into a number of 
subclasses and the chemokine receptors that they express are tied to their differentiation status 




1.31: Chemokine signaling promotes Treg localization during homeostasis. 
Chemokine signaling also plays a role in Treg function and localization during 
homeostasis. Two groups used flow cytometry to analyze the expression of chemokine receptors 
on circulating Tregs isolated from peripheral blood and found that the repertoire of chemokines 
expressed by Tregs changes from birth to adulthood. Tregs from neonatal cord blood express 
chemokine receptors that mediate lymphoid tissue homing like CD62L, CCR7, and CXCR4, and 
chemokine receptors that mediate gut homing such as CCR9 and α4β7 [226, 227]. By 3 years of 
age Tregs in peripheral blood upregulate inflammatory chemokine receptors and chemokine 
receptors that mediate entry into the skin and lung, such as CXCR3, CCR2, CCR4, CCR5, 
CCR6, CCR8; a few Tregs express the gut homing receptors CCR9 and α4β7 [226, 227]. 
Chemotaxis assays performed on Tregs isolated from infants and adults demonstrated that Tregs 
exhibit different migratory properties depending on the age of the donor [226]. Tregs from cord 
blood migrated in response to CCL19 and CCL25, the ligands for CCR7 and CCR9, 
respectively, while adult Tregs migrated in response to CCL22, the ligand for CCR4 [226]. 
These findings demonstrate that the shift in homing receptor expression observed on Treg cells 
seems to correspond to their actual migration properties.  
Murine models allow us to study early chemokine signals that govern Treg migration, 
and chemokine signaling positions murine Tregs in the skin during early development. Using 
flow cytometry, Scharschmidt et al. found a wave of Tregs enter mouse skin after postnatal day 6 
[149] and require CCR6 to follow hair follicle-derived CCL20 to migrate to the skin during 
neonatal development [152]. RT-PCR revealed that CCL20 RNA was upregulated in the skin of 
neonatal mice during the height of Treg migration to the skin and Tregs isolated from the skin of 
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mice during this period expressed CCR6 RNA [152]. In vitro, the exposure of human fetal skin 
explants to commensal skin bacteria or bacterial peptides augmented CCL20 expression, 
highlighting a role for commensal bacteria in promoting cutaneous Treg populations. Flow 
cytometry revealed that Tregs in neonatal skin expressed significantly higher levels of CCR6 
than Tregs in SDLNs and skin-resident CD4+ and CD8+ Teffs [152]. CCR6-/- Tregs co-
transferred into RAG2-/- mice with WT Tregs exhibited a decreased ability to migrate to the skin 
of 2 week old mice compared to WT Tregs, and these results demonstrated that CCL20/CCR6 
interactions play an important role in establishing skin resident Treg populations during neonatal 
development [152]. 
 
1.32: Chemokine signaling promotes Treg migration and suppression in peripheral tissues. 
Various chemokine signals promote Treg migration to peripheral tissues during 
inflammation. Tregs upregulate specific chemokine receptors in response to activating stimuli 
and this facilitates lymph node exit and migration to non-lymphoid tissue entry. Lee et al. 
reported that murine Tregs initially express secondary lymphoid homing receptors after they 
develop in the thymus, and these CD62L+CCR7+CXCR4low Tregs preferentially migrate to the 
spleen and LNs [228]. Tregs in LNs up-regulated inflammatory receptors like CCR2, CCR4, 
CCR5, CCR6, CCR8, CCR9, CXCR3, CXCR5, and CXCR6, while simultaneously down-
regulating LN homing receptors in response to antigen exposure [228]. This shift in chemokine 
receptor expression upon antigen exposure facilitated efficient Treg migration to non-lymphoid 
tissues such as bone marrow and the small intestine [228].  Another in vitro study analyzed the 
ability of Tregs from peripheral human blood to migrate to various chemokines and revealed that 
Tregs readily migrated to CCL1, the ligand for CCR8, as well as CCL22 and CCL17, the ligands 
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for CCR4 [229]. Immunofluorescence confirmed that Tregs in human peripheral blood express 
skin homing receptors CCR8 and CCR4, suggesting circulating Tregs are primed to follow 
chemotactic signals to peripheral tissue [229].  
In a mouse model of GVHD Tregs required CCR8 signaling to prevent lethal GVHD. 
WT and CCR4-/- Tregs adoptively transferred into hosts were able to suppress lethal GVHD but 
CCR8-/- Tregs were unable to mediate a similar protective effect [230]. CCR8-/- Tregs were able 
to efficiently migrate to all lymphoid and non-lymphoid tissues analyzed but exhibited an 
increased susceptibility to death due to their inability to interact with DCs [230]. In this instance 
CCR8 signaling does not facilitate Treg-mediated suppression by promoting migration to 
peripheral tissues. Instead, CCR8 signaling facilitates Treg function by mediating interactions 
with DCs that promote Treg survival. In another transplantation model, Treg chemokine 
signaling facilitates the suppressive capabilities of Tregs. Zhang et al. observed that Tregs 
migrated from blood to a transplanted allograft where they promoted graft survival [231]. They 
observed that Tregs required CCR2, CCR4, and CCR5, as well as P- and E-selectin ligands to 
ultimately suppress T effector cell migration and proliferation in LNs and allografts [231].  
CCR4 signaling mediates Treg suppression in various models of inflammation, including 
a cardiac transplantation and IBD model of disease [232, 233]. Notably, Sather et al. 
demonstrated that the CCR4 signal facilitates Treg migration to the skin during inflammation. 
They performed flow cytometry on tissue from Foxp3GFP mice and observed Tregs distributed 
among all the tissues they analyzed, including the skin [154]. While Tregs in all tissues express 
some level of CCR4, nearly all the Tregs in the skin expressed CCR4 and CD103 and Tregs in 
SDLNs upregulated CCR4 and CD103 after exposure to antigen [154]. Sather et al. generated 
mixed bone marrow chimeras with congenically marked WT and CCR4-/- Tregs to compare their 
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ability to migrate to various tissues and found that CCR4-/- Tregs exhibited significantly impaired 
migration to the skin and lungs compared to WT Tregs [154]. CCR4 signaling in Tregs was 
important for protecting these tissues from inflammation, as only WT Tregs and not CCR4-/- 
Tregs adoptively transferred into neonatal scurfy mice could prevent systemic autoimmunity and 
skin inflammation, to which scurfy mice eventually succumb [154]. WT Tregs prevented 
inflammation in the skin, lungs, and liver of scurfy mice, but CCR4-/- Tregs only prevented 
inflammation in the liver and not the skin or lungs [154]. These results highlight a role for CCR4 
in promoting Treg migration and suppression in the skin and lung. 
CXCR3 is normally expressed by activated CD8+ T cells and Th1 CD4+ T cells but 
Tregs can also express CXCR3, and in some instances require CXCR3 signaling to mediate 
suppression. Koch et al. used flow cytometry to observe that Tregs in the spleens of WT mice 
express CXCR3 and found that Tregs upregulate CXCR3 expression in response to Th1 
inflammation [234]. T-bet is a transcription factor that controls the expression of Th1-associated 
genes like CXCR3, and Tregs seemed to require Th1 identity to suppress inflammation as WT 
Tregs but not T-bet-/- Tregs could suppress lymphadenopathy and splenomegaly upon adoptive 
transfer to scurfy mice [234]. In a model of EAE, Tregs require CXCR3 to migrate to the site of 
inflammation. When EAE is induced in WT and CXCR3-/- mice, CXCR3-/- mice exhibit more 
severe chronic disease and increased loss of myelin and axonal injury compared to WT mice 
[235]. Inflammation is more severe in the absence of CXCR3 and this correlates with a reduction 
of Tregs among CNS-infiltrating cells in CXCR3-/- mice [235]. CXCR3 signaling can also 
mediate Treg suppression in the skin. Suga et al. induced contact hypersensitivity (CHS) in WT 
and CXCR3-/- mice and observed that recovery from Th1-type CHS was delayed in CXCR3-/- 
mice [236]. After using microscopy to quantify fluorescently-labeled Tregs in inflamed ears, 
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Suga et al. counted less Tregs in the skin of CXCR3-/- mice compared to WT mice during CHS, 
suggesting that Tregs require CXCR3 to migrate to the skin and suppress Th1-mediated 
inflammation [236]. CXCR3+ Tregs injected i.v. into CXCR3-/- mice before CHS induction were 
capable of normalizing recovery from Th1 type inflammation, further supporting a role for 
CXCR3 in mediating Treg suppression in the skin [236]. 
CCR6-/- Tregs migrate to the site of inflammation less efficiently than WT Tregs in an 
inducible mouse model of EAE [237]. Chaudhry et al. observed that Stat3flox×Foxp3CRE Tregs 
and not WT Tregs fail to prevent colitis when adoptively transferred into Rag-/- mice with 
disease-causing CD4+ T effectors [238]. While Stat3flox×Foxp3CRE Tregs can suppress Teffs in 
vitro, they express significantly lower levels of CCR6 and exhibit a diminished capacity to 
migrate to the gut when compared to Tregs from littermate controls [238]. Similarly, CCR6-/- 
Tregs exhibited diminished suppressive capabilities compared to WT Tregs in another mouse 
model of colitis and the number of CCR6-/- Tregs relative to effectors was reduced compared to 
WT Tregs [239]. These studies demonstrate that CCR6 can mediate Treg suppression in the gut 
and central nervous system during inflammation by facilitating their migration to these 
peripheral tissues. CCL20/CCR6 signaling has also been reported to mediate Treg suppression of 
inflammation in the skin.  Barth et al. subcutaneously injected the footpads of WT and CCR6-/- 
mice with Leishmania major and found that footpad swelling was enhanced in the absence of 
CCR6 [240]. Disease-causing T cells were more abundant in the skin of CCR6-/- mice and the 
number of Tregs was significantly reduced in the skin draining lymph nodes of CCR6-/- mice 
compared to WT mice [240]. Interestingly the number of Tregs in the skin was comparable 
between WT and CCR6-/- mice but nonetheless the importance of CCR6 for recruiting Tregs to 
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the draining lymph node to suppress excessive effector cell activation and subsequent skin 
damage is clear. 
CCR5 signaling can also mediate Treg migration to peripheral tissue and subsequent 
suppression during inflammation. In a mouse model of GVHD, CCR5-/- Tregs were less effective 
than WT Tregs in suppressing GVHD and prolonging median survival time of engrafted host 
mice [241]. While CCR5-/- Tregs isolated from host GVHD target tissues like the spleen and 
liver were capable of suppressing T cell proliferation in vitro, significantly fewer CCR5-/- Tregs 
infiltrated GVHD affected tissues [241]. This suggests that the reduced ability of CCR5-/- Tregs 
to suppress GVHD stems from a migratory defect and not a functional defect. Similarly, CCR5 
signaling promotes the accumulation of Tregs in the heart in a model of myocardial infarction 
that subsequently prevents uncontrolled post-infarction inflammation [242]. CCR5 ligands were 
highly expressed in the infarcted myocardium of WT mice and after the induction of myocardial 
infarction in WT and CCR5-/- mice there were significantly fewer Tregs in the mononuclear 
infiltrate from the infarcted hearts of CCR5-/- mice [242]. This reduced Treg migration 
accompanied increased inflammation indicated by the marked upregulation of proinflammatory 
cytokines in the hearts of CCR5-/- mice [242].  
In paracoccidioidomycosis, a fungal infection, Tregs accumulate in skin lesions and 
contribute to persistent infection by suppressing local antifungal immune responses [243]. Tregs 
in the skin during infection express CCR5 and CCR5 ligands are highly expressed in lesional 
skin [243]. In a mouse model of this disease, Tregs in CCR5-/- mice exhibit impaired migration 
to pulmonary lesions [244] and together these studies suggest CCR5 may promote Treg 
localization and suppression in peripheral tissues. CCR5 signaling has also been reported to 
promote the cutaneous localization of Tregs during inflammation. Yurchenko et al. used RT-
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PCR and flow cytometry to demonstrate that Tregs isolated from the LNs of mice express more 
CCR5 at the transcriptional and protein level than CD4 T cells [245]. Consequently, Tregs 
migrated more readily than CD4+ T cells in response to the CCR5 ligands CCL3, CCL4, and 
CCL5 during in vitro transwell assays [245]. Tregs isolated from CCR5-/- mice suppress the in 
vitro proliferation of T cells in response TCR stimulation as well as WT Tregs, but when Rag-/- 
mice are infected with Leishmania major and reconstituted with effectors, CCR5-/- Tregs fail to 
control effector T cell expansion and IFN-γ production in inflamed dermis, while WT Tregs are 
effective [245]. CCR5-/- Tregs migrated to the inflamed dermis less efficiently than WT Tregs 
[245] and these results suggest that CCR5 promotes the migration of Tregs to the skin during 
inflammation to mediate effector suppression.  
 
1.33: Working toward better understanding of the regulatory factors involved during vitiligo. 
In order to mediate depigmentation, CD8+ T cells must overwhelm the mechanisms of 
peripheral tolerance that the body has evolved to prevent autoimmunity. While the factors that 
contribute to depigmentation have been well studied, few have addressed the suppressive factors 
at play during disease. Vitiligo skin is characterized by patchy depigmentation with white spots 
surrounded by unaffected skin, and cases of complete depigmentation are rare. Why don’t 
disease causing Teffs depigment the entire epidermis? What causes Teffs to eventually stop 
where they do, at the lesional border?  To answer these questions I hypothesize that regulatory 
factors function in the skin during vitiligo to keep Teffs from mediating their maximum 
destructive potential. If we understand the mechanisms of suppression used during vitiligo, we 
can use this information to improve existing treatment strategies or discover new ones. Tregs and 
LHCs reside in the skin during vitiligo and have been shown to potentiate T cell responses 
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during inflammation, as well as autoimmunity. In light of this they are properly positioned to 
protect melanocytes in the skin during disease and I investigated whether these populations 
suppress depigmentation during vitiligo.  
In the following chapters I use a number of strategies within our mouse model of vitiligo 
to investigate the contributions of Tregs and LHCs to vitiligo. I investigated the severity of 
disease in the absence of Tregs in Chapter I and explore their interactions with Teffs in the skin 
during human and mouse disease. In Chapter II I investigated whether LHCs play in 
immunogenic or tolerogenic role during vitiligo and the mechanisms of their function during 
disease. Finally in Chapter III I investigated the chemotactic signals that facilitate Treg function 




CHAPTER II: REGULATORY T CELLS SUPPRESS DEPIGMENTATION 
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In this study I explored the role of T regulatory cells (Tregs) in suppressing effector T 
cell responses during vitiligo. In a mouse model of vitiligo we observed that depletion of Tregs 
with both CD4-depleting antibody and in diphtheria toxin-treated Krt14-Kitl×Foxp3-DTR hosts 
resulted in worsened disease as well as an increase in Teff skin infiltration, suggesting that Tregs 
also play a suppressive role in vitiligo. While characterizing the distribution of Tregs in the skin, 
I observed that regions of skin with more Tregs depigment less readily in our mouse model of 
disease.  This suggests that Tregs function in the skin under homeostatic conditions to suppress 
depigmentation and that Treg number in the skin is important for suppressing disease. In vitiligo 
patients the Treg/Teff ratio is decreased in lesional skin compared to non-lesional skin, further 
reflecting what I observed in our mouse model and further supporting the importance of Treg 
number in the skin for suppression. Using in situ confocal microscopy we observed that Tregs 
directly contact Teffs in lesional mouse skin during vitiligo, and we observed similar interactions 
in human lesional skin, suggesting that Tregs interact with Teffs in the skin to potentially 





Tregs in human vitiligo 
Treg suppressive function may be compromised during vitiligo. Tregs isolated from the 
PBMCs of vitiligo patients were reported to have a reduced ability to suppress the proliferation 
and cytokine production of Teffs isolated from the vitiligo PBMCs in vitro [246]. In contrast, 
another study reported that Tregs in PBMCs from vitiligo patients and healthy controls equally 
suppress CD4+ T Cell proliferation but Tregs from vitiligo patients have a reduced capacity to 
migrate to skin [247].  Whether the presence of Tregs in the skin of vitiligo patients affects 
disease severity has not been definitively proven. Ahmed et al. compared Treg numbers from 
vitiligo patients and healthy controls and saw no significant differences in the skin or in PBMCs 
[248]. Terras et al. also saw no differences in skin Treg number after performing 
immunohistochemistry on skin biopsies from vitiligo patients and healthy controls [249]. In 
contrast, another study where immunohistochemistry was performed on skin biopsies from 
vitiligo patients found the CD4/CD8 ratio is decreased among the skin infiltrating cells of vitiligo 
patients [62]. Abdallah et al. also performed immunohistochemical analysis of skin biopsies and 
saw a significant reduction in the number of Foxp3+ Tregs [250]. In another study Klarquist et 
al. stained frozen sections from lesional vitiligo and healthy skin with CD3 and FoxP3 to count 
Tregs and observed that the percentage of Tregs among skin infiltrating T cells is reduced in 
vitiligo patients compared to healthy controls [247]. In this study Klarquist found circulating 
Treg numbers were unchanged in vitiligo patients but CCL22 expression – which facilitates Treg 
skin migration – was reduced in vitiligo, potentially explaining the reduced Treg number in 
vitiligo skin [247]. These studies suggest that reduced Treg number in the skin during vitiligo 




Treg suppression in mouse models of vitiligo 
A few groups performed studies in mouse models of vitiligo to demonstrate that 
increased Treg recruitment to the skin correlates with reduced disease severity. In two different 
murine models of spontaneous vitiligo, gene gun treatment to induce CCL22 expression in the 
skin led to increased cutaneous Treg migration and decreased depigmentation [155]. Another 
group found that adoptively transferring 2×105 Tregs to 3 week old vitiligo prone mice increased 
numbers of Tregs in the skin and almost completely abrogated development of disease [251]. 
Teffs in SDLNs are not suppressed and in light of this, the authors correlated disease prevention 
with increased Treg number and suppression specifically in the skin [251].  Miao et al. injected 
vitiligo prone mice with PD-L1-Fc and this enhanced Treg accumulation in the skin and 
markedly reversed depigmentation [252]. These results support the hypothesis that Treg number 
in skin is important for reducing Teff-driven depigmentation and that mouse models of vitiligo 
will prove invaluable for understanding exactly how Tregs work during vitiligo. 
A number of groups have developed mouse models of vitiligo to investigate the role of 
Tregs by CD4 or CD25 depletion. Gregg et al. developed a spontaneous mouse model of vitiligo 
based on the human tyrosine epitope, Tyr369, recognized by CD8+ T cells. They bred AAD mice 
that express a recombinant MHC I molecule containing the binding region of human HLA-
A*0201 specific for Tyr369 to albino mice that do not express tyrosine in the thymus and thus do 
not establish immunological tolerance to tyrosine [74]. As result, autoreactive T cells with TCRs 
targeting the melanocyte protein tyrosinase escape thymic deletion and mediate depigmentation 
as early as postnatal day 3 [74]. Chatterjee et al. used the h3AT2 mouse, which spontaneously 
develops vitiligo and expresses an HLA-A2 restricted human TCR that recognizes the tyrosinase 
epitope tyrosinase368-376 [75, 251]. Both of these groups observed an increase in the severity of 
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vitiligo after treating mice with CD4 depleting antibody or CD25 depleting antibody that 
preferentially targets Tregs [74, 251] and these results suggest that CD4+CD25+ Tregs suppress 
depigmentation during vitiligo.  
Despite the increasing evidence that Tregs affect disease severity, many questions remain 
regarding Treg function. We have developed a mouse model of vitiligo in which hosts develop 
depigmentation characteristic of human disease. In our model, IFNγ drives CD8+ T cell 
destruction of melanocytes that are retained in the epidermis and the hair retains pigment, even in 
depigmented skin. The similarities between our mouse model of vitiligo and human disease 
allow us to investigate how Tregs affect vitiligo in the proper context and potentially address 
some of the inconsistencies about how Tregs function in vitiligo and other cases of peripheral 
inflammation. In light of this, I used our mouse model of vitiligo to investigate the role of Tregs 
during vitiligo.  
 
2.3 Results 
2.3.1: CD4 Depletion Exacerbates Vitiligo. 
I tested previously established methods of Treg depletion in our mouse model of vitiligo 
to assess the severity of disease in the absence of Tregs. I hypothesized that mice without Tregs 
will exhibit increased disease since two other groups have observed that Tregs suppress vitiligo 
in their mouse models of disease using CD4 or CD25 depleting antibodies [74, 251]. I induced 
vitiligo as previously described in Krt14-Kitl×FoxP3-GFP mice, with Tregs expressing GFP 
under control of the FoxP3 reporter.  After 2 weeks, I treated one group of mice with 0.2mg of 
GK1.5 CD4 depleting antibody once weekly to deplete Tregs. To serve as controls, I treated 
another group of mice with PBS. After 5 weeks of treatment, a separate observer blinded to the 
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experimental groups quantified the severity of depigmentation on ears, nose, hind footpad and 
tail skin.  Each site was given a vitiligo score that corresponds to the percent of skin depigmented 
and the score at each site can be combined to represent a total vitiligo score. When I compared 
the severity of disease, I observed that CD4-depleted mice exhibited almost 3 times more 
depigmentation than PBS treated mice, and CD4-depleted mice had an average vitiligo score of 
13.6 ± 1.408 compared to an average score of 4.3 ± 1.375 in PBS controls (Fig 1A). This mirrors 
observations from the other previously described mouse models of vitiligo. Previous studies in 
our mouse model demonstrated that disease severity correlates with the number of disease 
causing Teffs in the skin [79, 253]. Seven weeks after disease induction, I harvested skin from 
mice, mechanically separated the dermis from the epidermis and used flow cytometry to count 
the number Teffs in digested tissues. I found significantly more Teffs in the skin of mice treated 
with CD4-depleting antibody compared to mice treated with PBS (Fig 1B). I also observed more 
Teffs in the SDLNs of mice treated with CD4-depleting antibody but this difference was not 
significant. The number of Tregs relative to Teffs was significantly decreased in the SDLNs, tail 
and ear skin of CD4-depleted mice (Fig 1C), confirming that CD4 depletion affects Treg 
number. This data suggests that CD4 T cells are dispensable for disease progression and a subset 









































































































































































































































































































































Figure 1: CD4 depletion exacerbates vitiligo. Tissues harvested from Krt14-Kitl×FoxP3-GFP 
mice with vitiligo and treated with either PBS or GK1.5 CD4 depleting antibody (CD4 Depl) 
were analyzed by flow cytometry 5 weeks after disease induction. Graphs depict; (A) 
quantification of depigmentation; (B) the average number of Thy1.1+ Teffs normalized to the 
number of live single cells in the indicated tissues; or (C) The number of  GFP+ Tregs divided 
by the number of Thy1.1+ Teffs in the indicated tissues represented as a Treg/Teff ratio; N=10, 






2.3.2: CD4 depletion does not increase Teff proliferation in the skin. 
I hypothesized that increased Teff proliferation in the skin was responsible for the 
significant increase in Teff number in the absence of Tregs. To test this, I induced vitiligo and 
injected Bromodeoxyuridine (BrdU) i.v. 6 hours before takedown into mice that received CD4-
depleting antibody or PBS. BrdU is a thymidine analog that cells incorporate into newly 
synthesized DNA during replication and proliferating cells can be identified with antibodies 
against BrdU. I sacrificed mice 3 or 5 weeks post disease induction, processed skin and SDLN 
tissue into single cell suspensions, permeablized and stained cells with fluorescent anti-BrdU 
antibodies and identified proliferating cells with flow cytometry. I found few Teffs in mice 
treated with PBS or CD4-depleting antibody incorporated BrdU in the skin. In the SDLNs I 
observed a significant increase in Teff proliferation in mice treated with CD4 depleting antibody 
at week 3 and week 5 (Fig 2A). Since Teffs in the skin do not incorporate more BrdU after 
treatment with CD4 depleting antibody, it is unlikely that Teff proliferation in the skin was 
responsible for the increase in Teff number in the absence of Tregs. In contrast to Teffs, I 
observed that CD45- cells incorporated BrdU in the skin at week 3 and week 5 and amount of 
BrdU incorporating cells does not significantly change after treatment with CD4 depleting 
antibody. 
 
2.3.3: Tregs suppress depigmentation in a mouse model of vitiligo. 
CD4 depletion will affect Tregs and all other CD4+ cells. To address the role of only 
Tregs in vitiligo, I generated Krt14-Kitl×FoxP3-DTR mice. In these mice Tregs express the 
diphtheria toxin receptor under control of the FoxP3 promoter and treatment with diphtheria 
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Figure 2: CD4 depletion does not increase Teff 





Figure 2: CD4 depletion does not increase Teff proliferation in the skin. Vitiligo mice 
treated with either PBS or GK1.5 CD4 depleting antibody (CD4 Depl) were dosed with 
Bromodeoxyuridine (BrdU) i.v. 6 hours before harvested tissues were analyzed using flow 
cytometry. (A) Graph depicts the average number of BrdU incorporating Thy1.1+ Teffs 
normalized to the number of single cells in the indicated tissues; (B) Graph depicts the average 
number of BrdU incorporating CD45- cells normalized to the number of single cells in the skin is 




deplete Tregs since they are crucial for development and survival, as scurfy mice with mutations 
in the Foxp3 gene die within 3 to 4 weeks of age [113]. Depletion of Tregs only during vitiligo 
will allow mice to develop normally without other lethal autoimmunity. I induced vitiligo in 
Krt14-Kitl×FoxP3-DTR mice and, 2 weeks post disease induction, I specifically depleted Tregs 
by treating mice with 50µg/kg of DTX or PBS every other day for 2 weeks. I chose to treat mice 
for 2 week windows since repeated DTX administration results in toxicity after continuous 
dosing for 2 weeks. At 7 weeks post disease induction, a separate observer blinded to the 
experimental groups quantified the severity of depigmentation on ears, nose, hind footpad and 
tail skin to generate a vitiligo score. I observed that depigmentation was increased in DTX 
treated mice compared to PBS treated mice (Fig 3A). I processed the SDLNs and skin of these 
mice into single cell suspensions and used flow cytometry to compare Teff numbers in mice 
treated with DTX or PBS. I observed the number of Teffs in the SDLN of DTX treated mice is 
increased but not significantly (Fig 3B). I also observed an increase in the number of Teffs in the 
ear skin but interestingly not in the tail skin of DTX treated mice (Fig 3B). When I measured 
disease severity I observed that the difference in depigmentation between DTX treated and PBS 
treated mice was more pronounced in ear skin than in tail skin (Fig 3C). This may be explained 
by the fact the Teff number does not increase in the tails of mice treated with DTX (Fig 3B).  
Overall Krt14-Kitl×FoxP3-DTR mice exhibit increased depigmentation when treated with DTX. 
These results mirror findings from the CD4 depletion studies and suggest that Tregs are the 






Figure 3: Tregs suppress depigmentation in a 

































































































































































































































































































































Figure 3: Tregs suppress depigmentation in a mouse model of vitiligo. Krt14-Kitl×FoxP3-
DTR vitiligo mice were treated with PBS or diphtheria toxin (DTX) and tissues harvested 7 
weeks post disease induction were analyzed by flow cytometry. (A) Graph depicts 
depigmentation quantified by a blinded observer 7 weeks post disease induction; N=19 PBS, 
N=13 DTX; students T-test; bars represent s.e.m.; (B) Graph depicts the average number of 
Thy1.1+ Teffs normalized to the number of live single cells in the indicated tissues; N=8; 
students T-test; bars represent s.e.m.; (C) Graph depicts depigmentation on tail and ear skin of 





2.3.4: Treg number in the skin correlates with disease severity. 
Vitiligo is more severe in mice treated with DTX but Treg depletion seems to affect ears 
more than tails (Fig 3C). To explore why different regions of skin seem more susceptible to 
disease after Treg depletion I used flow cytometry to count Tregs in the skin of 8-week-old 
Krt14-Kitl×FoxP3-GFP mice without vitiligo. After mechanically separating ear and tail dermis 
from epidermis and processing skin and SDLN tissue into single cell suspensions, I counted 
GFP+ Tregs in each location. I counted few Tregs in the ear or tail epidermis and I observed that 
the majority of the Tregs reside in the dermis (Fig 4A). I compared the number of Tregs between 
the ear and tail dermis and found that there are almost four-fold more Tregs in the ear dermis 
(Fig 4A). I compared the extent of depigmentation between the ears and tails of 177 mice with a 
total vitiligo score of at least 5 and I observed that tail skin generally exhibits more 
depigmentation than ear skin 5 to 7 weeks after disease induction (Fig 4B). In light of this data I 
reasoned that the increased number of Tregs in ear skin may promote a more immunosupressive 
environment in ear skin than in tail skin. This could be why tails are more susceptible to 
depigmentation than ears and why Treg depletion affects ears more than tails.  
After observing that the number of Tregs in mouse skin may affect disease severity I 
sought to use flow cytometry to compare Treg numbers between lesional and non-lesional skin 
of human vitiligo patients. In collaboration with others in the lab, we used suction blistering to 
isolate skin infiltrating cell populations from the lesional and non-lesional skin of vitiligo 
patients and I used flow cytometry to count CD3+CD8+ T cells and CD3+CD4+CD25+FOXP3+ 
Tregs. I observed that the Treg/CD8 ratio is decreased in lesional skin compared to non-lesional 



































































































































Figure 4: Treg number in the skin inversely 
correlates with disease severity. 
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Figure 4: Treg number in the skin correlates with disease severity. (A) Tissues harvested 
from 8-week-old Krt14-Kitl×FoxP3-GFP mice without vitiligo were analyzed by flow cytometry 
and graphs depict the average number of GFP+ Tregs normalized to the number of live single 
cells in the indicated tissues; N=12, students T-test, bars represent s.e.m.; (B) Comparison of 
depigmentation between the ears and tails of mice with a total vitiligo score of at least 5;  N=177, 
students T-test, bars represent s.e.m; (C) Cells isolated from the skin of vitiligo patients by 
suction blistering were analyzed by flow cytometry and graph depicts the number of Tregs 
divided by the number of Teffs in a sample is represented as a Treg/Teff ratio; N=18 lesional, 





2.3.5: Tregs and Teffs accumulate in the skin with similar kinetics. 
Previous studies in our mouse model demonstrated that Teffs migrate to the skin to 
facilitate disease but the kinetics of Treg migration were not explored. To investigate Treg 
migration in our mouse model I induced vitiligo in Krt14-Kitl×FoxP3-GFP mice and used flow 
cytometry to quantify the number of Teffs and Tregs in the SDLNs and skin of mice 3, 5, 7 and 
12 weeks post disease induction. I identified very few Tregs in the ear epidermis and the number 
of Tregs remained minimal at all weeks as disease progressed (Fig 5a). The majority of Tregs in 
the ear were in the dermis and I observed the number of Tregs reached its peak at 5 weeks post 
disease induction, what we have previously observed as the peak of disease. By week 12 the 
number of Tregs contracts to levels comparable to week 3 early in disease progression (Fig 5a). I 
observed Tregs in the tail epidermis but the number of Tregs peaked at week 3, early in disease, 
and remained almost the same for the duration of disease (Fig 5b). I also found that similar to the 
ear, most of the Tregs in the tail were in the dermis and Treg numbers in the tail dermis begin to 
increase between week 0 and week 3 and peak at week 5 (Fig 5b). After week 5, Treg numbers 
begin to wane and reached levels comparable to week 3 early in disease progression (Fig 5b). 
During disease, at all weeks, I observed the most Tregs in the ear dermis. In fact, the number of 
Tregs in the ear dermis at the beginning of disease induction is comparable to the number of 
Tregs in the tail dermis at week 5, when I observed the most Tregs in the tail. The peak number 
of Tregs in ear dermis is on average more than two fold greater than the peak number of Tregs in 
the tail (Fig 5a,b). While the magnitude of Treg number is different in the ear and tail dermis, 
overall the trend is the same: the number of Tregs begins to increase between 0 and 3 weeks post 
disease induction and peaks at 5 to 7 weeks before contracting to levels comparable to the early 







































































































































































































































Figure 5: Tregs and Teffs accumulate in the 
skin with similar kinetics. 
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Figure 5: Tregs and Teffs accumulate in the skin with similar kinetics. Tissues harvested 
from Krt14-Kitl×FoxP3-GFP vitiligo mice were analyzed by flow cytometry at the indicated 
times post disease induction. (A-C) Graphs depict the average number of GFP+ Tregs 
normalized to the number of live single cells in the indicated tissues; or (D,E) The average 
number of GFP+ Tregs and Thy1.1+ Teffs normalized to the number of live single cells in the 




numbers start higher and dip at week 5, when Treg recruitment is at its peak in the skin (Fig 5c). 
By week 7 the number of Tregs begins to increase and at week 12 as disease stabilizes, the 
number of Tregs in SDLNs reaches levels comparable to those at disease induction (Fig 5c).  
When I looked at Teff numbers in skin I observed more Teffs in tail skin than in ear skin 
(Fig 5d,e), potentially due the decreased number of Tregs in the tail compared to the ear (Fig 
5a,b). When I compared Treg migration to Teff migration during disease, I observed that while 
there are generally more Teffs than Tregs in skin, Treg and Teff numbers increase and decrease 
simultaneously suggesting that Teffs and Tregs migrate to the skin with similar kinetics (Fig 5d, 
e).  Both populations peak between 5 and 7 weeks post disease induction, during the height of 
disease.  Interestingly, when I compared Treg migration and Teff migration in ear skin I 
observed that at the peak of disease, numbers of Tregs and Teffs are almost equal (Fig 5e). This 
may explain why ear skin is more protected supporting the previous observations I made in 
human skin and those reported in the literature that suggest the Tregs/Teff ratio in skin affects 
disease severity.  
 
2.3.6: Tregs directly contact Teffs in the skin during vitiligo. 
After observing that Tregs and Teffs migrate to the skin with similar kinetics, I 
investigated whether Tregs and Teffs interact in the skin during vitiligo. To do this I induced 
vitiligo in Krt14-Kitl×FoxP3-GFP mice with GFP+ Tregs as previously described. I crossed B6-
RFP mice with PMEL mice to generate Teffs that express RFP and induced vitiligo with RFP+ 
Teffs (Fig 6a). After 5 weeks I harvested lesional ears, split the dorsal and ventral sides, mounted 
the ears on slides and used fluorescent and confocal microscopy to examine them en face. Using 






Figure 6: Tregs directly contact Teffs in the 






Figure 6: Tregs directly contact Teffs in the skin during vitiligo. (A) Vitiligo was induced in 
Krt14-Kitl×FoxP3-GFP mice as previously described using RFP+ Teffs; (B) Representative 
florescent microscopy image (20x) of lesional ears from Krt14-Kitl×FoxP3-GFP mice 5 weeks 
post vitiligo induction; (C) Representative confocal microscopy image (40x) of lesional ears in 
Fig. 6b. Black arrows identify Tregs extending projections to directly contact Teffs in Treg-Teff 
clusters; (D) Representative immunohistochemistry image (20x) of human perilesional skin 





skin during vitiligo (Fig 6b). I used confocal microscopy to examine these Treg-Teff clusters 
with greater resolution and I observed a number of Tregs and Teffs in direct contact in ear skin 
(Fig 6c). Teffs appear to extend projections to contact Tregs suggesting that this contact is 
intentional and not merely coincidental (Fig 6c). In collaboration with other members in our lab, 
we performed immunohistochemistry on lesional skin from vitiligo patients and stained for CD8 
to identify Teffs and Foxp3 to identify Tregs. I found that human Tregs closely associated with 
Teffs mirroring the findings in our mouse model (Fig 6d). Together, this data suggests that Tregs 
migrate to the skin with kinetics similar to Teffs and contact Teffs in lesional skin. I have 
observed that Tregs suppress Teffs to control depigmentation and the seemingly intentional 
contact between the two cells that I observed in ear skin suggests that Tregs may use contact-
dependent mechanisms of suppression to control disease.  
 
2.3.7: Tregs do not induce CCR7 to control Teff number in the skin. 
 After observing contact between Tregs and Teffs in the skin, I investigated the 
mechanisms that Tregs could be using to suppress Teffs. In previous studies I found minimal 
BrdU incorporation in the skin with or without Tregs, suggesting that Tregs suppress Teffs 
without inhibiting their proliferation in the skin. In in vitro suppression assays conducted by 
Maeda et al., Tregs induced the expression of the chemokine receptor CCR7 on human 
melanocyte-specific Teffs that they suppressed [255]. The ligands for CCR7 are the chemokines 
CCL19 and CCL21, and CCR7 expression mediates T cell exit from the skin via CCL19 and 
CCL21 rich afferent lymphatics [256, 257]. Therefore, I hypothesize that Tregs control 
depigmentation during vitiligo by up-regulating CCR7 on autoreactive Teffs that they encounter 
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Figure 7: Tregs do not induce CCR7 to 


















































































































































































































Figure 7: Tregs do not induce CCR7 to control Teff number in the skin. (A) Once Tregs 
contact Teffs in the skin, Tregs induce surface CCR7 expression on Teffs to promote Teff egress 
from the skin; Naïve splenic Teffs cultured with or without Tregs for 2 days in uncoated wells or 
wells coated with αCD3/αCD28 antibody were analyzed using flow cytometry. Graphs depict 
(B) the percentage of Teffs expressing CCR7; N=3, students T-test, bars represent s.e.m.; or (C) 
the percentage of Teffs expressing CCR7 correlated with the percentage of Teffs expressing 
IFNγ; (D) Teffs cultured alone or with Tregs for 2 days in wells coated with αCD3/αCD28 
antibody were isolated from in vitro cultures, combined at a 1:1 ratio and injected into mouse 
ears. After 18 hours SDLNs were harvested and flow cytometry was used to quantify the 
proportion of Teffs recovered relative to their proportion at input; N=16, students T-test, bars 
represent s.e.m.; Tissues harvested from Krt14-Kitl×FoxP3-GFP vitiligo mice treated with PBS 
or GK1.5 CD4 depleting antibody (CD4 Depl) were analyzed by flow cytometry. Graphs show 
(E) The percentage of Thy1.1+ Teffs and GFP+ Tregs expressing CCR7 in PBS treated mice; or 
(F) the percentage of Thy1.1+ Teffs expressing CCR7 in PBS or CD4 Depl treated mice; N=10, 




 I performed in vitro suppression assays to investigate whether Tregs drive CCR7 
expression on the Teffs used to induce vitiligo in our mouse model.  I isolated Tregs from Krt14-
Kitl×FoxP3-GFP mice and melanocyte-specific Teffs from TCR transgenic donors. I co-cultured 
Tregs and naïve Teffs for 48 hours in the presence of αCD3/αCD28 antibodies and used flow 
cytometry to quantify CCR7 expression on Teffs. I observed that significantly more Teffs 
expressed CCR7 in co-cultures with Tregs than those in cultures without Tregs and Teffs 
cultured alone without αCD3/αCD28 stimulation expressed the most CCR7 (Fig. 7b). I observed 
an inverse correlation between CCR7 staining and IFNγ expression when I quantified levels in 
Teffs co-cultured with Tregs at a 0:1, 0.5:1 and 1:1 Treg:Teff ratio. This supports the hypothesis 
that increased Treg-mediated suppression induces CCR7 expression (Fig. 7c).  
 After observing increased CCR7 expression by Teffs cultured with Tregs, I investigated 
whether Tregs can promote increased Teff egress from skin. To do this I stimulated Teffs in vitro 
with αCD3/αCD28 antibodies in the presence or absence of Tregs. After 48 hours I harvested the 
cells and used flow cytometry to quantify Teffs in cultures before I combined Teffs cultured 
alone with Teffs from Treg co-cultures at a 1:1 ratio. I intradermally injected the Teff mixture 
into the ears of C57BL/6 mice and after 18 hours I harvested the ear draining lymph nodes then 
used flow cytometry to compare the numbers of Teffs that migrated out of the ear. I used 
congenic markers to differentiate Teffs cultured alone from Teffs cultured with Tregs. In 
draining lymph nodes, I recovered significantly more Teffs that were stimulated in the presence 
of Tregs than Teffs that were stimulated alone (Fig. 7d). This observation supports our 
hypothesis that Tregs can promote Teff egress from the skin but subsequent experiments 




To investigate whether Teffs express CCR7 in the skin during vitiligo, I induced disease 
in Krt14-Kitl×FoxP3-GFP mice and used flow cytometry to compare CCR7 expression between 
Tregs and Teffs in the SDLNs and skin of mice 7 weeks post disease induction. Comparable 
numbers of Tregs and Teffs express CCR7 in the SDLNs and skin during vitiligo (Fig. 7e). This 
was surprising since I hypothesized that Tregs drive CCR7 on Teffs to promote their exit and if 
Tregs in the skin express comparable levels of CCR7 as Teffs, it is unlikely that CCR7 is 
functioning as an “exit” signal that exclusively affects Teffs during vitiligo. 
 To investigate whether Tregs induce CCR7 on Teffs as a mechanism of suppression 
during vitiligo, I induced vitiligo in Krt14-Kitl×FoxP3-GFP hosts and depleted Tregs as 
previously described with GK1.5 CD4 depleting antibody. When I used flow cytometry to 
quantify CCR7 expression on Teffs in the SDLN and skin after seven weeks, I observed that 
comparable numbers of Teffs express CCR7 during vitiligo with or without Tregs (Fig. 7f). This 
suggests that Tregs do not control Teff number in the skin by promoting their egress through 
CCR7 upregulation.  
2.3.8: Tregs in lesional human skin express less TGF-β1 than Tregs in healthy skin. 
Tregs can use surface bound TGF-β1 to suppress in a contact-dependent manner [144-
146], and Tregs in our mouse model could be suppressing Teffs in the skin through a mechanism 
involving surface bound TGF-β1. In collaboration with other lab members, we isolated Tregs 
from healthy skin and lesional vitiligo skin using suction blistering and profiled genes expressed 
by Tregs in human skin with single cell RNA sequencing (Fig. 8a). Tregs in lesional vitiligo skin 
express less TGF-β1 than Tregs in healthy skin and this could explain why Tregs fail to control 
Teffs in the skin during vitiligo (Fig. 8b). Future experiments in our mouse model targeting 




Figure 8: Tregs in lesional human skin express 
less TGF-β1 than Tregs in healthy skin.  
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Figure 8: Tregs in lesional human skin express less TGF-β1 than Tregs in healthy skin. (A) 
Skin infiltrating cells were aspirated from a blister induced by heat and negative pressure on the 
skin of healthy patients or vitiligo patients and subjected to single cell RNA-sequencing. The 
tSNE plot generated from single cell RNA-seq data demonstrates that different cell types within 
the infiltrate are separated based on the expression of cell specific genes; (B) the violin plot 
generated from RNA-seq data shows quantification of TGF-β1 expression by Tregs in healthy 
human skin and vitiligo skin; the left y axis measures the magnitude of individual events 
(colored dots) and the right y axis measures the magnitude of the group average (black dot); 




Many studies have addressed the role of Tregs in vitiligo. Defects in Treg function [246, 
258] and reduction in Treg number have been reported [246, 259] but the field remains 
conflicted on exactly how Tregs affect depigmentation during disease. In our mouse model of 
vitiligo melanocytes are retained in mouse skin and CD8+ T cell-mediated depigmentation 
affects the skin instead of the hair, providing a unique opportunity to study vitiligo in a context 
similar to human disease. In light of this I used our model to address the role that Tregs play in 
the development of vitiligo.  
 After inducing vitiligo, I treated mice with CD4 depleting antibody and observed that 
CD4 depletion exacerbates depigmentation. As measured by a blinded observer, CD4-depleted 
mice have nearly 3-fold more total body depigmentation than mice treated with PBS. Other 
groups have used their mouse models of vitiligo to investigate the role of Tregs by CD4 or CD25 
depletion. Gregg et al. and Chatterjee et al. also observed an increase in the severity of vitiligo 
after treating mice in their models of disease, with CD4 depleting antibody or CD25 depleting 
antibody that preferentially targets Tregs [74, 251]. These results suggest that a CD4s are 
dispensable for disease progression and that CD4+CD25+ Tregs suppress depigmentation during 
vitiligo.  
There are a few key differences between the mouse models used to test Treg involvement 
that could influence how results are interpreted. In the Gregg model CD8 T cells drive epidermal 
depigmentation and extensive hair depigmentation while in our model of disease, the hair is 
spared even in depigmented skin. While both models are suitable for examining the ability of 
Teffs to mediate melanocyte destruction, the epidermis and the hair follicle have distinct 
characteristics. The hair follicle is an immune privileged site with its own complex biology and 
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these differences could confound conclusions [5]. In our model the pattern of depigmentation 
reflects human disease and gives us a unique opportunity to study vitiligo in a context closely 
resembling what we see in patients. Compelling evidence exists that identifies CD8+ T cells as 
the cell type that mediates human vitiligo [63, 260]. In the h3TA2 mouse depigmentation is 
mediated by a CD3+CD4-CD8- T Cell and this difference could complicate attempts to make 
conclusions about human disease. Our model relies on CD8+ T cells to mediate depigmentation 
and again gives us an opportunity to study vitiligo in a context closely resembling what we see in 
patients. One advantage the other models hold is that they provide the opportunity to study 
disease in a spontaneous context. To induce vitiligo in our model we infect mice with 
recombinant vaccinia virus to break tolerance. One caveat of our approach is while we deplete 
Tregs two weeks after virus infection, when a CD8+ T Cell virus response should already be 
resolved, Treg depletion could impair viral immune responses [261] and the increased viral load 
could confound conclusions. In future experiments, tissue titering should be performed on tissues 
to confirm that viral titers are comparable between PBS treated and Treg-depleted mice.    
I used flow cytometry to count T cell populations is PBS treated and CD4-depleted mice. 
I saw that GFP+ Tregs were not completely depleted in mice treated with CD4 depleting 
antibody. CD4 depletion did significantly reduce the number of Tregs relative to Teffs, 
represented as a Treg/Teff ratio in the skin and SDLNs. In future experiments, a higher dose of 
CD4 depleting antibody could prove more effective but the reduced Treg/Teff ratio in skin 
suggests that the number of Tregs in lesional skin affects disease severity. This observation 
aligns with studies in which immunohistochemistry on skin biopsies from vitiligo patients 
revealed that the CD4/CD8 ratio is decreased among the skin infiltrating cells of vitiligo patients 
[62], and the percentage of Tregs among skin infiltrating T cells is reduced in vitiligo patients 
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compared to healthy controls [247]. Treg/Teff ratios are also decreased in the SDLN and my 
study does not rule out Treg suppression in SDLNs. Future studies that restrict Tregs to the 
lymph node would definitively answer whether Treg suppression in the skin or LN is important 
but it is likely that suppression occurs in both locations.  Some studies report differences in Treg 
number between vitiligo skin and healthy skin and other studies report no difference so the field 
is conflicted on whether Treg number in the skin inversely correlates with disease severity. This 
study suggests Treg number in the skin is important for suppressing depigmentation.  
I observed that CD4 depletion leads to an increased accumulation of Teffs in the skin. 
Similarly, Chatterjee observed an increase in the amount of skin infiltrating CD3+ effector cells 
resulting from treatment with CD25 depleting antibody [251]. Gregg et al. also depleted Tregs in 
their model of vitiligo but they did not report the impact of Treg depletion on Teff skin 
infiltration [74]. Increased Teff number in the absence of Tregs suggests that Tregs control 
depigmentation during vitiligo by limiting the number of disease-causing Teffs in the skin. Other 
models of autoimmunity demonstrate that Tregs may facilitate suppression by limiting Teff 
number in peripheral tissue as Treg depletion resulted in increased epidermal CD8+ T cells 
infiltration and exacerbated skin inflammation in a mouse model of psoriasis [166].  
I hypothesized that Tregs could limit Teff number by limiting Teff proliferation in the 
skin and this was why there were more Teffs after Treg depletion. I saw little to no Teff 
proliferation in the skin, with or without Tregs suggesting Tregs do not inhibit Teff proliferation 
in the skin during vitiligo. Tregs use many mechanisms to suppress that require cell-cell contact, 
secretion of inhibitory cytokines or even downregulation of co-stimulatory signals that antigen 
presenting cells provide Teffs [108]. These mechanisms have been extensively studied and result 
in the suppression of naïve Teff activation or proliferation [108]. The Teffs that Tregs encounter 
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in the skin have presumably already been activated and proliferate in SDLNs before receiving 
signals to go to skin. In fact, by flow cytometry we have seen Teffs in our model express 
activation markers like CD69. Thus, it is unlikely that Teffs would undergo subsequent rounds of 
proliferation in the skin or that Tregs would use mechanisms that aim to prevent activation or 
proliferation in the skin. This could explain why we see little BrdU incorporation in the skin but 
in contrast see appreciable amounts of BrdU incorporation in SDLN. Teffs proliferate more in 
SDLNs of mice treated with CD4 depleting antibody. This increase in Teff proliferation in 
SDLNs of CD4-depleted mice could explain the increased Teff skin infiltration, as more Teffs 
are available to migrate from SDLNs to the skin of mice without Tregs during vitiligo. This 
would suggest that Treg suppression of Teffs in the SDLNs is important but does not rule out the 
possibility that Tregs suppress Teffs in skin. Regardless, this result suggests the mechanism 
Tregs use to suppress Teffs in the skin do not suppress Teff proliferation. Again, experiments 
where Tregs are restricted from skin and present only to SDLNs will help answer if Tregs need 
to be in skin to with Teffs to suppress depigmentation.  
CD4 depletion will affect Tregs but also all other CD4 bearing cells. CD25 depletion will 
preferentially affect Tregs since they express elevated levels of CD25 [108] but activated cells 
can also express CD25. To specifically deplete Tregs I treated FoxP3-DTR mice with DTX and 
saw increased levels of depigmentation similar to CD4 depletion. This suggests that Tregs are 
the CD4+ cell that suppresses depigmentation during vitiligo.  It is worth noting that Teffs can 
still drive vitiligo even though Tregs are present, but vitiligo is much worse when Tregs are 
depleted. This suggests that even though spots are forming, Tregs are still actively suppressing 




I found that most of the Tregs in the skin were in the dermis and this mirrors observations 
in human skin where Tregs are found clustered around hair follicles [150]. Interestingly, I 
noticed that ear skin was affected by Treg depletion more than tail skin. Additionally, when we 
induce vitiligo in mice tails readily depigment but ears seem protected. Since more Tregs exist in 
the ear dermis than in the tail dermis in mice without vitiligo and during disease, I hypothesize 
that the increased number of Tregs in ear skin promotes a more immunosuppressive environment 
in ear skin. This would explain why ears do not depigment as readily as tails.  
Whether the presence of Tregs in the skin of vitiligo patients affects disease severity has 
not been definitively proven and studies quantifying Tregs in lesional skin reported conflicting 
results [62, 247-249]. In our studies analyzing skin infiltrating cells in vitiligo patients I observed 
that the Treg/Teff ratio is reduced in lesional skin compared to non-lesional skin. The absolute 
Treg number was comparable between lesional and non-lesional skin but the number of Teffs 
increased in lesional skin. Nonetheless, these findings suggest that the number of Tregs relative 
to the number of Teffs in the skin may be important for controlling pathogenesis. Rosenblum et 
al. used a mouse model to demonstrate that resident memory Tregs reside in skin and provide 
expedited protection against skin inflammation [151]. This finding supports the notion that Tregs 
function in skin and the Tregs we see in skin could be important for suppressing Teff function. 
Studies in mouse models of vitiligo reported that increased Treg recruitment to the skin resulted 
in reduced disease, further supporting the hypothesis that Treg number in skin can reduce Teff 
driven depigmentation [155, 251, 252]. In light of this, it is reasonable to hypothesize that the 
increased number of Tregs in the ear compared to the tail before and during vitiligo, promotes a 
more immunosuppressive environment in ear skin that renders the ear less susceptible to 
depigmentation than the tail. This strongly suggests that Treg activity in the skin is important for 
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Treg suppression during vitiligo but does not preclude the contribution of Treg suppression in 
SDLNs. 
One group used flow cytometry to examine differences in Treg number between different 
areas of human skin. Treg number seemed to correlate with hair follicle density as areas of skin 
with more hair follicles (face and scalp) had more Tregs than areas with low hair follicle density 
(trunk and upper proximal extremities) [150]. Vitiligo more commonly presents on the face 
which contradicts the idea that increased Tregs in certain areas of skin confers more protection 
but other factors like antigen density may contribute to depigmentation in people [262].  
In lesional mouse ear skin I observed Tregs extending projections to contact Teffs 
suggesting contact between the T cells is intentional not merely coincidental. Tregs directly 
contact Teffs in lesional human skin from vitiligo patients mirroring what we see in mice. This 
contact is significant because it suggests that Tregs interact with Teffs in the skin during vitiligo 
and may be using contact-dependent mechanisms to suppress Teffs in the skin. The mechanisms 
Tregs use to suppress Teffs have been extensively studied but a lot of these studies were 
performed in vitro. Tregs can suppress Teffs using a variety of mechanisms and Vignali et al. 
argue that the mechanisms Tregs use could depend on where they encounter inflammatory 
activity [263]. Therefore, experiments performed in vitro could lead to incomplete conclusions 
since they cannot examine Treg function in the proper context. Our mouse model of vitiligo 
gives a unique opportunity to study mechanisms of Treg suppression in an in vivo model of 
peripheral tolerance and our observation that Tregs interact with Teffs in lesional skin suggests 
Tregs use contact-dependent mechanisms to suppress in peripheral tissue. A few mechanisms of 
contact-dependent suppression have been described. Bopp et al. reported that Tregs express high 
levels of cAMP and Tregs suppress CD4+ T cells by transferring cAMP to CD4+ T cells via gap 
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junctions in co-cultures [143]. This suppression was contact-dependent [143] and Tregs could be 
using this mechanism to suppress Teffs in the skin during vitiligo. A number of studies 
demonstrate that Tregs use surface bound TGF-β1 to suppress in a contact-dependent manner 
[144-146] and Tregs in lesional vitiligo skin express less TGF-β1 than Tregs in healthy skin. If 
surface bound TGF-β1 contributes to Treg suppression, reduced TGF-β1 expression could lead 
to the uncontrolled Teffs activity evident in the skin during vitiligo. Tregs could use membrane 
bound TGF-β1or cAMP to suppress Teffs during vitiligo and these possibilities should be 
explored in future studies.  
I investigated whether Tregs suppress depigmentation by inducing CCR7 on Teffs to 
drive their egress from the skin during vitiligo. While Teffs suppressed by Tregs expressed more 
CCR7 than Teffs activated alone in vitro, the number of Teffs expressing CCR7 in the skin did 
not significantly change when mice were treated with CD4 depleting antibody. The latter 
observation suggests that Tregs do not target CCR7 to suppress Teffs during disease and using 
CCR7 deficient Teffs to induce vitiligo in our mouse model would further address this question. 
If Treg-driven induction of CCR7 on Teffs is necessary to control depigmentation by limiting 
Teff number in the skin, hosts with CCR7 deficient Tregs will exhibit increased disease and 
increased cutaneous Teff accumulation. If disease is comparable between hosts with WT and 
CCR7 deficient Teffs, than Tregs likely do not induce CCR7 on Teffs to suppress 
depigmentation. 
   Defining the mechanisms that Tregs use to suppress autoimmunity during vitiligo 
would help us further understand how Tregs function in the periphery and potentially help 




2.5: Materials and Methods 
Mice 
KRT14-Kitl*4XTG2Bjl (Krt14-Kitl) mice were a generous gift from B. J. Longley (University 
of Wisconsin). I isolated Teffs from PMEL TCR transgenic mice that are Thy1.1+ and were 
obtained from The Jackson Laboratory, stock no. 005023, B6.Cg Thy1a/CyTg(TcraTcrb)8Rest/J.  
RFP mice were obtained from The Jackson Laboratory, stock no. 005884, B6.Cg-Tg(CAG-
mRFP1)1F1Hadj/J. RFP mice were bred to PMEL TCR transgenic mice to generate Teffs that 
express RFP. The following strains were bred to Krt14-Kitl mice to use as hosts in a mouse 
model of vitiligo: FoxP3-GFP mice generated by VJ Kuchroo, FoxP3-DTR mice (The Jackson 
Laboratory, stock no. 016958, B6.129(Cg)-Foxp3tm3(DTR/GFP)Ayr/J). The Krt14-Kitl allele was bred 
heterozygous on all mice used in experiments. All mice were bred on a C57BL/6J background 
and mice were maintained in pathogen-free facilities at the University of Massachusetts Medical 
School (UMMS), and procedures were approved by the UMMS Institutional Animal Care and 
Use Committee and in accordance with the National Institutes of Health (NIH) Guide for the 
Care and Use of Laboratory Animals. 
 
Vitiligo induction 
Vitiligo was induced through adoptive transfer of CD8+ T cells isolated from PMEL mice 
(Teffs) as described previously [79]. Teffs were isolated from the spleens of PMEL TCR 
transgenic mice through negative selection using a Miltenyi Biotec (Bergisch Gladbach, 
Germany) CD8 isolation kit according to the manufacturer’s instructions. 106 purified Teffs were 
injected intravenously into 8 to 12 week old hosts sublethally irradiated with 500 rads 1 day 
before transfer. Hosts were also infected with 106 plaque-forming units (PFU) of rVV-hPMEL 
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through intraperitoneal injection (N. Restifo, National Cancer Institute, NIH) on the same day of 
adoptive transfer. Depigmentation was reported using a vitiligo score. The vitiligo score was 
determined by an observer blinded to the experimental groups, using a point scale based on the 
extent of depigmentation at four locations, the ears, tail, nose and hind footpads as previously 
described [79]. Each location was examined, and the extent of depigmentation was assigned a 
number based on the estimated percentage of depigmentation at the anatomic site. Both left and 
right ears and left and right rear footpads were estimated together and therefore evaluated as 
single sites. The scoring system used is as follows: no depigmentation = 0, >0 to 10% = 1 point, 
>10 to 25% = 2 points, >25 to 75% = 3 points, >75 to <100% = 4 points and 100% = 5 points. 
The “vitiligo score” was the sum of the scores at all four sites, with a maximum score of 20 
points. 
 
CD4 depletion and Treg depletion by DTX treatment 
For CD4 depletion experiments vitiligo was induced in Krt14-Kitl×FoxP3-GFP mice as 
previously described. After 2 weeks, I treated mice once a week with 0.2mg of GK1.5 CD4 
depleting antibody (CD4-Depl) (BioXcell; West Lebanon, NH; Cat: BE0003-1) or PBS by 
intraperitoneal (i.p.) injection. After 5 weeks of treatment, a blinded observer quantified 
depigmentation on ears, nose, hind footpad and tail skin to generate a vitiligo score and tissues 
were harvested to be processed for flow cytometry. For DTX depletion experiments vitiligo was 
induced in Krt14-Kitl×FoxP3-DTR mice as previously described. After 2 weeks, I treated mice 
with 50µg/kg of diphtheria toxin (DTX) (Sigma-Aldrich; Darmstadt, Germany; Cat: D0564) or 
PBS every other day for 2 weeks. At 7 weeks post disease induction, a blinded observer 
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quantified depigmentation on ears, nose, hind footpad and tail skin to generate a vitiligo score 
and tissues were harvested to be processed for flow cytometry.   
 
BrdU pulsing experiments 
Vitiligo was induced in Krt14-Kitl×FoxP3-GFP mice as previously described and after 2 weeks I 
treated mice with CD4 depleting antibody once a week with 0.2mg of GK1.5 CD4 depleting 
antibody (αCD4) or PBS. After 3 or 5 weeks mice were injected with Bromodeoxyuridine 
(BrdU) (BD Pharmingen; San Jose, CA; Cat: 552598) i.v. 6 hours before takedown and tissues 
were harvested to be processed for flow cytometry. BrdU incorporation was detected by 




Ears, tails and skin-draining lymph nodes were harvested. Lymph nodes were mechanically 
disrupted. To separate the dermis and epidermis, harvested ear and tail skin samples were 
incubated with dispase (50 U/ml and 5 U/ml in PBS, respectively) (Roche) for 1 hour at 37°C. 
Epidermis was removed and mechanically disrupted with 70-mm cell strainers. Dermis samples 
were incubated with 1 mg/ml collagenase IV and 2 mg/ml DNase I (Sigma-Aldrich) in RPMI for 
45 minutes at 37°C on a shaker. After incubation dermis was dissociated by gentle agitation. 
Cells from lesional human skin were obtained by suction blistering. The following antibodies 
were obtained from BioLegend (San Diego, CA): mouse (CD3, CD8b, CD4, CD45 and CD90.1) 
and human (CD3, CD4, CD8, CD45, CD25 and FOXP3). For extracellular staining cells were 
washed in FACS buffer (1% FBS in PBS) and then incubated with antibodies at a 1:200 dilution 
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at 4̊ C in the dark for 20 minutes. For intracellular FoxP3 staining, surface staining was 
performed and cells were fixed and permeablized using the FoxP3/Transcription factor staining 
buffer set from eBioscience (Santa Clara, CA) according to the manufacturer’s 
recommendations. The data were collected and analyzed with a BD LSR II flow cytometer (BD 
Biosciences) and FlowJo (Tree Star Inc.). 
 
Quantifying Treg and Teffs during vitiligo 
To quantify Tregs in mice without vitiligo tissues from 8 week old Krt14-Kitl×FoxP3-GFP mice 
were harvested to be processed for flow cytometry. Tissue processing and surface staining were 
performed as previously described and CD45+CD3+CD4+GFP+ Tregs were quantified using a 
BD LSR II flow cytometer (BD Biosciences). To quantify Tregs and Teffs in mouse tissues 
during vitiligo I induced vitiligo in Krt14-Kitl×FoxP3-GFP mice as previously described and 
after 3, 5, 7 and 12 weeks post disease induction tissues were harvested to be processed for flow 
cytometry. Tissue processing and surfaces staining were performed as previously described and 
CD45+CD3+CD8+CD90.1+ Teffs and CD45+CD3+CD4+GFP+ Tregs were quantified using a 
BD LSR II flow cytometer (BD Biosciences). To quantify Tregs and Teffs in human skin during 
vitiligo skin infiltrating T cells were obtained from lesional and non-lesional skin by suction 
blistering. Suction blistering was performed as previously described [264]. Blisters that were 
approximately 1 cm in diameter were induced on the skin by using the Negative Pressure 
Instrument Model NP-4 (Electronic Diversities, Finksburg, MD). Suction chambers were placed 
on the skin with 10-15 mm Hg of negative pressure and a constant temperature of 40̊ C. After 30 
to 60 minutes blisters formed and the blister fluid was aspirated through blister roofs using a 1 
mL insulin syringe. Single cell RNA sequencing was performed on blister fluid obtained. Skin 
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infiltrating cells within the blister fluid were pelleted at 330×g for 10 minutes and then stained to 
be analyzed with flow cytometry. CD45+CD3+CD4+CD25+FOXP3+ Tregs and 
CD45+CD3+CD8+ Teffs were quantified using a BD LSR II flow cytometer (BD Biosciences). 
All flow cytometry data was analyzed with FlowJo (Tree Star Inc.). 
 
Imaging Treg-Teff interactions 
To visualize interactions between murine Tregs and Teffs, vitiligo was induced in Krt14-
Kitl×FoxP3-GFP mice as previously described using RFP expressing Teffs from PMEL×RFP 
donors.  After 5 weeks, mice were euthanized and lesional ears were excised. Following light 
treatment of ears with Nair to remove hair, the dorsal and ventral sides were separated and 
mounted on slides for imaging. All confocal imaging was performed on a Leica SP8 confocal 
microscope. To visualize interactions between Tregs and Teffs in lesional human skin during 
vitiligo immunohistochemistry was performed on biopsies from peri-lesional vitiligo skin. Teffs 
were identified by CD8 staining and Tregs were identified by FoxP3 staining.  
 
Statistical analyses 
All statistical analyses were performed with GraphPad Prism software. Dual comparisons were 







CHAPTER III: LANGERHANS CELLS SUPPRESS THE INCIDENCE OF 
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Langerhans cells (LHCs) are a dendritic cell (DC) population that resides in the 
epidermis where they survey the skin for the presence of foreign pathogen. Since LHCs are 
tightly packed adjacent to melanocytes in the epidermis, they are ideally positioned to interact 
with Teffs infiltrating the skin during vitiligo and in this study,  I explored the contributions of 
LHCs to disease. Numerous studies examining the role that LHCs play in models of 
inflammation, report conflicting results. In some of these studies LHCs behaved in an 
immunogenic manner while in others LHCs played a tolerogenic role. Our mouse model of 
vitiligo provides a unique opportunity to bring clarity to this in the context of vitiligo.  In our 
studies we observed that the incidence of disease increased in the absence of LHCs, suggesting 
that LHCs suppress depigmentation by reducing disease incidence. Epidermal Teff number also 
increases in the absence of LHCs, and the epidermal/dermal Treg ratio decreases so I 
hypothesize that LHCs may suppress disease by promoting the proper positioning of Tregs. 
LHCs have been reported to interact with Tregs in the skin. After observing that LHC-derived 
CXCL10 is necessary for suppression, I hypothesized that LHCs attract both Tregs and Teffs to 
the epidermis with CXCL10 and then tether both cells with MHC-TCR interactions in order to 
increase the efficiency of Treg-mediated Teff suppression. After observing LHC-Treg-Teff 
interaction in lesional mouse skin, I induced vitiligo in hosts with MHCII-deficient LHCs and 








What role do LHCs play during vitiligo? 
LHCs are of special interest in vitiligo. They exist in the epidermis in close proximity to 
melanocytes so during vitiligo they can potentially present melanocyte antigens to mediate 
disease pathogenesis, or contribute to the peripheral suppression of disease causing Teffs.  A few 
groups have studied LHCs during vitiligo and when Brown et al. compared LHC numbers 
between lesional and uninvolved skin from vitiligo patients they found no significant differences 
[265]. Another group similarly found that the number of epidermal LHCs in vitiligo skin was 
similar to the number of LHCs observed in the healthy skin [266]. In contrast Itoi et al. 
performed immunohistochemistry on skin biopsies from vitiligo patients and observed an 
increased number of LHCs in lesional skin compared to non-lesional skin [267]. Itoi et al. also 
concluded LHCs were more activated in lesional skin based on observations that LHCs in 
lesional skin were larger and had more Birbeck granules [267]. These results led them to 
conclude that LHCs stimulate CD8+ T cell responses during vitiligo.  
Wang et al. also performed immunohistochemistry on non-lesional and peri-lesional skin 
from vitiligo patients and counted more CD207+ LHCs in peri-lesional skin than in non-lesional 
skin [268]. Dermal dendritic cells in peri-lesional skin localized near the dermal-epidermal 
junction and there were more dDCs in peri-lesional skin than in non-lesional skin [268]. Wang et 
al. observed LHCs in peri-lesional skin expressed higher levels of HLA-DR suggesting LHCs are 
more activated in lesional skin during vitiligo, and similar to Itoi et al., they hypothesize that skin 
DCs drive T cells responses during vitiligo [268]. More work needs to be done to elucidate the 
role LHCs play during vitiligo and by using our mouse model of disease we used the many 
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genetic tools available in mice to study the contributions of LHCs to immunity in a model of 
autoimmune antigen presentation.  
 
3.3: Results 
3.3.1: The absence of Langerhans cells increases the incidence of disease in a mouse model of 
vitiligo 
In collaboration with others in the lab, I induced vitiligo in mice without langerhans cells 
(LHCs) to investigate the role of LHCs during disease. In huLangerin-DTA mice, the expression 
of the active subunit of diphtheria toxin is driven by huLangerin an LHC-specific promoter 
[206]. In these mice, LHCs are constitutively absent but langerin expressing dermal dendritic 
cells are unaffected [206]. I bred Krt14-Kitl×huLangerin-DTA (LHC-KO) mice to generate hosts 
that retain melanocytes in the epidermis while constitutively lacking LHCs and I induced vitiligo 
in these mice as previously described. I induced vitiligo in Krt14-Kitl mice to serve as wild-type 
(WT) controls. At 7 weeks post disease induction, a blind observer quantified the severity of 
depigmentation on ears, nose, hind footpad and tail skin to generate a vitiligo score. I compared 
depigmentation between WT and LHC-KO mice and observed that the extent of depigmentation 
is not significantly affected by the absence of LHCs; WT mice had an average vitiligo score of 
4.8 ± 0.6 and LHC-KO mice had an average score of 5.4 ± 0.6 (Fig. 9a). While the absence of 
LHCs does not affect the extent of depigmentation, it does increase the incidence of disease. I 
observed that 14 of the 48 WT mice induced with vitiligo exhibit no disease (Fig. 9a) and this 
characteristic of disease incidence in our mouse model – 1/3 of mice do not depigment (not 
shown). However only 1 of the 34 LHC-KO mice induced with vitiligo exhibited no 
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Figure 9: The absence of Langerhans cell 
increases the incidence of disease. 
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Figure 9: The absence of Langerhans cells increases the incidence of disease. Tissues 
harvested from LHC-KO vitiligo mice were analyzed by flow cytometry 7 weeks post disease 
induction. (A) Graph depicts depigmentation on mice with vitiligo; WT N=48, LHC-KO N=34, 
students T-test, bars represent s.e.m.; (B, C) Graphs show the average number of Thy1.1+ Teffs 
normalized to the number of live single cells in the tail epidermis and dermis; or (D) the number 
of epidermal FoxP3+ Tregs divided by the number of dermal Tregs represented as a Treg ratio; 
WT N=32, LHC-KO N=25, students T-test, bars represent s.e.m.; (E) CFSE labeled Teffs 
harvested from the spleens of uninfected or rVV-gp100 infected mice were analyzed by flow 
cytometry. The representative flow plot shows CFSE dilution in Teffs isolated from the spleens 




depigmentation during vitiligo with mechanisms that ultimately reduce the frequency of 
depigmentation.  
Seven weeks after disease induction, I harvested tail skin from both groups of mice, 
mechanically separated the dermis from the epidermis and used flow cytometry to count the 
number Teffs in digested tissues. I counted significantly more Teffs in the epidermis of LHC-KO 
mice than WT mice, 1002 ± 230 cells compared to 295.6 ± 69.7 cells, respectively (Fig. 9b). 
More Teffs accumulated in the dermis of LHC-KO mice than in the dermis of WT mice as well, 
420.5 ± 117.8 cells compared to 123.7 ± 32.8 cells, respectively (Fig. 9c). This further suggests 
that LHCs control disease and may do so by controlling Teff number in the skin. To ensure that 
increased depigmentation was not an artifact of altered priming of Teffs LHC-KO mice, I 
adoptively transferred CFSE-labeled Teffs into LHC-KO or WT mice and infected both groups 
with 1×106 PFU rVV-gp100. After three days I harvested spleens from both groups of mice and 
used flow cytometry to compare Teff CFSE dilution as a measure of Teff proliferation. I found 
that the absence of LHCs does not affect Teff priming as Teffs in WT and LHC-KO mice 
exhibited comparable levels of CFSE dilution (Fig. 9e).  
Seneschal et al. reported that human LHCs can induce the activation and proliferation of 
skin resident Tregs [209]. Since LHCs suppress vitiligo in our mouse model of disease I 
reasoned that the absence of LHCs could affect Treg number during vitiligo. To test this, I 
induced vitiligo in WT and LHC-KO mice and after 7 weeks I harvested tail skin from both 
groups of mice, mechanically separated the dermis from the epidermis and used flow cytometry 
to count the number Tregs in digested tissues. I compared numbers of Tregs between LHC-KO 
and WT mice and saw an increase in the number of dermal Tregs and a decrease in the number 
of epidermal Tregs in the absence of LHCs. I represented this as an epidermal/dermal ratio and 
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this ratio is decreased in LHC-KO mice compared to WT mice, 0.71 ± 0.28 compared to 1.68 ± 
0.28, respectively (Fig. 9d). Considering this I hypothesized that LHCs suppress disease by 
properly positioning Tregs in the epidermis during vitiligo to promote their suppressive 
interactions with Teffs.  
 
3.3.2: Tregs express CXCR3 and localize with CXCL10 expression in the skin during vitiligo 
I began to question how LHCs could promote Treg positioning and reasoned that they 
could make chemokines that Tregs follow. I previously observed that Teffs and Treg migrate to 
the skin with similar kinetics (chapter 1 Fig. 5D, E). This suggests that Tregs could be following 
the same signal as Teffs to get to the skin and previous studies from our group established that 
Teffs require CXCR3 to follow CXCL10 to migrate to the epidermis and mediate 
depigmentation [253]. The receptor for CXCL10 is CXCR3 and if Tregs follow the same signal 
as Teffs they must express CXCR3. Published studies have reported that Tregs express CXCR3 
[234] so I investigated whether Tregs express the chemokine receptor in the skin during vitiligo. 
I induced vitiligo in Krt14-Kitl×FoxP3-GFP and 5 weeks later I harvested tail and ear skin and 
used flow cytometry to measure levels of CXCR3 on Tregs in the skin during vitiligo. I observed 
that the same number of Tregs and Teffs express CXCR3 in the ear and tail epidermis and 
dermis during vitiligo (Fig. 10a). In light of this, I hypothesized that Tregs can follow the same 
CXCL10 gradients that Teffs do to get to the skin and cluster with Teffs (ch.1, Fig 6). To 
investigate the possibility that CXCR3 expressing Tregs follow CXCL10 in the skin during 
vitiligo I crossed a CXCL10/CXCL9 reporter mouse (REX3, Reporting Expression of CXCR3 
Ligands) to Krt14-Kitl×FoxP3-GFP to generate mice with GFP expressing Tregs and the 
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Figure 10: Tregs express CXCR3 and localize 
































































































 Figure 10: Tregs express CXCR3 and localize with CXCL10 in the skin during vitiligo. (A) 
Skin harvested from Krt14-Kitl×FoxP3-GFP vitiligo mice was analyzed by flow cytometry 5 
weeks post disease induction and the graph depicts the percentage of Thy1.1+ Teffs and GFP+ 
Tregs; N=7, students T-test, bars represent s.e.m.; (B) Vitiligo was induced as previously 
described in FoxP3-GFP×REX3 mice with GFP+ Tregs and BFP expression driven by the 
CXCL10 promoter; (C) Representative confocal microscopy image (40x) of lesional ears from 
FoxP3-GFP×REX3 mice with vitiligo 5 weeks post disease induction; representative image of 2 




weeks I harvested lesional ears, split the dorsal and ventral sides, mounted the ears on slides and 
used confocal microscopy to image ears en face. I observed that Tregs co-localized with areas of 
CXCL10 expression in the skin during vitiligo (Fig. 10c) and this observation supported the 
hypothesis that Tregs localize with Teffs by following the same chemokine signals.  
 
3.3.3: LHC-derived CXCL10 promotes optimal suppression in a mouse model of vitiligo 
Our group previously reported CXCL10 expression is upregulated in mouse and human 
skin during vitiligo [253]. We induced vitiligo in Krt14-Kitl×REX3 mice to investigate the 
source of CXCL10 and found that the majority of CXCL10 is expressed in the epidermis during 
vitiligo and LHCs are one of the major producers of CXCL10 [269]. After observing that LHCs 
suppress vitiligo, make CXCL10, affect the epidermal positioning of Tregs that express CXCR3, 
and localize with CXCL10 in the skin during vitiligo, I hypothesized that LHCs use CXCL10 to 
attract Tregs and Teffs in the skin and facilitate the interactions that we see between the two cell 
types (ch.1, Fig 6). To test this I investigated whether LHCs suppression requires CXCL10. 
Because CXCL10 conditional knockout mice have not been developed, I generated mixed 
chimeras to determine the role of LHC-derived CXCL10 during vitiligo in collaboration with 
others in the lab. I lethally irradiated LHC-KO host and reconstituted them with 50% bone 
marrow from LHC-KO donors (contribute 50% of BM-derived cells except LHCs) and 50% 
marrow from WT or CXCL10-/- mice (contribute to the entire LHC compartment and 50% to all 
other compartments) (Fig 11). After 8 weeks I verified that LHCs reconstituted the epidermal 
niche by harvesting ears, fixing ears to slides, removing the dermis and staining the remaining 
epidermal sheets for langerin to identify LHCs.  There are no LHCs in LHC-KO hosts and in 
chimeras receiving CXCL10-/- or WT bone marrow, BM-derived LHCs fill the empty LHC niche 
and distribute in similar patterns (Fig. 12a).  
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Figure 11: Generating mixed bone marrow 
chimeras with CXCL10-/- langerhans cells.  
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Figure 11: Generating mixed bone marrow chimeras with CXCL10-/- langerhans cells.  
Lethally irradiated LHC-KO hosts were reconstituted with 50% bone marrow from LHC-KO 
donors and 50% marrow from WT or CXCL10-/- mice. After 8 weeks LHC-KO donor bone 
marrow will reconstitute 50% of BM-derived cells except LHCs and CXCL10-/- or WT bone 






































































































Figure 12: Langerhans cells require CXCL10 





Figure 12: Langerhans cells require CXCL10 for optimal suppression. (A) Representative 
immunofluorescent microscopy images of ear epidermal sheets harvested from LHC-KO mice, 
WT mice, and mixed bone marrow chimeras were stained with anti-CD207 antibody to identify 
LHCs; WT/LHC-KO are mixed chimeras with 50% WT and 50% LHC-KO bone marrow,   
CXCL10-/-/LHC-KO are mixed chimeras with 50% CXCL10-/- and 50% LHC-KO bone 
marrow, representative images from 2 experiments; Tail skin harvested from chimeric vitiligo 
mice was analyzed by flow cytometry 7 weeks post disease induction. Charts show (B) 
quantification of depigmentation on mixed bone marrow chimeras; or (C) quantification of the 
average number of MHCII+ LHCs normalized to the number CD45+ cells in the tail epidermis; 




In collaboration with others in the lab I induced vitiligo in chimeric mice 8 weeks after 
bone marrow reconstitution and 7 weeks post disease induction, a separate observer blinded to 
the experimental groups quantified the severity of depigmentation on ears, nose, hind footpad 
and tail skin to generate a vitiligo score. I observed that chimeras with CXCL10-/- LHCs 
exhibited increased depigmentation compared to chimeras with WT LHCs, average total scores 
of 8.2 ± 1.6 and 4.2 ± 1.1, respectively (Fig. 12b).  I also harvested tail epidermis, processed the 
tissue into a single cell suspension and use flow cytometry to find comparable numbers of LHCs 
between WT mice and chimeras reconstituted with CXCL10-/- LHCs or WT LHCs (Fig. 12c). 
The findings suggest that LHCs require CXCL10 to suppress disease and support the hypothesis 
that LHCs use CXCL10 to facilitate interactions between Tregs and Teffs.  
 
3.3.4: Visualizing interactions between LHCs, Tregs and Teffs in murine skin during vitiligo 
CXCL10 promotes depigmentation in our mouse model of vitiligo and keratinocyte-
derived CXCL10 orchestrates epidermal Teff positioning to drive disease [253, 269]. Since 
LHC-derived CXCL10 promoted suppression I questioned how LHCs could suppress disease 
while keratinocytes promote disease using the same molecule. I reason that LHCs, unlike KCs, 
constitutively express MHC II and can interact with Tregs via MHCII-TCR interactions. In light 
of this I hypothesized that LHCs attract epidermal Tregs and Teffs with CXCL10 and then tether 
both cells through MHC-TCR interactions to promote direct cell-cell contact, and thus increase 
the efficiency of Treg-mediated suppression of Teffs (Fig. 13a). This interaction is likely as 
Seneschal et al. found that human LHCs activate skin resident Tregs in an MHC-TCR-dependent 
manner and observed Tregs in contact with LHCs in the epidermis [209]. To visualize whether 
Teffs, Tregs, and LHCs interact during vitiligo I adapted a method previously described [270] to 
108 
 
Figure 13: Langerhans cells as a scaffold to 









 Figure 13: Langerhans cells as a scaffold to facilitate interactions between Tregs and Teffs. 
(A) LHCs attract both Tregs and Teffs that are in the epidermis with CXCL10 and then tether 
both cells with MHC-TCR interactions to increase the efficiency of Treg-mediated Teff 
suppression (left panel). MHCIIflox/flox×LangerinCre mice with LHCs lacking MHCII, may still 
have Tregs in the skin capable of suppressing Teffs but the efficiency of their suppressive 
contact with Teffs may be reduced (right panels); Lesional ears harvested from Krt14-
KitL×FoxP3-GFP mice were stained with αLangerin antibody 5 weeks post RFP+ Teff transfer 
and analyzed using confocal microscopy. (B) A representative confocal microscopy image shows 
that LHCs (blue) frequently associated with both Teffs (red) and Tregs (green) in the skin during 
vitiligo; The left panel is a 10x image and the right panel is a 40x image, Representative 





label LHCs while preserving the integrity of the ears 3D architecture. I induced vitiligo in Krt14-
KitL×FoxP3-GFP hosts with RFP expressing Teffs and 5 to 7 weeks later, ears developed 
depigmentation and I intradermally injected lesional ears with an antibody cocktail containing 
αLangerin-APC. I used confocal microscopy to image ears two hours after intradermal injection 
and found that LHCs frequently associated with both Teffs and Tregs (Fig. 13b). In fact, 
dendritic projections from LHCs appeared to hold interacting Tregs and Teffs close together. 
These observations support the hypothesis that LHCs facilitate interactions between Tregs and 
Teffs in the skin during vitiligo. 
 
3.3.5: MHC-TCR interactions are dispensable for LHC-mediated suppression during murine 
vitiligo 
To test whether MHC-TCR interactions between Tregs and LHCs are functionally 
required for LHC-mediated suppression, I crossed Krt14-KitL×Langerin-cre and MHCIIflox mice 
to generate LHC-specific MHCII-deficient mice.  I induced vitiligo in 
MHCIIflox/flox×LangerinCre+ using MHCIIflox/flox×LangerinCre- and MHCII+/flox×LangerinCre+ 
littermates as controls. After 7 weeks mice developed depigmentation and a separate observer 
blinded to the experimental groups quantified the severity of depigmentation on ears, nose, hind 
footpad and tail skin to generate a vitiligo score. I observed no significant difference in vitiligo 
between mice with MHC deficient LHCs and littermate controls (Fig. 14a). I harvested tail skin, 
processed the tissue into single cell suspensions and used flow cytometry to analyze cell types in 
the skin. I first confirmed that LHCs lacked MHC II in MHCIIflox/flox×LangerinCre+ animals 
(Fig. 14b). I also noticed no difference in epidermal Teff number between 
MHCIIflox/flox×LangerinCre+ hosts and littermate controls (Fig. 14c). I also observed no 
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differences in the epidermal/dermal Treg ratio between MHCIIflox/flox×LangerinCre+ hosts and 
littermate controls (Fig. 14d). These results suggest MHC-TCR-mediated interactions between 















Figure 14: MHC-TCR interactions are 
dispensable for Langerhans cell suppression. 
WT  FloxhomoCre+ 
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Figure 14: MHC-TCR interactions are dispensable for Langerhans cell suppression. Tail 
skin harvested from MHCIIflox/flox×LangerinCre+ mice and littermate controls with vitiligo was 
analyzed by flow cytometry 7 weeks post disease induction. (A) Graph shows quantification of 
depigmentation on mice with vitiligo; (B) Representative flow plots showing MHCII expression 
on LHCs in WT and FloxhomoCre+ tails; (C) Graphs depict the average number of Thy1.1+ Teffs 
normalized to the number of live single cells in tail skin; or (D) the number of epidermal FoxP3+ 
Tregs divided by the number of dermal Tregs represented as a Treg ratio; WT N=11; 
FloxhomoCre+ N=18; FloxhomoCre- N=12; FloxhetCre+ N=13; FloxhetCre- N=13; WTCre+ N=10; 





Whether LHCs play an immunogenic or tolerogenic role during inflammation is still 
debated and the role LHCs play during vitiligo is not completely understood. I observed that 
while the extent of depigmentation was comparable between LHC-KO and WT mice, the 
incidence of disease is increased in the absence of LHCs (Fig 9a). This suggests that LHCs 
suppress depigmentation during vitiligo by suppressing incidence of disease and I hypothesized 
that LHCs might act as an immunological checkpoint that autoimmunity must overwhelm for 
disease to proceed. Studies investigating the role that LHCs play during vitiligo reported 
conflicting results regarding the number and activation status of LHCs during disease [265-268]. 
No functional studies depleting LHCs were performed since the aforementioned works were 
done in human patients and this study functionally demonstrates that LHCs play a suppressive 
role during vitiligo. 
Several studies report LHCs can play either an immunogenic or tolerogenic role during 
immune responses and CHS experiments using the same LHC-KO mouse used in this study, 
demonstrated that LHCs are dispensable for priming and suppress adaptive immunity [206]. I 
observed that the incidence of vitiligo is increased in the absence of LHCs (Fig 9a) mirroring 
previous findings in the context of T cell-mediated autoimmunity instead of delayed-type 
hypersensitivity response. A DCs maturation status influences whether a DC is immunogenic or 
tolerogenic [174-177] and the initial application of a hapten during CHS induction, could 
artificially activate DCs and influence that decision. In our model of vitiligo, we do not directly 
activate skin DCs to initiate disease providing a physiological context distinct from CHS to 
examine whether LHCs prime T cell responses. Models where OVA expression is driven by a 
skin specific promoter provide a physiological context to study disease as well but OT-I and OT-
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II responses are abnormally sensitive and this must be taken into account when interpreting 
results [271]. Our model of disease also has certain caveats as we examine LHC suppression in 
the context of a monoclonal T cell response and break tolerance by infecting mice I.P. with 
recombinant vaccinia virus but my observations that LHCs suppress the incidence of disease 
suggest LHCs are dispensable for T cell priming and suppress adaptive responses. 
I observed that the number of Teffs was increased in the skin of animals lacking LHCs 
(Fig 9b,c) and in light of this, I hypothesized that LHCs suppress depigmentation by controlling 
Teff number in the skin. Igyarto et al. observed an increase in disease and numbers of antigen 
specific T cells in the skin after inducing CHS in huLang-DTA mice [207] reflecting the 
observations I made in our model of vitiligo. Since I observed that Tregs suppress 
depigmentation during vitiligo by controlling Teff number (Fig. 1,3) and the number of Tregs in 
the skin is important for suppressing depigmentation (Fig 4), I hypothesized that Tregs may be 
affected in LHC-KO mice. I observed an increase in the number of dermal Tregs in LHC-KO 
mice and the epidermal/dermal ratio is decreased in LHC-KO mice compared to WT mice (Fig. 
9e). Considering this I hypothesized that LHCs suppress disease by properly positioning Tregs in 
the epidermis during vitiligo to promote their suppressive interactions with Teffs. Igyarto et al. 
observed no difference in Treg number between LHC deficient and WT mice after inducing 
immunity and the observations I made conflict this finding. Other studies demonstrate that 
tolerogenic DCs interact with Tregs to promote an immunosuppressive environment [176, 177] 
and LHCs have been shown to induce the proliferation of skin resident Tregs [209], so it is 
possible that LHCs coordinate with Tregs during vitiligo to suppress autoimmunity and it 




 Previous studies in our mouse model revealed that CXCL10 expression is upregulated in 
mouse and human skin during vitiligo [253]. The majority of CXCL10 is expressed in the 
epidermis during vitiligo and keratinocytes and LHCs are the major epidermal producers of 
CXCL10 [269]. I hypothesized that LHC-derived CXCL10 properly positions Tregs in the skin 
for optimal suppression. Few Tregs in the skin expressed CXCR3 on their surface when I 
analyzed skin infiltrating Tregs by flow cytometry but it is possible that Tregs internalize the 
receptor after exposure to chemokine. We know Teffs require CXCR3 and comparable numbers 
of Teffs in the skin expressed the receptor. When I analyzed lesional skin using confocal 
microscopy Tregs clustered around areas of CXCL10 expression but I cannot rule out the 
possibility that other cells or chemokines are mediating Treg clustering. These caveats must be 
considered but based on the observation that Tregs express CXCR3 and localize with CXCL10 
expression in the skin, I felt it was reasonable to hypothesize LHC-derived CXCL10 was 
important for positioning Tregs.  
In mixed bone marrow chimeras LHCs required CXCL10 for optimal suppression and 
this contrasted previously obtained data that demonstrated keratinocytes use CXCL10 to drive 
depigmentation [269]. To reconcile how the same chemokine could be used by two different 
cells to achieve opposite outcomes, I hypothesized that LHCs attract epidermal Tregs and Teffs 
with CXCL10 and then tether both cells through MHC-TCR interactions to promote direct cell-
cell contact, and thus increase the efficiency of Treg-mediated suppression of Teffs. Seneschal et 
al. reported that LHCs in human skin induced skin resident Treg proliferation in an MHCII- 
dependent manner and LHCs interact with skin resident Tregs in the epidermis or near the 
dermal-epidermal junction [209], supporting the notion that functional interactions between 
LHCs and Tregs occur in the skin. 
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Interactions I observed between LHCs, Tregs and Teffs in the skin support my hypothesis 
that LHCs facilitate interactions between Tregs and Teffs in the skin during vitiligo (Fig. 11b). 
The possibility that contact between Tregs, Teffs and LHCs occurs merely by coincidence cannot 
be ignored. LHCs are tightly packed in the epidermis adjacent to melanocytes and KCs and Teffs 
and Tregs that must squeeze into extracellular spaces as they enter the skin during vitiligo are 
likely to encounter LHCs. I tested whether MHC-TCR interactions mediate this scaffold and I 
observed no significant difference in depigmentation between mice with MHC deficient LHCs 
and littermate controls (Fig. 12a). There was also no difference in epidermal Teff number 
between MHCIIflox/flox×LangerinCre+ hosts and littermate controls (Fig. 12c) and no differences 
in the epidermal/dermal Treg ratio (Fig. 12d). These results suggest MHC-TCR-mediated 
interactions between LHCs and Tregs may be dispensable for LHC suppression during vitiligo. 
Taken together the observations made in this study suggest LHCs suppress the incidence 
of disease in a mouse model of vitiligo. In the absence of LHCs the number of Teffs infiltrating 
the skin increases and the epidermal/dermal Treg ratio decreases. How LHCs use CXCL10 to 
suppress depigmentation while keratinocytes use CXCL10 to promote depigmentation remains 
unanswered as LHCs do not require MHCII-TCR interactions to suppress vitiligo in our mouse 
model. It is possible that LHC-derived CXCL10 is enough to tether Teff and Tregs without 
MHC-TCR interactions. Groom et al. report that DCs in the lymph node tether T cells with 
CXCL10 [220] and if CXCL10 can tether Tregs and Teff to LHCs than it is still possible that 
LHCs can increase the efficiency of Treg-Teff interacts to facilitate suppression during vitiligo. 
Inducing vitiligo in IFNγRfl/fl × LangerinCre mice would further test whether LHCs require 
CXCL10 for suppression as LHCs in this mouse would be unable to make CXCL10, expressed 
as a result of IFNγR signaling. Also LHCs may not alter Tregs and act directly on Teffs to 
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control their numbers. Igyarto et al. reported LHCs make the suppressive cytokine IL-10 and 
require IL-10 express for optimal suppress of CHS induced immune responses [207]. 
Autoimmunity progresses and is even exacerbated in the absence of LHCs in a mouse model of 
vitiligo suggesting that LHCs suppress adaptive immunity. This observation contributes to the 
ongoing discussion concerning whether LHCs function in an immunogenic or tolerogenic 




3.5: Materials and Methods 
Mice 
KRT14-Kitl*4XTG2Bjl (Krt14-Kitl) mice were a generous gift from B. J. Longley (University 
of Wisconsin). I isolated Teffs from PMEL TCR transgenic mice that are Thy1.1+ and were 
obtained from The Jackson Laboratory, stock no. 005023, B6.Cg Thy1a/CyTg(TcraTcrb)8Rest/J.  
RFP mice were obtained from The Jackson Laboratory, stock no. 005884, B6.Cg-Tg(CAG-
mRFP1)1F1Hadj/J. RFP mice were bred to PMEL TCR transgenic mice to generate Teffs that 
express RFP. The following strains were bred to Krt14-Kitl mice to use as hosts in a mouse 
model of vitiligo: FoxP3-GFP mice generated by VJ Kuchroo, huLangerin-DTA (LHC-KO) 
mice (provided by D.H. Kaplan, University of Minnesota), REX3 mice (provided by A. Luster, 
Massachusetts General Hospital), MHCIIflox/flox mice (The Jackson Laboratory, stock no. 013181, 
B6.129X1-H2-Ab1tm1Koni/J), LangerinCre mice (NCI Mouse Repository, strain no. 01X66, 
B6.Cg-Tg(CD207-cre)1Dhka/Nci) and CXCL10-/- mice (The Jackson Laboratory, stock no. 
006087, B6.129S4-Cxcl10tm1Adl/J). REX3×Krt14-Kitl×FoxP3-GFP mice used as hosts for 
vitiligo were generated by crossing Krt14-Kitl×FoxP3-GFP mice and Krt14-Kitl×REX3 mice. 
Krt14-Kitl×MHCIIflox/flox×LangerinCre mice used as hosts for vitiligo were generated by 
crossing Krt14-Kitl×MHCIIflox/flox mice and Krt14-Kitl ×LangerinCre mice. The Krt14-Kitl 
allele was bred heterozygous on all mice used in experiments. All mice were bred on a 
C57BL/6J background and mice were maintained in pathogen-free facilities at the University of 
Massachusetts Medical School (UMMS), and procedures were approved by the UMMS 
Institutional Animal Care and Use Committee and in accordance with the National Institutes of 





Vitiligo was induced through adoptive transfer of CD8+ T cells isolated from PMEL mice 
(Teffs) as described previously [79]. Teffs were isolated from the spleens of PMEL TCR 
transgenic mice through negative selection using a Miltenyi Biotec (Bergisch Gladbach, 
Germany) CD8 isolation kit according to the manufacturer’s instructions. 106 purified Teffs were 
injected intravenously into 8 to 12 week old hosts sublethally irradiated with 500 rads 1 day 
before transfer. Hosts were also infected with 106 plaque-forming units (PFU) of rVV-hPMEL 
through intraperitoneal injection (N. Restifo, National Cancer Institute, NIH) on the same day of 
adoptive transfer. Depigmentation was reported using a vitiligo score. The vitiligo score was 
determined by an observer blinded to the experimental groups, using a point scale based on the 
extent of depigmentation at four locations, the ears, tail, nose and hind footpads as previously 
described [79]. Each location was examined, and the extent of depigmentation was assigned a 
number based on the estimated percentage of depigmentation at the anatomic site. Both left and 
right ears and left and right rear footpads were estimated together and therefore evaluated as 
single sites. The scoring system used is as follows: no depigmentation = 0, >0 to 10% = 1 point, 
>10 to 25% = 2 points, >25 to 75% = 3 points, >75 to <100% = 4 points and 100% = 5 points. 




Ears, tails and skin-draining lymph nodes were harvested. Lymph nodes were mechanically 
disrupted. To separate the dermis and epidermis, harvested ear and tail skin samples were 
incubated with dispase (50 U/ml and 5 U/ml in PBS, respectively) (Roche) for 1 hour at 37°C. 
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Epidermis was removed and mechanically disrupted with 70-mm cell strainers. Dermis samples 
were incubated with 1 mg/ml collagenase IV and 2 mg/ml DNase I (Sigma-Aldrich) in RPMI for 
45 minutes at 37°C on a shaker. After incubation dermis was dissociated by gentle agitation. The 
following antibodies were obtained from BioLegend (San Diego, CA): mouse Thy1.1, CD8, 
CD45, MHCII, CD3, CD207, FOXP3, For extracellular staining cells were washed in FACS 
buffer (1% FBS in PBS) and then incubated with antibodies at a 1:200 dilution at 4°C in the dark 
for 20 minutes. For intracellular FoxP3 staining, surface staining was performed and cells were 
fixed and permeablized using the FoxP3/Transcription factor staining buffer set from 
eBioscience (Santa Clara, CA) according to the manufacturer’s recommendations. The data were 




Teffs were isolated from the spleens of PMEL TCR transgenic mice through negative selection 
using a Miltenyi Biotec (Bergisch Gladbach, Germany) CD8 isolation kit according to the 
manufacturer’s instructions. Teffs were labeled with CellTrace CFSE from Thermo Fisher 
Scientific (Waltham, MA) before 106 purified Teffs were injected intravenously into 8 to 12 
week old hosts that were also infected with 106 plaque-forming units (PFU) of rVV-hPMEL 
through intraperitoneal injection (N. Restifo, National Cancer Institute, NIH). After 3 days 
spleens were isolated from mice, mechanically disrupted and CFSE dilution in splenic Teffs was 
analyzed with a BD LSR II flow cytometer (BD Biosciences) and FlowJo (Tree Star Inc.). 
 
Mixed bone marrow chimera generation 
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To generate mixed bone marrow chimeras, LHC-KO hosts were lethally irradiated with 800 rads 
one day prior to reconstituting hosts with bone marrow. Donor bone marrow was isolated from 
C57BL/6J mice, CXCL10-/- mice and LHC-KO mice. In one group of mice 5×106 total bone 
marrow cells consisting of equal numbers of cells from CXCL10-/- and LHC-KO mice were 
transferred i.v. into previously irradiated hosts. In the other group of mice 5×106 total bone 
marrow cells consisting of equal numbers of cells from C57BL/6J and LHC-KO mice were 
transferred i.v. into previously irradiated hosts. As controls previously irradiated hosts were 
reconstituted with bone marrow from C57BL/6J mice. After 8 weeks I induced vitiligo in mixed 
bone marrow chimeras as previously described. 
 
Confocal Microscopy 
For imaging experiments to visualize Tregs co-localizing with CXCL10 expression, vitiligo was 
induced in REX3×Krt14-Kitl×FoxP3-GFP mice as previously a described. After 5 weeks mice 
were euthanized, ears excised and following light treatment of ears with Nair to remove hair, the 
dorsal and ventral sides were separated before being mounted on slides for imaging. For imaging 
experiments to visualize interactions between LHCs, Tregs and Teffs, vitiligo was induced in 
Krt14-Kitl×FoxP3-GFP mice as previously described using RFP expressing Teffs from 
PMEL×RFP donors.  After 5 weeks lesional ears were intradermally injected with 40ul of an 
antibody cocktail containing 0.05mg/ml Langerin-APC clone 4C7 from Biolegend (Dedham, 
MA) and 0.35mg/ml FC block 2.4G2. Two hours after intradermal injection, mice were 
euthanized and ears excised. Following light treatment of ears with Nair to remove hair, the 
dorsal and ventral sides were separated and mounted on slides for imaging. All confocal imaging 




Epidermal sheet staining 
The dorsal and ventral sides of ears were mechanically separated, and each side was fixed to a 
glass slide, epidermis side down, with clear nail polish. 50 U/ml of dispase (Roche) was dropped 
into a hydrophobic barrier drawn around ears on the slides and slides were incubated at 37° C for 
an hour. After incubation the dermis was gently removed and following the remaining epidermal 
sheet was fixed in 4% paraformaldehye for 30 minutes at room temperature. After being washed 
with PBS epidermal sheets were incubated for 1 hour at 25° C with 2% (wt/vol) BSA in PBS and 
stained overnight at 4° C with a 1:1000 dilution of primary antibody, CD207 clone 4C7 from 
Biolegend (Dedham, MA), in 2% BSA. Sheets were washed thoroughly in PBS and were 
incubated with a 1:2000 dilution of secondary antibody, donkey anti-mouse AF647 or AF555 
from Life Technologies (Carlsbad, CA) in PBS 1% BSA (wt/vol) for 90 minutes at 37° C. 
Epidermal sheets were washed thoroughly with PBS and mounted on slides with Prolong Gold 
from Life Technologies (Carlsbad, CA).  
 
Statistical analyses 
All statistical analyses were performed with GraphPad Prism software. Dual comparisons were 
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Previous studies in our mouse model of vitiligo revealed that Teffs require CXCR3 to 
migrate to the skin in response to CXCL9 and CXCL10 chemokine signals. I also found that T 
regulatory cells (Tregs) suppress depigmentation in vitiligo and directly contact Teffs in human 
and murine lesional skin, suggesting that Tregs must colocalize with Teffs in the skin to 
efficiently suppress their function. In light of these observations, I investigated the mechanisms 
of Treg recruitment to the skin during vitiligo. To investigate the chemokine signals that promote 
Treg migration, we induced vitiligo in RAG-/- hosts that received wild-type (WT) or CXCR3-/- 
Tregs. WT and CXCR3-/- Treg recipients had comparable levels of depigmentation and 
comparable numbers of Teffs and Tregs in the skin, suggesting that CXCR3 is dispensable for 
the ability of Tregs to migrate to the skin and suppress vitiligo. In previous studies we observed 
that CCL5 and its receptor CCR5 are highly induced in the skin of vitiligo patients and mice, and 
published GWAS results identified CCR6 as a vitiligo susceptibility gene. We found that Tregs 
express CCR5 and CCR6 in mouse and human skin during vitiligo, and that eliminating either 
chemokine receptor on Tregs inhibited their ability to suppress depigmentation during vitiligo, 
however they affected Tregs differently. While the number of CCR6-/- Tregs was decreased in 
the skin of mice with vitiligo compared to WT Tregs, CCR5-/- Tregs were present in normal 
numbers, supporting a role for CCR5 in their function. Our results reveal that both CCR5 and 





Chemokine signaling regulates immune responses during vitiligo. 
One of the fundamental features of the immune system is its ability to carefully balance 
effector responses with mechanisms of immunosuppression and the chemokine signals that 
mediate T cell infiltration during vitiligo are well known. Rashighi et al. compared the gene 
expression profiles between lesional skin biopsies from vitiligo patients as well as healthy 
controls and found that chemokines associated with a Th1 immune response were upregulated in 
vitiligo skin. IFNγ-dependent chemokines like CCL5 and the CXCR3 ligands CXCL10, CXCL9, 
CXCL11 were highly induced during vitiligo and the most upregulated chemokines among these 
were CXCL10 and CCL5 [253]. Rashighi et al. found that the CCR4 ligands CCL17 and CCL22 
were induced as well, but to a much lower extent than the aforementioned IFNγ-dependent 
chemokines [253]. Rashighi et al. analyzed the gene expression profile in lesional ear skin in 
their mouse model of vitiligo and observed that CCL5, CXCL9 and CXCL10 were all markedly 
induced [253]. This expression profile was skewed towards an IFNγ-dependent signature, 
mirroring gene expression in patients. In patient serum levels of CXCL10 protein was 
significantly increased, and CXCL10 drove depigmentation in a mouse model of vitiligo [253]. 
Disease-causing Teffs required CXCR3 expression to enter the skin and mediate depigmentation, 
and treating mice with CXCL10 neutralizing antibody during disease induction almost 
completely abrogated disease [253]. Furthermore, treating already depigmented mice with 
CXCL10 neutralizing antibody induced repigmentation, establishing CXCL10 as a crucial signal 
for mediating Teff migration to the skin [253].  
In the same mouse model of disease Richmond et al. demonstrated that treating mice with 
CXCR3 blocking and depleting antibodies prevents disease and induces the repigmentation of 
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already depigmented skin [272]. This result further supports a role for CXCR3 signaling in 
facilitating Teff migration to the skin during disease and since nearly all CD8s isolated from 
lesional skin express CXCR3 [264], drugs targeting this pathway may promote repigmentation in 
patients.  
CXCR3 promoted Treg recruitment in other inflammatory models with a Th1 signature 
[234] and whether or not CXCR3 mediates Treg recruitment to the skin during vitiligo needs to 
be explored when considering interventions that disrupt CXCR3 signaling. Another study 
observed that protein levels of CCL5, CXCL8 and CXCL10 were increased in serum from 
patients with active vitiligo compared to patients with stable vitiligo or healthy controls [273]. 
Blister fluid from lesional skin revealed a significant increase in CXCL10 and CCL5 protein in 
the skin of patients with active disease compared to the skin of patients with stable disease or 
healthy controls [273]. Using flow cytometry they found that significantly more CD8+ T cells 
express CCR5 and CXCR3 in the peripheral blood of patient with active vitiligo compared to 
patients with stable vitiligo or healthy controls [273]. These results mirror previous findings that 
suggest IFNγ-dependent chemokines play a role in mediating vitiligo.  
Few have explored the chemotactic signals that drive Treg migration to the skin during 
vitiligo. Jin et al. identified an association of generalized vitiligo with SNPs in the CCR6 gene in 
a vitiligo genome wide association study [24]. Since CCR6 has been shown to mediate Th17 and 
Treg migration during inflammation [237-239] and establish Tregs in the skin during neonatal 
development [152], it is likely that a SNP affecting CCR6 would affect Tregs and not Teffs 
during vitiligo. Thus a loss of function or impaired function mutation could tip the balance in 
favor of proinflammatory migration during vitiligo. In one study Klarquist et al. used flow 
cytometry to compare chemokine receptor expression between Tregs isolated from the PBMCs 
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of vitiligo patients or healthy controls. They observed that levels of CCR4, CCR5 and CCR8 
were comparable between circulating Tregs in vitiligo patients and controls [247]. Klarquist et 
al. performed immunostaining on skin biopsies to compare chemokine expression between 
healthy and lesional skin. While levels of CCL1 and CCL17 were similar between healthy and 
lesional skin, CCL22 expression was significantly reduced in vitiligo skin and the authors 
suggest that this decrease leads to reduced Treg migration to lesional skin and consequently, 
diminished suppression in lesional skin [247].  
In two different murine models of spontaneous vitiligo, Eby et al. used gene gun 
treatment to express CCL22 expression in the skin and saw increased cutaneous Treg migration 
and decreased depigmentation [155]. These results support a role for CCR4/CCL22 signal as 
sufficient to promote Treg skin migration, but one caveat of this treatment method was its limited 
durability, as treated mice depigmented two weeks after the end of treatment [155]. It is possible 
that other chemokines along with CCL22 mediate Treg migration and that targeting these 
chemokines as well could provide longer lasting protection. The chemokine signals that mediate 
Treg migration to the skin during vitiligo are not completely understood. Fully elucidating the 
chemokine signals that draw Tregs to the skin could lead to the discovery of new treatments or 
refine existing treatments for patients with vitiligo. In this study I use a mouse model of vitiligo 
to understand the chemokine signals that Tregs follow during vitiligo.  
In our mouse model I observed exacerbated disease in the absence of Tregs and a greater 
increase in depigmentation in ear skin than in tail skin after Treg depletion (Fig. 1 & 3). In our 
model of vitiligo, ear skin depigments to a lesser extent compared to tail skin (Fig. 4), and I 
found that there are more Tregs in ear skin than tail skin in mice both before vitiligo induction 
and during disease progression (Fig. 4 & 5). Together this data suggests that the number of Tregs 
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in the skin affects disease severity. In support of this hypothesis, I found a lower Treg/Teff ratio 
in lesional skin than in non-lesional skin (Fig. 4). I found Tregs in direct contact with Teffs in 
mouse and human skin, suggesting that Treg suppression occurs in the skin (Fig. 6) and I 
questioned what signals help Tregs find Teffs in the skin to mediate suppression. Understanding 
the signals that mediate Treg migration to the skin during could improve treatments that aim to 
increase Treg number in the skin. 
 
4.3: RESULTS 
4.3.1: Tregs do not require CXCR3 to suppress disease in a mouse model of vitiligo. 
We previously published that CXCL10, the ligand for CXCR3, is upregulated in the skin 
of vitiligo patients and mice, and Teffs require CXCR3 to migrate to the epidermis in a 
CXCL10-dependent manner and mediate depigmentation [253, 272]. Since I observed that Tregs 
and Teffs migrate to the skin with similar kinetics (Fig. 5), that Tregs express CXCR3, and that 
Tregs localize with CXCL10 expression in mouse skin during vitiligo (Fig. 9), I hypothesized 
that Tregs follow the same signal as Teffs, CXCL10, to get to the skin. In this scenario Tregs can 
interact with and suppress Teffs since both T cells will inevitably end up in the same areas if they 
follow the same signal.  
To test whether Tregs require CXCR3 to migrate to the skin and mediate suppression 
during vitiligo, I modified a Rag-/- mouse model of melanoma [274]. Since Rag-/- mice lack T 
cells, I can induce vitiligo in Rag-/- hosts by adoptively transferring Teffs and Treg-depleted CD4 
T cells. I can then use Rag-/- hosts to screen whether Tregs require CXCR3 to suppress vitiligo 
by comparing the extent of depigmentation between hosts reconstituted with CXCR3-/- or WT 
Tregs. I can use this strategy to test the necessity of any molecule for Treg suppression during 
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vitiligo instead of breeding KO strains to use as hosts in our mouse model. I generated Krt14-
Kitl×Rag-/- hosts that lack T cells and retain melanocytes in the epidermis. I adoptively 
transferred 106 Treg-depleted CD4 cells and 105 Tregs that I isolated from spleens WT B6 mice 
of donors using miltenyi columns. After 4 weeks I used flow cytometry to quantify 
CD45+CD3+Thy1.2+GFP+ Tregs in SDLNs, ear skin and tail skin. I observed that in most 
areas, Treg numbers in Rag-/- mice were comparable to Treg numbers in our Krt14-Kitl×FoxP3-
GFP mice (Fig. 13a). The only exception was the ear dermis where we observed more Tregs in 
Rag-/- hosts than in Krt14-Kitl×FoxP3-GFP mice, an average of 263.02 ± 55.37 cells compared 
to 86.10 ± 9.73 cells, respectively (Fig. 15a). To ensure that the addition of Tregs suppresses 
depigmentation I induced vitiligo in sublethally irradiated Krt14-Kitl×Rag-/- hosts with 106 Teffs, 
106 Treg-depleted CD4s and 105 WT Tregs or no Tregs (Fig. 15b). I infected hosts with rVV-
gp100 on the day of adoptive transfer. After 5 weeks, I compared ear skin depigmentation 
between groups, since I previously observed that ear skin exhibited the most pronounced 
difference in depigmentation between untreated and Treg-depleted hosts (Fig. 3). I observed that 
hosts that received no Tregs had extensive ear depigmentation but hosts that received WT Tregs 
had minimal ear depigmentation, 4.17± 0.17 compared to 1.33 ± 0.61, respectively (Fig. 15c). 
This result mirrors my previous findings that demonstrate Tregs suppress depigmentation and 
establishes a model assay to screen Treg function. 
To test whether Tregs require CXCR3 to control depigmentation, I induced vitiligo in our 
Krt14-KitL×Rag-/- hosts with 106 Teffs, 106 Treg-depleted CD4s and 105 WT Tregs, CXCR3-/- 
Tregs, or no Tregs (Fig 16a). After 5 weeks, a blinded observer quantified the extent of 
depigmentation on ear skin to generate a vitiligo score and I compared ear skin depigmentation 






Figure 15: Tregs suppress depigmentation in a Rag-/- 
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Figure 15: Tregs suppress depigmentation in a Rag-/- model of vitiligo. Tissues harvested 
from Krt14-Kitl×FoxP3-GFP mice (WT) and Rag-/- hosts 4 weeks after adoptive Treg transfer 
were analyzed by flow cytometry. (A) Graph shows the average number of 
CD45+CD3+Thy1.2+GFP+ Tregs normalized to the number of live single cells in the indicated 
tissues; Rag-/- mice: N=4, students T-test, bars represent s.e.m.; FoxP3-GFP mice: N=12, 
students T-test, bars represent s.e.m; (B) Sublethally irradiated, rVV-gp100 infected Krt14-
Kitl×Rag-/- hosts received 106 Teffs, 106 Treg-depleted CD4s and 105 WT Tregs or no Tregs; and 
in (C) graph depicts quantification of ear depigmentation in Rag-/- hosts from both groups 






Figure 16: Tregs do not require CXCR3 to suppress 




 Figure 16: Tregs do not require CXCR3 to suppress depigmentation in a Rag-/- model of 
vitiligo. (A) Sublethally irradiated, rVV-gp100 infected Krt14-Kitl×Rag-/- hosts received 106 
Teffs, 106 Treg-depleted CD4s and no Tregs, 105 WT Tregs or 105 CXCR3-/- Tregs; and in (B) 
graph depicts quantification of ear depigmentation in Rag-/- hosts represented as a vitiligo score; 
Tissues harvested from Rag-/- hosts were analyzed by flow cytometry 5 weeks post vitiligo 
induction and graphs show the average number of (C) Thy1.1+ Teffs; or (D) CD3+Thy1.2+ 
Tregs normalized to the number of live single cells in the indicated tissues; N=6, students T-test, 







depigmentation and hosts that received WT Tregs had minimal ear depigmentation (Fig. 16b).  
Hosts that received CXCR3-/- Tregs had comparable levels of ear depigmentation as hosts 
receiving WT Tregs, with vitiligo scores of 1.50 ± 0.56 compared to 1.33 ± 0.61, respectively 
(Fig. 16b). This observation suggests that Tregs do not require CXCR3 to prevent Teff-mediated 
depigmentation. I harvested SDLNs, ear and tail skin, separated the dermis from the epidermis 
and used flow cytometry to quantify CD45+CD3+Thy1.1+ Teffs in the skin and SDLNs. I found 
comparable numbers of Teffs in the SDLNs and ear skin of mice receiving CXCR3-/- and WT 
Tregs (Fig. 16c). Hosts that received no Tregs had the most Teffs in ear skin (Fig. 16c).  I also 
used flow cytometry to quantify Tregs in SDLNs, ear and tail skin and I observed that WT and 
CXCR3-/- Tregs migrate to the ear skin of Rag-/- mice during vitiligo (Fig. 16d). I observed more 
CXCR3-/- Tregs in the ear dermis and the fact that this difference is not statistically significant 
may be explained by the power of the study. While Teffs require CXCR3 to get to the skin and 
mediate disease, these results suggest that CXCR3 is dispensable for Treg suppression and 
migration to the skin. These findings also suggest that treatments targeting the CXCL10/CXCR3 
axis to counteract Teff-mediated depigmentation will not affect Treg suppression, which appears 
to operate independent of CXCR3.  
 
4.3.2: Tregs in human and murine skin express CCR6 during vitiligo. 
After I determined that Tregs do not require CXCR3 to suppress depigmentation, I 
investigated which chemokines and receptors drive Treg migration to the skin during vitiligo. 
GWAS studies have identified CCR6 as a vitiligo susceptibility gene [275], CCR6 has been 
reported to facilitate Treg migration to mouse skin [152] and areas of inflammation in other 
models of disease [237], and  based on these observations I hypothesized that CCR6/CCL20 
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signaling contributes to Treg migration during vitiligo.  
In collaboration with other members of the lab, I used suction blistering to isolate cells 
from the skin of vitiligo patients and using single cell RNA-seq, I identified Teffs based on CD8 
expression and Tregs based on CD4 and FOXP3 expression. Single cell RNA-seq revealed that 
Teffs and Tregs express CCR6 at the RNA level (Fig. 17a). I used flow cytometry to quantify 
CCR6 expression on CD45+CD8+ Teffs and CD45+CD4+CD25+FOXP3+ Tregs isolated from 
the lesional skin of vitiligo patients by suction blistering. I observed that approximately 90% of 
Tregs and 60% of Teffs isolated from lesional skin express CCR6 (Fig. 17b). Tregs also express 
significantly higher levels of CCR6 than Teffs, with an average median florescence intensity 
(MFI) of 2719 ± 479.1 compared to 750 ± 70.4, respectively (Fig. 17c).   
I harvested SDLNs, ear and tail skin from Krt14-KitL×Foxp3-GFP mice and used flow 
cytometry to investigate receptor levels on GFP+ Tregs without vitiligo. I didn’t find appreciable 
numbers of Tregs in the epidermis in mice without vitiligo so I focused Tregs in the SDLNs and 
dermis for analysis. I found that few Tregs in SDLNs express CCR6, 9.11 ± 1.02%, but that 
52.26 ± 5.082% of Tregs in ear skin and 40.14 ± 6.87% of Tregs in tail skin express CCR6 (Fig. 
17d). Tregs in the skin also express significantly higher levels of CCR6 than Tregs in the SDLNs 
with an average MFI of 146.2 ± 35.5 in SDLNs compared to an average MFI of 406.5 ± 45 in ear 
skin and 384.8 ± 42.9 in tail skin (Fig. 17e). These observations suggest that CCR6-expressing 
Tregs are enriched in the skin due to homing and this supports findings that Tregs require CCR6 
to get to the skin.  
I induced vitiligo in Krt14-KitL×Foxp3-GFP mice and 5 weeks later I harvested SDLNs, 
ear and tail skin, processed the tissue into single cell suspensions and used flow cytometry to 
























































































































































































































































Figure 17: Tregs in human and murine skin express 
CCR6 during vitiligo. 
Gene Expression in Lesional Human Skin 
Lesional Human Skin Lesional Human Skin Mice w/o Vitiligo Mice w/o Vitiligo 
Mice with Vitiligo Mice with Vitiligo 
138 
 
Figure 17: Tregs in human and murine skin express CCR6 during vitiligo. Skin infiltrating 
cells isolated from the lesional skin of patients by suction blistering were analyzed by single cell 
RNA-sequencing and flow cytometry. (A) The tSNE plot generated from the RNA-seq data 
shows different cell types within lesional skin and  skin Tregs express CD4, FoxP3 and CCR6; 
graphs depict flow cytometry data quantifying (B) the average percentage of T cells expressing 
CCR6; or  (C) the average MFI of CCR6 expression on T cells in lesional skin; N=5, students T-
test, bars represent s.e.m.; GFP+ Tregs in tissues harvested from 8-week-old Krt14-Kitl×FoxP3-
GFP were analyzed by flow cytometry and (D) graphs depict the average percentage of Tregs 
expressing CCR6; or (E) the average MFI of CCR6 expression on Tregs in the indicated tissues; 
N=8, students T-test, bars represent s.e.m.; GFP+ Tregs and Thy1.1+ Teffs in tissues harvested 
from Krt14-Kitl×FoxP3-GFP vitiligo mice were analyzed by flow cytometry and graphs depict 
(F) the average percentage of T cells expressing CCR6; or (G) the average MFI of CCR6 




express CCR6 in the SDLNs but in the skin more Tregs make CCR6 than Teffs and this 
difference is statistically significant everywhere except the ear epidermis (Fig. 17f). I observed a 
similar trend when I compared the MFI between Tregs and Teffs during vitiligo as Tregs express 
significantly higher levels of CCR6 than Teffs in SDLNs and ear and tail skin (Fig. 17g). I 
observed that Tregs express CCR6 in the skin during vitiligo and express more CCR6 than Teffs, 
suggesting that treatments aimed at recruiting more Tregs into the skin by targeting the 
CCR6/CCL20 axis will preferentially affect Tregs.  
 
4.3.3: Tregs in human and murine skin express CCR5 during vitiligo. 
In previous gene expression studies CCL5, the ligand for CCR5, was upregulated in the 
lesional skin of vitiligo patients [253]. CCR5 has also be has been reported to facilitate Treg 
function and migration in other inflammatory disease models [241, 242] and based on these 
observations I hypothesized that CCR5 signaling may contribute to Treg migration during 
vitiligo.  
In collaboration with other members of the lab, I used suction blistering to isolate cells 
from the lesional skin of vitiligo patients and single cell RNA-seq to analyze gene expression in 
skin infiltrating cells. I identified Teffs based on CD8 expression and Tregs based on CD4 and 
FOXP3 expression and I observed that Teffs and Tregs express CCR5 at the RNA level (Fig. 
18a). I used flow cytometry to quantify CCR5 expression on T cells isolated by suction 
blistering. I identified Teffs as CD45+CD8+ and Tregs as CD45+CD4+CD25+FOXP3+ and 
observed that an average of 76.66 ± 10.47% of Teffs express CCR5 on their surface and an 
average of 98.5 ± 0.89% of Tregs express CCR5 (Fig. 18b). Tregs express more CCR5 than 
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Figure 18: Tregs in human and murine skin express 
CCR5 during vitiligo. 
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Figure 18: Tregs in human and murine skin express CCR5 during vitiligo. Skin infiltrating 
cells isolated from the lesional skin of patients by suction blistering were analyzed by single cell 
RNA-sequencing and flow cytometry. (A) The tSNE plot generated from the RNA-seq data 
shows different cell types within lesional skin and skin Tregs express CD4, FoxP3 and CCR5; 
graphs depict flow cytometry data quantifying (B) the average percentage of T cells expressing 
CCR5; or  (C) the average MFI of CCR5 expression on T cells in lesional skin; N=5, students T-
test, bars represent s.e.m.; GFP+ Tregs in tissues harvested from 8-week-old Krt14-Kitl×FoxP3-
GFP were analyzed by flow cytometry and (D) graphs depict the average percentage of Tregs 
expressing CCR5; or (E) the average MFI of CCR5 expression on Tregs in the indicated tissues; 
N=12, students T-test, bars represent s.e.m.; GFP+ Tregs and Thy1.1+ Teffs in tissues harvested 
from Krt14-Kitl×FoxP3-GFP vitiligo mice were analyzed by flow cytometry and graphs depict 
(F) the average percentage of T cells expressing CCR5; or (G) the average MFI of CCR5 




difference in MFI was not statistically significant (Fig. 18c).  
To investigate CCR5 levels on Tregs without vitiligo, I harvested SDLNs, ear and tail 
skin from Krt14-KitL×Foxp3-GFP mice and used flow cytometry to analyze receptor expression 
on GFP+ Tregs. I didn’t find appreciable numbers of Tregs in the epidermis in mice without 
vitiligo so I focused on Tregs in the SDLNs and dermis for analysis. I found that 1.81 ± 0.23% of 
Tregs in SDLNs express CCR5 and significantly more Tregs express CCR5 in ear and tail skin, 
33.23 ± 3.61% of Tregs in ear skin and 33.23 ± 4.97% of Tregs in tail skin (Fig. 18d). I observed 
the same trend when I compared CCR5 expression by MFI between Tregs in the SDLNs and 
skin as the average MFI of Tregs in the SDLN is 36.58 ± 1.33 compared to 137.3 ± 37.2 and 
129.2 ± 27.0 in ear and tail skin, respectively (Fig. 18e). These finding suggest Tregs upregulate 
CCR5 in the skin and may require CCR5 for optimal migration to the skin during vitiligo.  
To investigate CCR5 expression during vitiligo I used our mouse model of disease.  I 
induced vitiligo in Krt14-KitL×Foxp3-GFP mice and 5 weeks later I harvested SDLNs, ear and 
tail skin, processed the tissue into single cell suspensions and used flow cytometry to measure 
CCR5 expression on Teffs and Tregs during vitiligo. I observed that Tregs express CCR5 during 
vitiligo but fewer Tregs than Teffs express CCR5 in all tissues (Fig. 18f). I also observed that 
Teffs express more CCR5 when I compared MFI between Tregs and Teffs in all tissues (Fig. 
18g). This difference is statistically significant in all tissues. While Teffs and Tregs both express 
CCR5, Tregs seem to express high levels of CCR5 in the skin and not the SDLNs during vitiligo. 
Based on these findings I hypothesize that CCR5/CCL5 signaling contributes to Treg migration 





4.3.4: Tregs require CCR6 but not CCR5 for optimal migration in a mouse model of vitiligo.  
After I observed that Tregs express CCR6 and CCR5 in the skin during vitiligo I 
hypothesized that these chemokine receptors could promote Treg migration and suppression in 
the skin. To test this I used the Rag-/- model of vitiligo that I modified to investigate the ability of 
CCR6-/- and CCR5-/- Tregs to suppress Teff-mediated depigmentation. I induced vitiligo in 
Krt14-KitL×Rag-/- hosts with 106 Teffs, 106 Treg-depleted CD4 T cells and no Tregs or 105 
Tregs isolated from the spleens of WT B6 mice, CCR6-/- mice or CCR5-/- mice (Fig. 19a). After 
5 weeks, a blinded observer quantified the extent of ear skin depigmentation to generate a 
vitiligo score and I compared depigmentation between groups. Consistent with previous results, I 
observed that hosts that did not receive Tregs exhibited significantly more depigmentation than 
hosts that received WT Tregs, average vitiligo score of 3.69 ± 0.21 compared to 0.7 ± 0.29, 
respectively (Fig. 19b). Interestingly, hosts that received CCR6-/- Tregs had significantly more 
depigmentation than hosts with WT Tregs, average vitiligo score of 3.43 ± 0.37 compared to 
0.69 ± 0.29 (Fig. 19b). In fact, disease is comparable in hosts without Tregs and hosts with 
CCR6-/- (Fig. 19b).  
Hosts receiving CCR5-/- Tregs exhibited significantly more depigmentation than hosts 
receiving WT Tregs, average vitiligo score of 1.77 ± 0.38 compared to 0.69 ± 0.29, respectively. 
(Fig. 19b). This difference in depigmentation was statistically significant but the magnitude of 
depigmentation was much less in hosts receiving CCR5-/- Tregs than in hosts receiving CCR6-/- 
Tregs, with average vitiligo scores of 1.77 ± 0.38 and 3.43 ± 0.37, respectively (Fig. 19b). This 
suggests that Tregs require both receptors for optimal suppression but may require CCR6 to a 





Figure 19: Tregs require CCR6 but not CCR5 for 







Figure 19: Tregs require CCR6 but not CCR5 for optimal migration in a mouse model of 
vitiligo. (A) Sublethally irradiated, rVV-gp100 infected Krt14-Kitl×Rag-/- hosts received 106 
Teffs, 106 Treg-depleted CD4s and no Tregs, 105 WT Tregs, 105 CCR5-/- or 105 CCR6-/- Tregs; 
and in (B) graph depicts quantification of ear depigmentation in Rag-/- hosts 5 weeks post vitiligo 
induction, represented as a vitiligo score; N≥13, students T-test, bars represent s.e.m.; (C) 
Tissues harvested from Rag-/- hosts were analyzed by flow cytometry and graph show the 
average number of CD3+Thy1.2+ Tregs normalized to the number of live single cells in the 
indicated tissues; N=9, students T-test, bars represent s.e.m.; Tissues harvested from in Rag-/- 
vitiligo mice that received equal amounts of Thy1.1+1.2+ WT Tregs and Thy1.2+ CCR6-/- Tregs 
or Thy1.1+1.2+ WT Tregs and Thy1.2+ CCR5-/- Tregs were analyzed by flow cytometry. Graphs 
depict (D) the proportion of WT or CCR6-/- Tregs in the indicated tissue relative to input, N=8, 
students T-test, bars represent s.e.m.; or (E) the proportion of WT or CCR5-/- Tregs in the 




I harvested SDLNs, ear and tail skin, processed the tissue into single cell suspensions and 
used flow cytometry to quantify CD45+CD3+Thy1.2+ Tregs. I observed that the number of 
Tregs in the SDLNs was comparable between hosts that received WT Tregs and hosts that 
received CCR6-/- Tregs (Fig. 19c). In the ear skin however, there were significantly fewer CCR6-
/- Tregs than WT Tregs (Fig. 19c) and while there were fewer CCR6-/- Treg than WT Tregs in the 
tail skin as well, this difference was not statistically significant (Fig. 19c). These observations 
suggest that Tregs require CCR6 for optimal migration to the skin during vitiligo.  
In SDLNs, I observed significantly more Tregs in hosts receiving CCR5-/- Tregs than in 
hosts receiving WT Tregs (Fig. 19c). The absence of CCR5 did not impair the ability of Tregs to 
migrate to skin as I observed more Tregs in the ear and tail dermis of mice receiving CCR5-/- 
Tregs than in mice receiving WT Tregs (Fig. 19c). This increase was not statistically significant 
but suggests that CCR5 is dispensable for Treg migration to the skin. 
I compared the ability of CCR6-/- Tregs and WT Tregs to migrate to the skin during 
vitiligo in a competitive adoptive transfer model. I isolated WT Tregs from Thy1.1+1.2+ mice 
and CCR6-/- Tregs from CCR6-/-Thy1.2+ mice and induced vitiligo in Krt14-KitL×Rag-/- mice 
with 106 Teffs, 106 Treg-depleted CD4 T cells, 5.0×104 WT Tregs and 5.0×104 CCR6-/- Tregs. 
After 5 weeks, I harvested SDLNs, ear and tail skin and used flow cytometry to assess the 
relative capacity of Thy1.1+Thy1.2+ WT and Thy1.2+ CCR6-/- Tregs to migrate into the tissues 
collected. I adoptively transferred CCR6-/- and WT Tregs at approximately a 1:1 ratio and the 
proportion of WT Tregs to CCR6-/- Tregs I quantified in SDLNs was comparable to the 
proportion at input (Fig. 19d). In the skin the proportion of CCR6-/- Tregs to WT Tregs is 
reduced compared to the proportion at input, suggesting that CCR6-/- Tregs have a reduced 
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capacity to migrate to the skin during vitiligo compared to WT Tregs (Fig. 19d). This migratory 
defect translates to an impaired ability of CCR6-/- Tregs to control depigmentation.  
Similarly, I compared the ability of CCR5-/- Tregs and WT Tregs to migrate to the skin 
during vitiligo in a competitive adoptive transfer model. I isolated WT Tregs from Thy1.1+1.2+ 
mice and CCR5-/- Tregs from CCR5-/-Thy1.2+ mice and induced vitiligo in Krt14-KitL×Rag-/- 
mice with 106 Teffs, 106 Treg-depleted CD4 T cells, 5.0×104 WT Tregs and 5.0×104 CCR5-/- 
Tregs. After 5 weeks, I harvested SDLNs, ear and tail skin and used flow cytometry to assess the 
relative capacity of Thy1.1+Thy1.2+ WT and Thy1.2+ CCR5-/- Tregs to migrate into the tissues 
collected. I adoptively transferred CCR5-/- and WT Tregs at approximately a 1:1 ratio and the 
proportion of WT Tregs to CCR5-/- Tregs I quantified in SDLNs was comparable to the 
proportion at input (Fig. 19e). In the skin the proportion of CCR5-/- Tregs to WT Tregs is slightly 
reduced but not significantly different, suggesting that CCR5-/- Tregs have a comparable capacity 
to migrate to the skin during vitiligo as WT Tregs (Fig. 19e).  
I observed that Tregs require CCR6 and CCR5 to optimally suppress depigmentation 
during vitiligo. However, while CCR6-/- Tregs are reduced in the skin compared to WT Tregs, 
comparable numbers of CCR5-/- Tregs and WT Tregs are present in the skin. This suggests that 
unlike CCR6, CCR5 contributes to Treg suppression through a mechanism distinct from 
promoting Treg migration to the skin.  
 
4.3.5: Tregs do not require CCR5 to cluster with Teffs in the skin. 
In collaboration with other members of the lab, I used suction blistering to isolate cells 
from the lesional skin of vitiligo patients and single cell RNA-seq to analyze gene expression in 
skin infiltrating cells. I observed that T cells are the main producers of CCL5, a CCR5 ligand, in 
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lesional human skin (Fig. 20a). Melanocytes and macrophages also expressed CCL5 but CCL5 
expression was concentrated in the T cell cluster (Fig. 20a).  When I compared CCL5 expression 
between skin infiltrating CD4+ T cells and CD8+ T cells and I observed that CD8+ T cells make 
more CCL5 than CD4+ T cells (Fig. 20b).  Teff-derived CCL5 may promote the clustering I 
observed between Tregs and Teffs in the skin during disease (Fig. 6) and thus facilitate Treg 
suppression by helping cutaneous Tregs co-localize with Teffs (Fig 20c-d). In this scenario, a 
CCR5-/- Treg would still be able to migrate to the skin but would exhibit a reduced ability to co-
localize with and suppress Teffs (Fig. 20e). To investigate this possibility, I induced vitiligo in 
Krt14-KitL×Rag-/- hosts with 106 RFP+ Teffs, 106 Treg-depleted CD4 T cells and 105 GFP+ 
CCR5-/- Tregs or 105 GFP+ WT Tregs. After 5 weeks, I harvested lesional ears and used 
confocal microscopy to examine them en face. I observed CCR5-/- Tregs clustering with Teffs 
suggesting that CCR5/CCL5 signaling does not facilitate Treg suppression by driving Treg co-
localization with Teffs (Fig. 20f).   
 
4.3.6: Tregs require CCR5 but not CCR6 for optimal effector function.  
After observing CCR5-/- Tregs clustering with Teffs in lesional skin, I used an in vitro 
suppression assay to compare the ability of WT, CCR5-/- and CCR6-/- Tregs to suppress cytokine 
expression by Teffs upon activation. I used αCD3/αCD28 antibody to stimulate Teffs cultured 
alone or in the presence of no Tregs, WT Tregs, CCR5-/- Tregs or CCR6-/- Tregs and after 72 
hours I used flow cytometry to quantify TNFα and IFNγ expression by Teffs.  WT and CCR6-/- 
Tregs exhibited a comparable ability to suppress Teffs suggesting that the increased 
depigmentation in hosts receiving CCR6-/- Tregs is not due to a migratory and not functional 
defect (Fig. 21a, b). CCR5-/- Tregs marginally suppress Teff activation as significantly fewer 
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Figure 20: Tregs do not require CCR5 to cluster with Teffs in the skin. Skin infiltrating cells 
isolated from the lesional skin of patients were analyzed by single cell RNA-sequencing. (A) The 
tSNE plot generated from single cell RNA-seq data shows CCL5 expression in human skin; and 
(B) the violin plot generated from single cell RNA-seq data shows the quantification of CCL5 
RNA expression by CD4 and CD8 T cells in healthy human skin and vitiligo skin. The left y axis 
measures the magnitude of individual events (colored dots) and the right y axis measures the 
magnitude of the group average (black dot); N=296 healthy skin CD4 T cells; N=142 control 
skin CD4 T cells; N=760 vitiligo skin CD4 T cells; N=316 healthy skin CD8 T cells; N=119 
control skin CD8 T cells; N=736 vitiligo skin CD8 T cells; (C-E) Teff-derived CCL5 may 
promote the clustering between CCR5 expressing Tregs and Teffs in the skin during vitiligo, 
facilitating Treg suppression of Teffs and CCR5-/- may exhibit a reduced ability to co-localize 
with Teffs within the skin; (F) Ears harvested from sublethally irradiated, rVV-gp100 infected 
Krt14-Kitl×Rag-/- hosts that received RFP+ Teffs, 106 Treg-depleted CD4s and GFP+ CCR5-/- 
Tregs were analyzed using confocal microscopy. Representative confocal images show GFP+ 






































































































































































































































































Figure 21: Tregs require CCR5 but not CCR6 for 





Figure 21: Tregs require CCR5 but not CCR6 for optimal effector function. Naïve Teffs 
cultured alone or with WT, CCR5-/- or CCR6-/- Tregs in wells coated with αCD3/αCD28 for 3 
days were analyzed by flow cytometry. Graph shows the average percentage of Teffs expressing 
(A) TNFα; or (B) IFNγ; N≥10, students T-test, bars represent s.e.m.; Naïve WT or CCL5-/- 
Teffs cultured alone or with WT or CCR5-/- Tregs in wells coated with αCD3/αCD28 antibody 
for 3 days were analyzed by flow cytometry. Graphs show the average percentage of Teffs 




Teffs express cytokine when cultured with CCR5-/- Tregs than when cultured alone (Fig. 21a, b) 
but CCR5-/- Tregs exhibit a reduced ability to suppress Teffs compared to WT Tregs. 
Significantly more Teffs expressed cytokines when cultured with CCR5-/- Tregs than with WT 
Tregs (Fig. 21a, b), suggesting that CCR5/CCL5 signaling may be required for optimal Treg 
function. 
To further investigate the impact of CCR5/CCL5 signaling, I compared the ability of 
Tregs to suppress WT Teffs and CCL5-/- Teffs. I observed that comparable numbers of WT and 
CCL5-/- Teffs expressed TNFα and IFNγ when stimulated by αCD3/αCD28 antibodies in the 
absence of Tregs (Fig. 21c, d). As I previously observed, CCR5-/- Tregs suppress WT Teffs less 
efficiently than WT Tregs do but WT Tregs did not suppress CCL5-/- Teffs as well as they 
suppressed WT Teffs (Fig. 21c, d). This suggests that Teff-derived CCL5 may be required for 
optimal Treg function and during vitiligo CCR5-/- Tregs exhibit a functional defect and not a 







In this study I investigated the chemokine signals that drive Treg migration to the skin 
during vitiligo and I found that Tregs require CCR5 and CCR6 for optimal suppression in a 
mouse model of disease. The chemokine driven migration of Tregs to peripheral tissues 
facilitated Treg- mediated suppression in numerous models of inflammation [154, 230, 231, 235-
238, 240, 241, 243, 244]. While the role Tregs play during vitiligo is still not completely 
understood, a number of studies suggest that Treg number in skin is important for reducing Teff-
driven depigmentation during disease. Two separate groups that analyzed Treg number in 
lesional skin reported a reduction of Tregs in the skin of vitiligo patients [247, 250]. Studies 
performed in mouse models of vitiligo revealed that depigmentation is exacerbated in the 
absence of CD4+ or CD25+ T cells [74, 251] and strategies that increased Treg number in 
murine skin during vitiligo led to reduced disease [155, 251, 252]. While these studies 
demonstrate that the presence of Tregs in the skin can suppress depigmentation, little is known 
about the chemokine signals that promote Treg migration during vitiligo and if we understand 
these signals we can design treatments that target these pathways. Eby et al. demonstrated this 
when they suppressed disease in a mouse model of vitiligo by overexpressing CCL22 to draw 
murine Tregs to the skin [155].  
I found that Tregs did not require CXCR3 to suppress depigmentation in our mouse 
model of disease. CXCR3/CXCL10 signaling is critical for the progression of disease by 
promoting Teff migration to the skin [253, 272]. In previous studies I observed that murine Treg 
and Teff migration patterns during vitiligo are similar. In addition, murine Tregs express CXCR3 
and localize with CXCL10 expression in lesional skin during vitiligo. In light of these findings I 
hypothesized that CXCR3 could promote Treg suppression and migration to the skin. However 
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in a Rag-/- model of vitiligo CXCR3 signaling was dispensable for Treg migration and 
suppression.  
This finding is in contrast with results from previously published studies that found Tregs 
required CXCR3 to migrate to peripheral sites of inflammation and mediate suppression [234-
236]. In two of these studies Tregs required CXCR3 to suppress inflammation with a Th1 
signature [234, 236], the same signature of disease in our model of vitiligo [253], but only one 
study investigated whether Tregs require CXCR3 to suppress inflammation in the skin [236]. 
This study found increased inflammation and fewer Tregs in the inflamed skin of CXCR3-/- mice 
during a CHS response, so I was surprised to find Tregs do not require CXCR3 to suppress 
depigmentation in our model of vitiligo or efficiently migrate to lesional skin. Inflammation in 
CHS models an allergic response induced by re-exposure to hapten, and disease in our model of 
vitiligo models an autoimmune response to antigens expressed by melanocytes in murine skin 
[79]. CD4+ T cells drive CHS responses while CD8+ Teffs drive vitiligo in our model and this 
difference could explain why Tregs do not require CXCR3 to mediate suppression in our model 
of vitiligo but do require CXCR3 to suppress CHS responses. Nonetheless, the fact that CXCR3 
signaling is dispensable for Treg suppression during vitiligo suggests that treatments targeting 
CXCR3/CXCL10 signaling will only affect Teffs and not Tregs. This could reduce disease-
causing cells in the skin and promote an anti-inflammatory environment in the skin that could 
lead to repigmentation. 
After observing that CXCR3 is dispensable for Treg-mediated suppression during 
vitiligo, I investigated whether CCR6 promoted Treg suppression during disease.  Since CCR6 
signaling mediated the migration of Tregs to murine skin during neonatal development [152], 
Tregs required CCR6 to suppress inflammation in the skin [240], and CCR6 represents a 
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susceptibility gene for vitiligo identified in genome wide association studies [24], I hypothesized 
that CCR6 could promote Treg suppression during vitiligo. I observed that Tregs required CCR6 
to efficiently migrate to the skin and suppress depigmentation in a Rag-/- model of vitiligo. The 
number of CCR6-/- Tregs was comparable to the number of WT Tregs in SDLNs and the only 
migratory defect CCR6-/- Tregs exhibited was skin homing. This suggests that CCR6 promotes 
Treg suppression during vitiligo by facilitating Treg migration to the skin. These findings mirror 
previously published findings that established Tregs require CCR6 to migrate to the skin to 
suppress inflammation [240]. One study in particular reported that CCR6-/- Tregs transferred into 
Rag-/- mice did not migrate to neonatal skin as well as WT Tregs [152]. This finding presents a 
caveat to our study, as CCR6 may facilitate homeostatic skin migration to fill the empty Treg 
niche in mouse skin and may not mediate Treg migration during vitiligo. This caveat is an 
inevitable consequence of the Rag-/- vitiligo model but to further confirm a role for CCR6 in 
facilitating Treg migration to the skin to suppress depigmentation, I could induce vitiligo in WT 
mice and treat mice with CCR6 blocking or neutralizing antibodies to see if this exacerbates 
depigmentation by reducing Treg number in the skin. Since Tregs express significantly more 
CCR6 than Teffs, CCR6 neutralization will likely spare Teff migration. 
Whether decreased Treg number in the skin contributes to pathogenesis during vitiligo 
still needs to be studied and reduced Tregs numbers have been reported in the lesional skin of 
vitiligo patients [247, 250]. A number of studies report increasing Treg number in the skin can 
suppress depigmentation in animal models of disease, but my studies provide functional 
evidence that suggests reducing Treg number only in the skin, and not in the lymph nodes, leads 
to increased disease. These observations add to the increasing amount of evidence that suggests 
Tregs suppress Teff-mediated depigmentation directly in the skin. Fewer CCR6-/- Tregs than WT 
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Tregs were in the skin of Rag-/- mice during vitiligo but CCR6-/- Treg were not completely absent 
from the skin. This suggests that there are redundant chemokine signals that mediate Treg 
migration during vitiligo and more work needs to be done to completely elucidate these signals.  
I observed significantly increased depigmentation in hosts with CCR5-/- Tregs than in 
host with WT Tregs in our Rag-/- vitiligo model and, based on these observations, I concluded 
that Tregs require CCR5 for optimal suppression during vitiligo. Interestingly the increase in 
depigmentation is less severe in hosts reconstituted with CCR5-/- Tregs than in hosts with CCR6-
/- Tregs, suggesting that Tregs require CCR6 more than CCR5 for suppression. CCR5 has been 
implicated in Treg-mediated suppression of inflammation in peripheral tissues [241-245] and one 
of these studies demonstrated that CCR5 signaling promoted efficient suppression and Treg 
migration to inflamed skin in a Rag-/- model of Leishmania major infection [245]. My 
observations partially reflect these findings as Tregs required CCR5 to optimally suppress skin 
depigmentation but I was surprised to find that CCR5-/- Tregs were capable of migrating to the 
skin during vitiligo. Despite the presence of CCR5-/- Tregs in the skin, depigmentation was still 
significantly worse than in mice with WT Tregs. This suggests that CCR5 signaling contributes 
to Treg suppression by promoting Treg function and not Treg migration to the skin in a mouse 
model of vitiligo. 
In support of this, I found that CCR5/CCL5 signaling is important for Treg suppression 
in in vitro suppression assays. Several studies demonstrate a role for CCR5 in promoting Tregs 
suppression [241-245]. However, these studies limit the role of CCR5/CCL5 signaling to driving 
the chemotaxis that positions Tregs in sites of inflammation. A couple of studies also used in 
vitro suppression assays to investigate the suppressive capabilities of CCR5-/- Tregs and reported 
no differences between WT and CCR5-/- Tregs [241, 245]. These studies assessed the ability of 
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Tregs to suppress proliferation in CD4+CD25- T cells instead of CD8+ Teff but in RNA-seq 
studies performed in collaboration with other members of the lab, CD8+ T cells in vitiliginous 
skin expressed much more CCL5 than skin infiltrating CD4+ T cells. If CD8+ T cells make more 
CCL5 than CD4+ T cells upon activation, suppression assays that use CD4+ Teffs as targets may 
not recognize subtle differences between WT and CCR5-/- Tregs.  
A study performed in a model of colorectal cancer reports that CCR5/CCL5 signaling 
enhances the migration of Tregs to tumor sites and enhances the ability of Tregs to suppress 
CD8+ T cells in vitro and in vivo [276]. These studies partially support my observations that 
CCR5/CCL5 signaling promotes optimal Treg function and not migration during vitiligo, but in 
the colorectal models of disease the source of the CCL5 is the tumor. Based on the data that we 
have gathered, Teffs are the primary producers of CCL5 in the skin during vitiligo and thus 
participate in their own suppression by expressing the CCL5 that promotes optimal Treg 
function.  
I have not ruled out the possibility that CCR5 facilitates Treg suppression by positioning 
of Tregs in clusters with Teffs in the skin during vitiligo. It is possible that the clusters of Teffs 
and Tregs that we see in lesional mouse skin are formed as an activated Teff gets to the skin and 
draws both CCR5-expressing Tregs and Teff in close proximity through the expression of CCL5. 
Tregs can still get to the skin and encounter Teffs to enact suppression, but CCR5 may help 
Tregs colocalize with and suppress Teffs more efficiently. Similar effects have been reported in 
the literature [217, 220] and one study demonstrated that DCs and T cells in the LNs expressed 
CCR5 ligands to facilitate clusters that form when an immune response is initiated [217]. In light 
of this, it is possible that T cell-derived CCL5 could facilitate Treg suppression by drawing 
CCR5 expressing Teffs and Tregs to clusters where Tregs enact suppression.  
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While I did observe CCR5-/- Tregs clustering with Teffs in lesional murine skin, in future 
imaging experiments I would need to compare the frequency of contact between Teffs and WT 
or CCR5-/- Tregs. If the frequency of interactions between Tregs and Teffs is reduced in the 
absence of CCR5, this would support a role for CCR5 in promoting clustering between Tregs 
and Teffs in the skin.  
In this study I investigated the chemokine signals that promote Treg suppression during 
vitiligo. I observed that CCR5 and CCR6 signaling promotes Treg suppression but only CCR6 
signaling does this by facilitating the migration of Tregs to the skin. CCR5 signaling appears to 
promote optimal Treg function and the different impacts of these chemokine receptors on Tregs 
is uniquely highlighted by our mouse model of vitiligo. Understanding the signals that govern 
Treg migration to the skin to suppress autoimmunity during vitiligo would potentially help 






4.5: Materials and Methods 
 
Mice 
KRT14-Kitl*4XTG2Bjl (Krt14-Kitl) mice were a generous gift from B. J. Longley (University 
of Wisconsin). I isolated Teffs from PMEL TCR transgenic mice that are Thy1.1+ and were 
obtained from The Jackson Laboratory, stock no. 005023, B6.Cg Thy1a/CyTg(TcraTcrb)8Rest/J. 
Krt14-Kitl×Rag-/- (Rag-/-) mice were generated by crossing Krt14-Kitl mice with the B6.129S7-
Rag1tm1Mom/J strain (The Jackson Laboratory, stock no. 002216). Krt14-Kitl×FoxP3-GFP mice 
were generated by crossing Krt14-Kitl mice with FOXP3tm1Kuch generated by VJ Kuchroo. 
Thy1.1+Thy1.2+ mice were generated by crossing C57BL/6J mice with B6.PL-Thy1a/CyJ mice 
(The Jackson Laboratory, stock no 000406). B6.SJL-Ptprca Pepcb/BoyJ (CD45.1) mice were 
used as CD4 donors and were obtained from The Jackson Laboratory, stock no 002014. CCR6-/- 
mice were obtained from The Jackson Laboratory, stock no. 005793, B6.129P2-Ccr6tm1Dgen/J. 
CCR5-/- mice were obtained from The Jackson Laboratory, stock no. 005427, B6.129P2-
Ccr5tm1Kuz/J. CXCR3-/- mice were obtained from The Jackson Laboratory, stock no. 005796, 
B6.129P2-Cxcr3tm1Dgen/J.  The Krt14-Kitl allele was bred heterozygous on all mice used in 
experiments. All mice were bred on a C57BL/6J background and mice were maintained in 
pathogen-free facilities at the University of Massachusetts Medical School (UMMS), and 
procedures were approved by the UMMS Institutional Animal Care and Use Committee and in 






Vitiligo was induced through adoptive transfer of CD8+ T cells isolated from PMEL mice 
(Teffs) as described previously [79]. Teffs were isolated from the spleens of PMEL TCR 
transgenic mice through negative selection using a Miltenyi Biotec (Bergisch Gladbach, 
Germany) CD8 isolation kit according to the manufacturer’s instructions. 106 purified Teffs were 
injected intravenously into 8 to 12 week old hosts sublethally irradiated with 500 rads 1 day 
before transfer. Hosts were also infected with 106 plaque-forming units (PFU) of rVV-hPMEL 
through intraperitoneal injection (N. Restifo, National Cancer Institute, NIH) on the same day of 
adoptive transfer. Depigmentation was reported using a vitiligo score. The vitiligo score was 
determined by an observer blinded to the experimental groups, using a point scale based on the 
extent of depigmentation at four locations, the ears, tail, nose and hind footpads as previously 
described [79]. Each location was examined, and the extent of depigmentation was assigned a 
number based on the estimated percentage of depigmentation at the anatomic site. Both left and  
right ears and left and right rear footpads were estimated together and therefore evaluated as 
single sites. The scoring system used is as follows: no depigmentation = 0, >0 to 10% = 1 point, 
>10 to 25% = 2 points, >25 to 75% = 3 points, >75 to <100% = 4 points and 100% = 5 points. 
The “vitiligo score” was the sum of the scores at all four sites, with a maximum score of 20 
points. 
 
Rag-/- vitiligo  induction 
Vitiligo was induced in Rag-/- mice through adoptive transfer of purified Teffs isolated as 
previously described. Treg-depleted CD4+ T cells were isolated from the spleens of C57BL/6J or 
CD45.1 mice through negative selection using Miltenyi Biotec (Bergisch Gladbach, Germany) 
CD4+CD25+ isolation kits. Tregs were isolated from the spleens of C57BL/6J mice, CXCR3-/- 
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mice, CCR5-/- mice or CCR6-/- mice through positive selection using Miltenyi Biotec (Bergisch 
Gladbach, Germany) CD4+CD25+ isolation kits. To induce vitiligo in Rag-/- mice 106 Teffs, 106 
CD4s and no Tregs, 105 WT Tregs, CXCR3-/- Tregs, CCR5-/- Tregs or CCR6-/- Tregs were 
adoptively transferred into 8 to 12 week old Rag-/- hosts. Hosts were sublethally irradiated with 
500 rads 1 day before transfer and hosts were infected with 106 PFU of rVV-hPMEL through 
intraperitoneal injection (N. Restifo, National Cancer Institute, NIH) on the same day of adoptive 
transfer. In competitive Rag-/- vitiligo models vitiligo was induced by adoptive transfer of 106 
Teffs, 106 CD4+ T cells and equal numbers of WT and CCR5-/- or CCR6-/- Tregs. WT Tregs 
were isolated from the spleens of Thy1.1+Thy1.2 C57BL/6J mice as previously described. Hosts 
were sublethally irradiated with 500 rads 1 day before transfer and hosts were infected with 106 
PFU of rVV-hPMEL through intraperitoneal injection (N. Restifo, National Cancer Institute, 
NIH) on the same day of adoptive transfer. 
 
Flow Cytometry 
Ears, tails and skin-draining lymph nodes were harvested. Lymph nodes were mechanically 
disrupted. To separate the dermis and epidermis, harvested ear and tail skin samples were 
incubated with dispase (50 U/ml and 5 U/ml in PBS, respectively) (Roche) for 1 hour at 37°C. 
Epidermis was removed and mechanically disrupted with 70-mm cell strainers. Dermis samples 
were incubated with 1 mg/ml collagenase IV and 2 mg/ml DNase I (Sigma-Aldrich) in RPMI for 
45 minutes at 37°C on a shaker. After incubation dermis was dissociated by gentle agitation. 
Cells from lesional human skin were obtained by suction blistering. The following antibodies 
were obtained from BioLegend (San Diego, CA): mouse (CD3, CD8b, CD45, CD45.1, CD45.2, 
CD90.1, CD90.2, CCR5, CCR6) and human (CD3, CD4, CD8, CD45, CD25, FOXP3, CCR5 
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and CCR6). For extracellular staining cells were washed in FACS buffer (1% FBS in PBS) and 
then incubated with antibodies at a 1:200 dilution at 4̊ C in the dark for 20 minutes. CCR5 and 
CCR6 staining was done at 37̊ C in the dark for 30 minutes. For intracellular FoxP3 staining, 
surface staining was performed and cells were fixed and permeablized using the 
FoxP3/Transcription factor staining buffer set from eBioscience (Santa Clara, CA) according to 
the manufacturer’s recommendations. The data were collected and analyzed with a BD LSR II 
flow cytometer (BD Biosciences) and FlowJo (Tree Star Inc.).  
 
Suction blistering 
Suction blistering was performed as previously described [264]. Blisters that were approximately 
1 cm in diameter were induced on the skin by using the Negative Pressure Instrument Model NP-
4 (Electronic Diversities, Finksburg, MD). Suction chambers were placed on the skin with 10-15 
mm Hg of negative pressure and a constant temperature of 40̊ C. After 30 to 60 minutes blisters 
formed and the blister fluid was aspirated through blister roofs using a 1 mL insulin syringe. 
Single cell RNA sequencing was performed on blister fluid obtained. Skin infiltrating cells 
within the blister fluid were pelleted at 330×g for 10 minutes and then stained to be analyzed 
with flow cytometry.  
 
Statistical analyses 
All statistical analyses were performed with GraphPad Prism software. Dual comparisons were 




CHAPTER V: DISCUSSION 
5.1: Regulatory factors in the skin during vitiligo need further investigation 
A myriad of factors drive the epidermal depigmentation that characterizes vitiligo 
(reviewed in ch. 1.3 – 1.13). One theory suggests that intrinsic defects render melanocytes less 
capable of handling stress and exposure to external stressors can initiate innate responses that 
subsequently activate melanocyte targeting CD8+ Teffs. Teffs can then migrate to the skin where 
they destroy pigment producing melanocytes. Lesions are disfiguring and patients tend to have 
self-esteem issues due to the visible nature of vitiligo. Few treatments for vitiligo currently exist 
(reviewed in ch. 1.2). These therapies can induce repigmentation but success is variable and in 
some cases not durable. 
Depigmentation frequently occurs in patches with lesional skin surrounded by unaffected 
skin. This suggests that there are regulatory factors at play that keep Teffs from exerting their 
full destructive potential. Melanocytes in the hair follicle are often protected during vitiligo, even 
in depigmented skin due the immune privilege that protects the follicle. In light of this, it is 
possible that suppressive immune factors prevent Teffs from depigmenting the entire epidermis 
and I hypothesize that regulatory factors in the skin suppress depigmentation during vitiligo. 
Several mechanisms that end Teff responses during inflammation have been described (reviewed 
in ch. 1.13) and cells like tolerogenic DCs or Tregs can suppress Teff activity in peripheral tissue 
to prevent autoimmunity. In this work I investigated the roles that Tregs and LHCs, two 
populations in the skin during vitiligo, play during disease. 
 
5.2: A case for Treg suppression in the skin during vitiligo. 
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 Several groups report the presence of Tregs in the skin during vitiligo and drew 
conflicting conclusions in attempts to correlate Treg number with disease severity. These human 
studies did not functionally test whether Tregs suppression in the skin plays a role in disease. 
Additionally, studies in mouse models of vitiligo that investigated Treg function tested the ability 
of Tregs to suppress hair depigmentation instead of epidermal depigmentation and used depletion 
strategies that could potentially affect cells aside from Tregs. Furthermore, these depletion 
strategies affected Tregs in the entire body thus more work needs to be done to assess whether 
Tregs suppress Teffs in the skin.  
In chapter II I observed that vitiligo is exacerbated in a mouse model of disease when 
Tregs are depleted. The depletion strategy I used exclusively targeted Tregs in a mouse model of 
vitiligo while previous studies used CD4 or CD25 depletion that target Tregs as well as all other 
CD4 or CD25 bearing cells. The depletion experiments that I conducted globally depleted Tregs 
and thus do not completely address the contribution of Treg suppression in the skin since Treg 
numbers could also be diminished in the SDLNs. Whether Tregs suppress Teffs in the skin or 
SDLNs is an important question to address since answering this question would direct how we 
treat disease. Strategies that exclusively deplete Tregs in the skin or sequester Tregs to SDLNs 
are needed to definitively answer this question but if Tregs directly suppress Teffs that they 
encounter in the skin, interventions aimed at increasing cutaneous Treg number in lesional skin 
could promote repigmentation. 
 Data obtained from vitiligo patients supports this idea of an inverse correlation between 
cutaneous Treg number and disease severity as I observed a reduced Treg/Teff ratio in lesional 
skin compared to non-lesional skin. While the absolute number of Tregs was comparable 
between lesional and non-lesional skin, the fact that Treg number did not increase proportionally 
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with Teff number in lesional skin supports the notion that maintaining a favorable ratio of Tregs 
to Teffs in the skin may control depigmentation. In our mouse model of vitiligo Tregs and Teffs 
accumulate at almost equal number in ear skin which is less prone to disease than tail skin, where 
Teffs outnumber Tregs. The increased number of Tregs in ear skin could establish a more 
immunosuppressive environment and explain why depigmentation is decreased. This observation 
reflects the inverse correlation we see between cutaneous Treg number and depigmentation in 
vitiligo patients. Considering this, treating depigmentation by increasing Treg number in the skin 
may be a viable treatment option for patient.   
Observations reported in this work strongly suggests that Tregs suppress Teffs directly in 
the skin during vitiligo but do not preclude Treg suppression in SLOs. Suppression in both 
locales is likely important during disease and I can functionally address this question in future 
experiments with the tools we have developed to use in our mouse model of disease. I believe the 
observations that I have reported highlight an underappreciated role for Treg-mediated Teff 
suppression in the skin during vitiligo. In our mouse model of vitiligo Tregs directly contact 
Teffs in lesional skin (Fig. 6) and in our Rag-/- model of disease, I observed increased ear 
depigmentation in hosts with CCR6-/- Tregs that can migrate to SDLNs but exhibit a reduced 
ability to migrate to skin (Fig. 19).  In the latter experiment, the absence of CCR6 on Tregs 
reduces Treg number in the skin without significantly affecting Treg number in SDLNs and thus 
highlights the importance of cutaneous Treg number for controlling Teff-mediated 
depigmentation. These results do not preclude the possibility of Treg-mediated Teff suppression 
in SDLNs but do present compelling evidence that Treg suppression in the skin contributes to the 
regulation of Teff-mediated depigmentation during vitiligo. 
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I did not definitively define the mechanisms of suppression that Tregs use during vitiligo. 
After seeing contact between Tregs and Teffs in the skin I hypothesized that Tregs may use 
contact-dependent mechanisms of suppression to regulate Teff activity in the skin and explored 
mechanisms that Tregs could be using. I pursued the hypothesis that Tregs suppress 
depigmentation by inducing CCR7 on Teffs to drive their egress from the skin during vitiligo. In 
in vitro suppression assays more naïve Teffs expressed CCR7 in co-cultures with Tregs than 
those in cultures without Tregs and this could be because Tregs induce CCR7 on Teffs or Tregs 
prevent naïve Teffs from maturing and down-regulating CCR7. To address this caveat, I would 
use previously activated Teffs or Teffs isolated from lesional tissue in co-cultures with Tregs. 
Nonetheless, if Tregs induce CCR7 expression on Teffs to regulate cutaneous Teff number 
during disease, the number of CCR7 expressing Teffs would decrease in absence of Tregs. Treg 
depletion did not affect the number Teffs expressing CCR7 in our mouse model of disease and 
thus it is unlikely that Tregs induce CCR7 on Teffs as an “exit” signal during vitiligo. Since 
CCR7 regulates lymphocyte exit it may not be possible to catch Teffs in the skin once they have 
been suppressed and this may explain why receptor expression is unaffected by Treg depletion. 
To address this, I can induce vitiligo with CCR7 deficient Teffs and compare disease severity 
and Teff accumulation in the skin. 
In future experiments I can combine the tools that we have I developed to use in our 
mouse model to further investigate the mechanisms Tregs use to suppress Teffs. Data obtained 
from single cell RNA-sequencing performed on skin infiltrating cells from lesional skin provides 
insight in the genes that are differentially expressed between Tregs in lesional skin and healthy 
or non-lesional skin. Single cell RNA-seq identified that Tregs in lesional vitiligo skin express 
less TGF-β1 than Tregs in healthy skin (Fig. 8) and I can begin to test if TGF-β1 plays a role in 
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Treg suppression during vitiligo by inducing vitiligo in Rag-/- hosts reconstituted with TGF-β1-/- 
Tregs. Using this method of discovery in RNA-seq experiments followed by functional screening 
experiments in Rag-/- mice, I can quickly screen for molecules required for Treg suppression 
during vitiligo. If we discover the mechanisms that Tregs use to suppress Teffs during vitiligo, 
we can use that information to improve how we treat patients. 
 
5.3: Defining the distinct signals that facilitate Treg migration and function during vitiligo. 
Our group characterized the signals that drive Teff migration to the skin during vitiligo 
but few have investigated the chemokine signals Tregs follow to the skin during disease 
(reviewed in ch 4.2). Comparisons of chemokine receptor expression on circulating Tregs in 
patients and healthy controls revealed no significant differences and more work needs to be done 
to fully elucidate the signals Teffs follow to get to the skin during vitiligo. 
I developed a Rag-/- model of vitiligo to study the signals that Tregs use to migrate to the 
skin. Since Rag-/- mice lack all T cells, I can reconstitute Rag-/- hosts with Tregs from any 
C57BL/6J donor when I induce vitiligo. This strategy gives us the advantage of being able to 
screen molecules that Tregs need for suppression during vitiligo without having to breed Krt14-
KitL hosts with Treg specific deletions. In chapter IV, I used this Rag-/- model to test the 
chemokine signals that Tregs follow. I found that Tregs required CCR6 for optimal suppression 
in a mouse model of vitiligo and Treg numbers in the skin are reduced when CCR6 is absent 
(Fig. 19). This result functionally demonstrated that reducing Treg number in the skin while not 
affecting Treg number in SDLNs, results in increased depigmentation. Previous studies 
investigating Tregs affected Treg number in the whole body and the one study that exclusively 
affected Treg number in the skin reported increased Treg number suppresses depigmentation. 
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My results suggest the decreased Treg number relative to Teff number that we see in the skin in 
lesional patient skin could be one of the factors that allow Teffs to target melanocytes during 
vitiligo.  
Scharschmidt et al reported that CCR6-/- Tregs transferred into Rag-/- mice did not 
migrate to neonatal skin as well as WT Tregs [152]. In our Rag-/- studies CCR6 may actually 
facilitate homeostatic skin migration to fill the empty Treg niche in mouse skin instead of 
mediating Treg migration during vitiligo. This caveat is an inevitable consequence of the Rag-/- 
vitiligo model and a disadvantage compared to our traditional mouse model of disease. In future 
experiments I can specifically address this caveat by comparing the ability of WT and CCR6-/- 
Tregs to migrate to the skin in the absence of vitiligo in a competitive transfer model. This will 
address whether inflammation during vitiligo draws Tregs into the skin during disease and to 
further confirm a role for CCR6 in Treg migration during vitiligo I will generate Krt14-Kitl mice 
with CCR6-/- Tregs to use as hosts during vitiligo.  
I also observed that Tregs required CCR5 for optimal suppression in a Rag-/- model of 
vitiligo but Tregs did not require CCR5 to get to the skin (Fig. 19). Instead CCR5/CCL5 
signaling promoted optimal Treg function in vitro and these observations highlight an 
underappreciated role for CCR5 in enhancing Treg function instead of inducing Treg migration 
(Fig. 20). A few other groups have reported similar unconventional chemokine receptor 
signaling. CCR8 signaling potentiated the suppressive function of Tregs in vitro and in a model 
of EAE [277] and CCR5/CCL5 enhances the ability of Tregs to suppress CD8+ T cells in vitro 
and in vivo [276]. Furthermore, another study demonstrated that CCR5 signaling, which 
normally activates G proteins to mediate migration, can also activate the JAK/STAT pathway 
and regulate cell growth via alterations in JAK activity [278]. These observations combined with 
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those presented in this work challenges the conventional theories that hold chemokine receptor 
signaling merely directs cell migration.  In some instances, chemokine receptor signaling may 
potentiate function and this exciting hypothesis can be explored in future experiments. 
 
5.4: Defining the role of LHCs during vitiligo. 
LHCs are the only DC population in the epidermis and ideally positioned to interact with 
Teffs in the skin during vitiligo. Few have studied the role LHCs play during vitiligo and these 
studies report conflicting results regarding LHCs number and function during disease (reviewed 
in ch. 3.2). More work needs to be done to elucidate the role LHCs play during vitiligo. LHCs 
can behave in and immunogenic or tolerogenic manner in other models of inflammation 
(reviewed in ch. 1.26 – 1.27) and our results obtained in our mouse model of disease can 
contribute to the debate regarding the role LHCs play during other forms of autoimmunity.  
In our mouse model, I observed that while the extent of depigmentation was comparable 
between LHC-KO and WT mice, the incidence of disease is increased in the absence of LHCs 
(Fig 9). How LHCs affect the incidence of disease without affecting disease severity of is an 
important question that this work did not conclusively answer. It is possible that LHCs behave as 
an immunological check point Teffs must overcome in order to mediate depigmentation during 
the initiation phase of vitiligo. Our mouse model of disease is well-suited to study disease 
progression but not intended to model disease initiation since we infect with virus to induce 
autoimmunity. As a result, we may not be able to fully appreciate the role LHCs play using our 
mouse model. Spontaneous mouse models of vitiligo (review in chapter 1.9) accurately replicate 
processes involved in disease initiation and should be adapted to further investigate how LHCs 
impact disease. The Teff donor mice that we use in our model of vitiligo spontaneously develop 
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depigmentation over time and in future experiments, I will cross Teff donor mice with LHC-KOs 
to generate mice that spontaneously develop depigmentation while lacking epidermal LHCs. 
This will allow me to investigate whether LHCs impact disease initiation and address some of 
the remaining questions surrounding the role of LHCs during vitiligo.  
The observation that Tregs and Teffs directly interact in the skin during disease further 
suggested that Tregs suppress Teffs in the skin during vitiligo and led us to question how Tregs 
find Teffs in the skin. LHCs express the appropriate molecules to interact with both cell types so 
it is possible that LHCs participate in Teff suppression by facilitating interactions between Teffs 
and Tregs in the skin in an MHC-TCR-dependent manner. In this scenario LHCs would increase 
the efficiency of interactions between Tregs and Teffs but Tregs could still migrate to the skin to 
suppress Teffs. In chapter III I observed that LHCs suppression was not MHCII-TCR-dependent 
but LHC-derived CXCL10 was necessary for optimal suppression. LHCs could participate in 
suppression by tethering Tregs and Teffs directly with CXCL10 to facilitate interactions between 
the two cell types and I can test this hypothesis in future experiments. In chapter II I observed 
more Tregs in ear skin than tail skin and I focused on ear skin as the main area of Treg 
suppression in chapter II and IV. In chapter III I investigated LHCs function in tail skin and if 
LHCs do synergize with Tregs to suppress Teffs, I should have focused on ear skin in LHC-KO 
experiments. This caveat must be considered when interpreting the data present and ear tissue 
should be analyze in future experiments investigating LHC function during vitiligo. 
 Another interesting possibility is that LHCs are directly suppressing Teffs in the skin. 
LHCs have been shown to suppress Teffs responses using immunosuppressive cytokines like IL-
10 (reviewed in chapter 1.27) and considering this, it is possible that LHCs use IL-10 to suppress 
Teffs that they encounter in the skin. I could explore this possibility by inducing vitiligo in hosts 
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with IL-10-/- LHCs to see if this replicates the phenotype that I observed in LHC-KO mice with 
vitiligo.  
Whether LHCs play an immunogenic or tolerogenic role during inflammation is still 
debated. Autoimmunity progresses and is even exacerbated in the absence of LHCs in our model 
of vitiligo suggesting that LHCs suppress Teff function. While I have not completely 
characterized the mechanism of LHC suppression, the observations reported in this work 
contribute to the ongoing discussion concerning LHCs function in vitiligo and other immune 
responses.  
 
5.5: Combining observations: a model for Treg-mediated Teff suppression in the skin during 
vitiligo. 
 In vitiligo patients, cases of complete depigmentation are rare and I hypothesize that 
regulatory factors function in the skin during vitiligo to keep Teffs from mediating their 
maximum destructive potential. My observations are consistent with the notion that that Teff 
suppression in the skin contributes to the overall suppression of depigmentation during vitiligo. I 
observed an inverse correlation between cutaneous Treg number and disease severity in murine 
and human skin and a reduction in cutaneous Treg number in Rag-/- experiments with CCR6-/- 
Tregs, resulted in increased depigmentation. One question that remains is how do Tregs localize 
with Teffs in the skin to mediate suppression? I hypothesize that LHCs provide chemotactic 
signals to direct Tregs to Teffs and that this interaction happens at the epidermal dermal 
interface. The majority of Tregs are in the dermis during disease (Fig. 5) but I still observed 
epidermal LHCs interacting with Treg and Teffs. If these interactions occur at the 
epidermal/dermal junction, basal LHCs will be properly positioned to interact with epidermal 
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and dermal populations. I observed that Tregs require CCR5 signaling for optimal suppressive 
function and I hypothesize that once Tregs contact Teffs in the skin, Teff-derived CCL5 
potentiates Treg function (Fig. 22). More work needs to be done to completely comprehend how 
skin resident cell types interact during inflammation, but this model begins to fill some gaps in 
our understanding of the complex network of cells and signals at play during skin immune 
responses including vitiligo.  
 
5.6: Conclusions 
During vitiligo, Tregs suppress Teff-mediated depigmentation and require CCR6 and 
CCR5 for optimal suppression. LHCs also suppress incidence of disease and may participate in 
suppression by promoting interactions between Tregs and Teffs (Fig. 22). New effective 
treatments for vitiligo that will induce long lasting repigmentation will help the 1% of the 
population afflicted by disease. Understanding the regulatory factors that suppress Teff-mediated 
depigmentation in the skin could inform the creation of treatments designed to augment the 








Figure 22: A model for Treg-mediated Teff 
suppression in the skin during vitiligo. 
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Figure 22: A model for Treg-mediated Teff suppression in the skin during vitiligo. (A) 
During vitiligo CXCL10/CXCR3 signaling promotes Teff migration to the epidermis while 
CCL20/CCR6 signaling promotes Treg migration to the epidermal/dermal interface. (B,C) At the 
basal layer of the epidermis LHC-derived CXCL10 attracts both cutaneous Tregs and Teffs to 
facilitate Treg-mediated Teff suppression. Once Tregs contact Teffs, Teff-derived CCL5 
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